JP2014520803A - ジヒドロピラゾール - Google Patents
ジヒドロピラゾール Download PDFInfo
- Publication number
- JP2014520803A JP2014520803A JP2014518909A JP2014518909A JP2014520803A JP 2014520803 A JP2014520803 A JP 2014520803A JP 2014518909 A JP2014518909 A JP 2014518909A JP 2014518909 A JP2014518909 A JP 2014518909A JP 2014520803 A JP2014520803 A JP 2014520803A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- max
- area ratio
- hal
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 title abstract description 8
- 108010060374 FSH Receptors Proteins 0.000 claims abstract description 57
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 102000008175 FSH Receptors Human genes 0.000 claims abstract description 11
- 208000021267 infertility disease Diseases 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 174
- 238000000034 method Methods 0.000 claims description 83
- 125000004432 carbon atom Chemical group C* 0.000 claims description 78
- -1 isoxazyl Chemical group 0.000 claims description 77
- 125000001424 substituent group Chemical group 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 239000004480 active ingredient Substances 0.000 claims description 36
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 23
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000004434 sulfur atom Chemical group 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 230000004720 fertilization Effects 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 9
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000004276 dioxalanyl group Chemical group 0.000 claims description 3
- 125000000532 dioxanyl group Chemical group 0.000 claims description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
- 125000005412 pyrazyl group Chemical group 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims 3
- 230000003281 allosteric effect Effects 0.000 abstract description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 392
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 299
- 239000007787 solid Substances 0.000 description 227
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 118
- 238000005481 NMR spectroscopy Methods 0.000 description 97
- 239000000203 mixture Substances 0.000 description 52
- 102000018343 Follicle stimulating hormone receptors Human genes 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 150000003254 radicals Chemical class 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 34
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 34
- 229940028334 follicle stimulating hormone Drugs 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000007858 starting material Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- 238000003756 stirring Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 239000011734 sodium Chemical class 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- QQFLDHKHGSUZKO-UHFFFAOYSA-N 1-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-2-phenylethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)CC=2C=CC=CC=2)CC1 QQFLDHKHGSUZKO-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000011345 viscous material Substances 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 230000016087 ovulation Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GMRIWVSOEBGRDP-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-methylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 GMRIWVSOEBGRDP-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000006254 arylation reaction Methods 0.000 description 5
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- HSSNCUJHRGPSFH-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(dimethylamino)propan-1-one Chemical compound COC1=CC=C(C(=O)CCN(C)C)C=C1OC HSSNCUJHRGPSFH-UHFFFAOYSA-N 0.000 description 4
- BCBQVYDRJUOYOT-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-4,5-dihydro-1h-pyrazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNCC1 BCBQVYDRJUOYOT-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- UZFKBUMEIWFMMZ-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(F)=C1 UZFKBUMEIWFMMZ-UHFFFAOYSA-N 0.000 description 4
- CQNNYYPEELGXLS-UHFFFAOYSA-N [5-(3-bromophenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(Br)C=CC=2)=C1 CQNNYYPEELGXLS-UHFFFAOYSA-N 0.000 description 4
- IQZLUWLMQNGTIW-UHFFFAOYSA-N acetoveratrone Chemical compound COC1=CC=C(C(C)=O)C=C1OC IQZLUWLMQNGTIW-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- AUIPLRJYEVPHIY-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CC1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 AUIPLRJYEVPHIY-UHFFFAOYSA-N 0.000 description 3
- ZINLHDQMINPWQI-UHFFFAOYSA-N (3-fluorophenyl)-[5-[3-(2-phenylethynyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 ZINLHDQMINPWQI-UHFFFAOYSA-N 0.000 description 3
- HMXZTPPNEGCDLT-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CC(OC(F)(F)F)=CC=2)=C1 HMXZTPPNEGCDLT-UHFFFAOYSA-N 0.000 description 3
- BKYIZXCKEIWNIA-UHFFFAOYSA-N 1,3-benzodioxol-5-yl-[5-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=NN(C(=O)C=2C=C3OCOC3=CC=2)CC1 BKYIZXCKEIWNIA-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- IGJSKKUADGHSBY-UHFFFAOYSA-N 3-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]benzonitrile Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(C=CC=2)C#N)=C1 IGJSKKUADGHSBY-UHFFFAOYSA-N 0.000 description 3
- FMUITMRKNWNBKG-UHFFFAOYSA-N 3-chloro-1-(3,4-dimethoxyphenyl)-2,2-dimethylpropan-1-one Chemical compound COC1=CC=C(C(=O)C(C)(C)CCl)C=C1OC FMUITMRKNWNBKG-UHFFFAOYSA-N 0.000 description 3
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 3
- ANHNHZKQDLLFKO-UHFFFAOYSA-N 5-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazole-2-carbonyl]-2-methylisoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3C(=O)N(C)C(=O)C3=CC=2)CC1(C)C ANHNHZKQDLLFKO-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 0 COc(ccc(C1=*CC1)c1)c1OC Chemical compound COc(ccc(C1=*CC1)c1)c1OC 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 3
- XGPLNTGCUQQQSX-UHFFFAOYSA-N [5-(benzylamino)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(NCC=3C=CC=CC=3)CC2)=C1 XGPLNTGCUQQQSX-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000005488 carboaryl group Chemical group 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002710 gonadal effect Effects 0.000 description 3
- 210000002503 granulosa cell Anatomy 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- GXBNINQSBNKKBR-UHFFFAOYSA-N (2,2-difluoro-1,3-benzodioxol-5-yl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3OC(F)(F)OC3=CC=2)CC1 GXBNINQSBNKKBR-UHFFFAOYSA-N 0.000 description 2
- IHKVEZIORFCLGX-UHFFFAOYSA-N (2,3-difluoro-4-methylphenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(C)=CC=2)F)CC1 IHKVEZIORFCLGX-UHFFFAOYSA-N 0.000 description 2
- HJHMPHGXXITBKC-UHFFFAOYSA-N (2-chloro-3-fluorophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)Cl)CC1(C)C HJHMPHGXXITBKC-UHFFFAOYSA-N 0.000 description 2
- QZHOHXVQKPJNFI-UHFFFAOYSA-N (3,4-difluorophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(F)=CC=2)CC1 QZHOHXVQKPJNFI-UHFFFAOYSA-N 0.000 description 2
- MRDXBLGYZBWFCA-UHFFFAOYSA-N (3,4-difluorophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(F)=CC=2)CC1(C)C MRDXBLGYZBWFCA-UHFFFAOYSA-N 0.000 description 2
- IHMYZOSHMURVIV-UHFFFAOYSA-N (3-bromophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(Br)C=CC=2)CC1 IHMYZOSHMURVIV-UHFFFAOYSA-N 0.000 description 2
- NGCCNBITZJHKDR-UHFFFAOYSA-N (3-fluorophenyl)-(5-naphthalen-2-yl-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C=CC=CC3=CC=2)=C1 NGCCNBITZJHKDR-UHFFFAOYSA-N 0.000 description 2
- PXJDSJLUIOPYQM-UHFFFAOYSA-N (3-fluorophenyl)-(5-pyridin-4-yl-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CN=CC=2)=C1 PXJDSJLUIOPYQM-UHFFFAOYSA-N 0.000 description 2
- UTYDLMHXMCRNBK-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-methoxy-4-methylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(C)C(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 UTYDLMHXMCRNBK-UHFFFAOYSA-N 0.000 description 2
- ZPNRAOOOVRZNGI-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-methoxy-4-phenylmethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=CC=C1OCC1=CC=CC=C1 ZPNRAOOOVRZNGI-UHFFFAOYSA-N 0.000 description 2
- CMTJTMFXBTXMPJ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxy-3-propan-2-yloxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 CMTJTMFXBTXMPJ-UHFFFAOYSA-N 0.000 description 2
- CBJQAEUEVGWNHP-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methylsulfanylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(SC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 CBJQAEUEVGWNHP-UHFFFAOYSA-N 0.000 description 2
- GBGYUSZAJYWRCW-UHFFFAOYSA-N (3-fluorophenyl)-[5-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1 GBGYUSZAJYWRCW-UHFFFAOYSA-N 0.000 description 2
- XVPLUMJAXYZSPQ-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(Cl)=CC=2)CC1 XVPLUMJAXYZSPQ-UHFFFAOYSA-N 0.000 description 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
- CNEFCAYXAMXLEH-UHFFFAOYSA-N (5-chloro-3,4-dihydropyrazol-2-yl)-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(Cl)CC2)=C1 CNEFCAYXAMXLEH-UHFFFAOYSA-N 0.000 description 2
- GUKJQJVVIYZEFP-UHFFFAOYSA-N 1,3-benzodioxol-5-yl-[5-(4-methylsulfanylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(SC)=CC=C1C1=NN(C(=O)C=2C=C3OCOC3=CC=2)CC1 GUKJQJVVIYZEFP-UHFFFAOYSA-N 0.000 description 2
- AMLUCUXKZRJUOC-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-methylbut-2-en-1-one Chemical compound COC1=CC=C(C(=O)C=C(C)C)C=C1OC AMLUCUXKZRJUOC-UHFFFAOYSA-N 0.000 description 2
- JYAQYXOVOHJRCS-UHFFFAOYSA-N 1-(3-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=C1 JYAQYXOVOHJRCS-UHFFFAOYSA-N 0.000 description 2
- RJRNKBOZXJWGHO-UHFFFAOYSA-N 1-(3-fluorobenzoyl)pyrazolidin-3-one Chemical compound FC1=CC=CC(C(=O)N2NC(=O)CC2)=C1 RJRNKBOZXJWGHO-UHFFFAOYSA-N 0.000 description 2
- JECUZQLBQKNEMW-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)ethanone Chemical compound CSC1=CC=C(C(C)=O)C=C1 JECUZQLBQKNEMW-UHFFFAOYSA-N 0.000 description 2
- DNZZNEBPMUIUDR-UHFFFAOYSA-N 1-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-2-(3-fluorophenyl)ethanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)CC1=CC=CC(F)=C1 DNZZNEBPMUIUDR-UHFFFAOYSA-N 0.000 description 2
- MOEXTBIPPMLEFX-UHFFFAOYSA-N 1-[4-(trifluoromethoxy)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(OC(F)(F)F)C=C1 MOEXTBIPPMLEFX-UHFFFAOYSA-N 0.000 description 2
- ZJCBHOZBJCYVLW-UHFFFAOYSA-N 1-[4-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 ZJCBHOZBJCYVLW-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- UNJVSKADGVVUBF-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-5,5-dimethyl-1,4-dihydropyrazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNC(C)(C)C1 UNJVSKADGVVUBF-UHFFFAOYSA-N 0.000 description 2
- RIYVAXXFFBTVLH-UHFFFAOYSA-N 3-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazole-1-carbonyl]benzonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(C#N)=C1 RIYVAXXFFBTVLH-UHFFFAOYSA-N 0.000 description 2
- UPWHZOWQLRFRQE-UHFFFAOYSA-N 3-chloro-5,5-dimethyl-1,4-dihydropyrazole;hydrochloride Chemical compound Cl.CC1(C)CC(Cl)=NN1 UPWHZOWQLRFRQE-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- IBTSNZJBUMUAPI-UHFFFAOYSA-N 4-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 IBTSNZJBUMUAPI-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- BEUWBSAVSYYTEI-UHFFFAOYSA-N 5,5-dimethylpyrazolidin-3-one Chemical compound CC1(C)CC(=O)NN1 BEUWBSAVSYYTEI-UHFFFAOYSA-N 0.000 description 2
- PTMBVQZRBWAHHB-UHFFFAOYSA-N 5,5-dimethylpyrazolidin-3-one;hydrochloride Chemical compound Cl.CC1(C)CC(=O)NN1 PTMBVQZRBWAHHB-UHFFFAOYSA-N 0.000 description 2
- BWHAHLSRFUDNMT-UHFFFAOYSA-N 6-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-2,3-dihydroisoindol-1-one Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C(=O)NCC3=CC=2)=C1 BWHAHLSRFUDNMT-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- RGJIVRPADVNRPK-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(4-phenoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 RGJIVRPADVNRPK-UHFFFAOYSA-N 0.000 description 2
- OLSWHWCXNAKDDR-UHFFFAOYSA-N [5,5-dimethyl-3-(2-methylphenyl)-4h-pyrazol-1-yl]-(3-fluorophenyl)methanone Chemical compound CC1=CC=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(F)=C1 OLSWHWCXNAKDDR-UHFFFAOYSA-N 0.000 description 2
- MWERQGMVALUENV-UHFFFAOYSA-N [5-(1-benzothiophen-5-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C=CSC3=CC=2)=C1 MWERQGMVALUENV-UHFFFAOYSA-N 0.000 description 2
- LVKLIUGSXUGRFD-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(2,3,4,5-tetrafluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(F)=C(F)C=2)F)CC1 LVKLIUGSXUGRFD-UHFFFAOYSA-N 0.000 description 2
- ADNNWSYTYLDVMG-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-ethoxyphenyl)methanone Chemical compound CCOC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(OC)C(OC)=CC=2)=C1 ADNNWSYTYLDVMG-UHFFFAOYSA-N 0.000 description 2
- AJVJXXXBAOZUJN-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluoro-4-methoxyphenyl)methanone Chemical compound C1=C(F)C(OC)=CC=C1C(=O)N1N=C(C=2C=C(OC)C(OC)=CC=2)CC1 AJVJXXXBAOZUJN-UHFFFAOYSA-N 0.000 description 2
- ILESQPJPNZIWKK-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-hydroxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(O)C=CC=2)CC1 ILESQPJPNZIWKK-UHFFFAOYSA-N 0.000 description 2
- DDICZKLHDVRYAW-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1(C)C DDICZKLHDVRYAW-UHFFFAOYSA-N 0.000 description 2
- FYLIOVBOKPYEKJ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(F)=CC=2)CC1(C)C FYLIOVBOKPYEKJ-UHFFFAOYSA-N 0.000 description 2
- FXXFNSGVMKZJLS-UHFFFAOYSA-N [5-(5-fluoro-6-methoxypyridin-3-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(F)C(OC)=NC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 FXXFNSGVMKZJLS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000008217 follicular development Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- DFXGNZFHDLIEGD-UHFFFAOYSA-N n-[3-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 DFXGNZFHDLIEGD-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- NDGRWYRVNANFNB-UHFFFAOYSA-N pyrazolidin-3-one Chemical compound O=C1CCNN1 NDGRWYRVNANFNB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- HYIOJVGGMBSCNJ-UHFFFAOYSA-N (2,2-difluoro-1,3-benzodioxol-5-yl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3OC(F)(F)OC3=CC=2)CC1(C)C HYIOJVGGMBSCNJ-UHFFFAOYSA-N 0.000 description 1
- WPMUVEYNVLODLO-UHFFFAOYSA-N (2,3-difluoro-4-methoxyphenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(OC)=CC=2)F)CC1 WPMUVEYNVLODLO-UHFFFAOYSA-N 0.000 description 1
- JOELNMMMDRXXTN-UHFFFAOYSA-N (2,3-difluoro-4-methylphenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(C)=CC=2)F)CC1(C)C JOELNMMMDRXXTN-UHFFFAOYSA-N 0.000 description 1
- NJVAQSWEELVDHO-UHFFFAOYSA-N (2,3-difluorophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)F)CC1 NJVAQSWEELVDHO-UHFFFAOYSA-N 0.000 description 1
- AYFHQQWROKLCTQ-UHFFFAOYSA-N (2,3-difluorophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)F)CC1(C)C AYFHQQWROKLCTQ-UHFFFAOYSA-N 0.000 description 1
- KNPWSSIIHSDVRV-UHFFFAOYSA-N (2,3-dimethoxyphenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(OC)C=CC=2)OC)CC1 KNPWSSIIHSDVRV-UHFFFAOYSA-N 0.000 description 1
- IDWMMVNNKWSNAY-UHFFFAOYSA-N (2,5-dimethoxyphenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC=C(OC)C(C(=O)N2N=C(CC2)C=2C=C(OC)C(OC)=CC=2)=C1 IDWMMVNNKWSNAY-UHFFFAOYSA-N 0.000 description 1
- YEEWIRQXTWAZSR-UHFFFAOYSA-N (2,5-dimethoxyphenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound COC1=CC=C(OC)C(C(=O)N2N=C(C(C)(C)C2)C=2C=C(OC)C(OC)=CC=2)=C1 YEEWIRQXTWAZSR-UHFFFAOYSA-N 0.000 description 1
- DHJDPKMBOVYRPW-UHFFFAOYSA-N (2-bromo-3-fluorophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)Br)CC1(C)C DHJDPKMBOVYRPW-UHFFFAOYSA-N 0.000 description 1
- WBFACTQJQDDXOV-UHFFFAOYSA-N (2-chloro-3-fluorophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)Cl)CC1 WBFACTQJQDDXOV-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- PFCJOHXAMIDIMQ-UHFFFAOYSA-N (3,4-difluorophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(F)C(F)=C1 PFCJOHXAMIDIMQ-UHFFFAOYSA-N 0.000 description 1
- CFTUZTUJIWCUNT-UHFFFAOYSA-N (3-bromophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(Br)=C1 CFTUZTUJIWCUNT-UHFFFAOYSA-N 0.000 description 1
- SAVHWOCRBNFKCP-UHFFFAOYSA-N (3-bromophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(Br)C=CC=2)CC1(C)C SAVHWOCRBNFKCP-UHFFFAOYSA-N 0.000 description 1
- CDAOBUJIBAOILN-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(F)C(Cl)=C1 CDAOBUJIBAOILN-UHFFFAOYSA-N 0.000 description 1
- YIAZDXFMEODISJ-UHFFFAOYSA-N (3-chloro-5,5-dimethyl-4h-pyrazol-1-yl)-(3-fluorophenyl)methanone Chemical compound CC1(C)CC(Cl)=NN1C(=O)C1=CC=CC(F)=C1 YIAZDXFMEODISJ-UHFFFAOYSA-N 0.000 description 1
- RLEQYVQTHSWMKP-UHFFFAOYSA-N (3-chlorophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(Cl)=C1 RLEQYVQTHSWMKP-UHFFFAOYSA-N 0.000 description 1
- XTQNEPQATGBGQR-UHFFFAOYSA-N (3-chlorophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(Cl)C=CC=2)CC1 XTQNEPQATGBGQR-UHFFFAOYSA-N 0.000 description 1
- XJMGIVMLBOYCRA-UHFFFAOYSA-N (3-chlorophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(Cl)C=CC=2)CC1(C)C XJMGIVMLBOYCRA-UHFFFAOYSA-N 0.000 description 1
- NYNQGFBQMPOYEX-UHFFFAOYSA-N (3-fluorophenyl)-(5-phenyl-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CC=CC=2)=C1 NYNQGFBQMPOYEX-UHFFFAOYSA-N 0.000 description 1
- BPNCONBOQWXDHK-UHFFFAOYSA-N (3-fluorophenyl)-(5-phenylmethoxy-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(OCC=3C=CC=CC=3)CC2)=C1 BPNCONBOQWXDHK-UHFFFAOYSA-N 0.000 description 1
- GYLNVIJUORVKRM-UHFFFAOYSA-N (3-fluorophenyl)-(5-pyrimidin-5-yl-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=NC=NC=2)=C1 GYLNVIJUORVKRM-UHFFFAOYSA-N 0.000 description 1
- NDEGCSLSSQZDIA-UHFFFAOYSA-N (3-fluorophenyl)-(5-quinolin-6-yl-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C=CC=NC3=CC=2)=C1 NDEGCSLSSQZDIA-UHFFFAOYSA-N 0.000 description 1
- NHANZFCYWTVUSD-UHFFFAOYSA-N (3-fluorophenyl)-(5-thiophen-3-yl-3,4-dihydropyrazol-2-yl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C2=CSC=C2)=C1 NHANZFCYWTVUSD-UHFFFAOYSA-N 0.000 description 1
- PCOSRYSIPRHJJQ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(1-methylindazol-6-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C2N(C)N=CC2=CC=C1C(CC1)=NN1C(=O)C1=CC=CC(F)=C1 PCOSRYSIPRHJJQ-UHFFFAOYSA-N 0.000 description 1
- HZCSSGJHNXQHMY-UHFFFAOYSA-N (3-fluorophenyl)-[5-(1-methylindol-5-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C=1C=C2N(C)C=CC2=CC=1C(CC1)=NN1C(=O)C1=CC=CC(F)=C1 HZCSSGJHNXQHMY-UHFFFAOYSA-N 0.000 description 1
- WGFWYEBZGCVQGJ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(1h-indol-5-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C=CNC3=CC=2)=C1 WGFWYEBZGCVQGJ-UHFFFAOYSA-N 0.000 description 1
- ROQBMFQCZRTGAD-UHFFFAOYSA-N (3-fluorophenyl)-[5-(1h-indol-6-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3NC=CC3=CC=2)=C1 ROQBMFQCZRTGAD-UHFFFAOYSA-N 0.000 description 1
- VEVFRQKJIBAHEY-UHFFFAOYSA-N (3-fluorophenyl)-[5-(1h-pyrrolo[2,3-b]pyridin-5-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C=CNC3=NC=2)=C1 VEVFRQKJIBAHEY-UHFFFAOYSA-N 0.000 description 1
- YGYCMALWNXKRJN-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2,3,4-trimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 YGYCMALWNXKRJN-UHFFFAOYSA-N 0.000 description 1
- UKSUEKZUVYOFSC-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-hydroxy-3-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1O UKSUEKZUVYOFSC-UHFFFAOYSA-N 0.000 description 1
- NGCFDHMGBMVQGE-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound OC1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 NGCFDHMGBMVQGE-UHFFFAOYSA-N 0.000 description 1
- PXFUUTZRYTYROY-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 PXFUUTZRYTYROY-UHFFFAOYSA-N 0.000 description 1
- PVWLAQBECUHMBV-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methoxypyridin-3-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=NC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 PVWLAQBECUHMBV-UHFFFAOYSA-N 0.000 description 1
- BRNVPTRTSIQSJB-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methoxypyridin-4-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=NC(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 BRNVPTRTSIQSJB-UHFFFAOYSA-N 0.000 description 1
- WEBRVSYUEKFCBQ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methoxypyrimidin-5-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=NC(OC)=NC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 WEBRVSYUEKFCBQ-UHFFFAOYSA-N 0.000 description 1
- YDPGLVIZGCANMD-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methyl-1,3-benzoxazol-6-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C2OC(C)=NC2=CC=C1C(CC1)=NN1C(=O)C1=CC=CC(F)=C1 YDPGLVIZGCANMD-UHFFFAOYSA-N 0.000 description 1
- MKWMTUHWLXMFAC-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methylpyrimidin-5-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=NC(C)=NC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 MKWMTUHWLXMFAC-UHFFFAOYSA-N 0.000 description 1
- NBAZJLCUWFZDAZ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-methylsulfanylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CSC1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 NBAZJLCUWFZDAZ-UHFFFAOYSA-N 0.000 description 1
- GITSJXIVISDWNL-UHFFFAOYSA-N (3-fluorophenyl)-[5-(2-phenylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C(=CC=CC=2)C=2C=CC=CC=2)=C1 GITSJXIVISDWNL-UHFFFAOYSA-N 0.000 description 1
- VKCZBTIYOYOOGV-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-fluorophenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(F)C=CC=2)=C1 VKCZBTIYOYOOGV-UHFFFAOYSA-N 0.000 description 1
- IPHHYHWXODHSGT-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-hydroxy-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(O)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 IPHHYHWXODHSGT-UHFFFAOYSA-N 0.000 description 1
- XQOURVMULPGURY-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound OC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 XQOURVMULPGURY-UHFFFAOYSA-N 0.000 description 1
- GIKIQVUQWNMEHV-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-methoxypyridin-4-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CN=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 GIKIQVUQWNMEHV-UHFFFAOYSA-N 0.000 description 1
- ACFQAEBFIIIHNA-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-methylbenzimidazol-5-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C2N(C)C=NC2=CC=C1C(CC1)=NN1C(=O)C1=CC=CC(F)=C1 ACFQAEBFIIIHNA-UHFFFAOYSA-N 0.000 description 1
- KNRORGASUJDKJZ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-methylsulfanylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CSC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 KNRORGASUJDKJZ-UHFFFAOYSA-N 0.000 description 1
- PIWKAHXKFHJYLD-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-phenylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(C=CC=2)C=2C=CC=CC=2)=C1 PIWKAHXKFHJYLD-UHFFFAOYSA-N 0.000 description 1
- OHLFUQSMLFSNMO-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-propan-2-ylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CC(C)C1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 OHLFUQSMLFSNMO-UHFFFAOYSA-N 0.000 description 1
- TXVXOBRESKXVEM-UHFFFAOYSA-N (3-fluorophenyl)-[5-(3-pyrazol-1-ylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(C=CC=2)N2N=CC=C2)=C1 TXVXOBRESKXVEM-UHFFFAOYSA-N 0.000 description 1
- GLOWDKIJMXCOTK-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(O)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 GLOWDKIJMXCOTK-UHFFFAOYSA-N 0.000 description 1
- ZCEHXNDMNPDNGD-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxy-2-methylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CC1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 ZCEHXNDMNPDNGD-UHFFFAOYSA-N 0.000 description 1
- WJUAASRWPAKUIT-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxy-3-methylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(C)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 WJUAASRWPAKUIT-UHFFFAOYSA-N 0.000 description 1
- AIGNNSHDWOXGCZ-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxy-3-morpholin-4-ylsulfonylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC=C(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)C=C1S(=O)(=O)N1CCOCC1 AIGNNSHDWOXGCZ-UHFFFAOYSA-N 0.000 description 1
- AKUFHBOUUVKWEL-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxy-3-nitrophenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 AKUFHBOUUVKWEL-UHFFFAOYSA-N 0.000 description 1
- INGQNIVJQIIWPP-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxy-3-phenylmethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC=C(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)C=C1OCC1=CC=CC=C1 INGQNIVJQIIWPP-UHFFFAOYSA-N 0.000 description 1
- WQQYCVOGTOCMTH-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 WQQYCVOGTOCMTH-UHFFFAOYSA-N 0.000 description 1
- KPRHPVQJQSPPBF-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 KPRHPVQJQSPPBF-UHFFFAOYSA-N 0.000 description 1
- MHUIURCXQJZWJU-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-methylsulfonylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 MHUIURCXQJZWJU-UHFFFAOYSA-N 0.000 description 1
- HZCGIMQGANLCFH-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-phenoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 HZCGIMQGANLCFH-UHFFFAOYSA-N 0.000 description 1
- PIRUXWMWSVAOAR-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-phenylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 PIRUXWMWSVAOAR-UHFFFAOYSA-N 0.000 description 1
- VQBGMIFGTQJDEX-UHFFFAOYSA-N (3-fluorophenyl)-[5-(4-propan-2-ylphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(C(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 VQBGMIFGTQJDEX-UHFFFAOYSA-N 0.000 description 1
- MHBUXILDDLSPGO-UHFFFAOYSA-N (3-fluorophenyl)-[5-(5-methoxy-1-benzofuran-2-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C=1C2=CC(OC)=CC=C2OC=1C(CC1)=NN1C(=O)C1=CC=CC(F)=C1 MHBUXILDDLSPGO-UHFFFAOYSA-N 0.000 description 1
- UMNIJOYJGSBDTM-UHFFFAOYSA-N (3-fluorophenyl)-[5-(5-methoxypyridin-3-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CN=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 UMNIJOYJGSBDTM-UHFFFAOYSA-N 0.000 description 1
- CWZIFJAUXIPUEM-UHFFFAOYSA-N (3-fluorophenyl)-[5-(5-phenylthiophen-2-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2SC(=CC=2)C=2C=CC=CC=2)=C1 CWZIFJAUXIPUEM-UHFFFAOYSA-N 0.000 description 1
- SOKRBAKERABUQG-UHFFFAOYSA-N (3-fluorophenyl)-[5-(6-methoxy-2-methylpyridin-3-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound CC1=NC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 SOKRBAKERABUQG-UHFFFAOYSA-N 0.000 description 1
- TVQLHELGDXWJEN-UHFFFAOYSA-N (3-fluorophenyl)-[5-(6-methoxypyridin-3-yl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=NC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 TVQLHELGDXWJEN-UHFFFAOYSA-N 0.000 description 1
- XDTRVAPFQYEIFY-UHFFFAOYSA-N (3-fluorophenyl)-[5-[(3-fluorophenyl)methyl-methylamino]-3,4-dihydropyrazol-2-yl]methanone Chemical compound N=1N(C(=O)C=2C=C(F)C=CC=2)CCC=1N(C)CC1=CC=CC(F)=C1 XDTRVAPFQYEIFY-UHFFFAOYSA-N 0.000 description 1
- TXABTDBOSRUULB-UHFFFAOYSA-N (3-fluorophenyl)-[5-[(3-methoxyphenyl)methyl-methylamino]-3,4-dihydropyrazol-2-yl]methanone Chemical compound COC1=CC=CC(CN(C)C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 TXABTDBOSRUULB-UHFFFAOYSA-N 0.000 description 1
- XUNQMTZEFRUYHP-UHFFFAOYSA-N (3-fluorophenyl)-[5-[(4-fluorophenyl)methyl-methylamino]-3,4-dihydropyrazol-2-yl]methanone Chemical compound N=1N(C(=O)C=2C=C(F)C=CC=2)CCC=1N(C)CC1=CC=C(F)C=C1 XUNQMTZEFRUYHP-UHFFFAOYSA-N 0.000 description 1
- RPSVLHPUCDSQKJ-UHFFFAOYSA-N (3-fluorophenyl)-[5-[(4-fluorophenyl)methylamino]-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(F)=CC=C1CNC1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 RPSVLHPUCDSQKJ-UHFFFAOYSA-N 0.000 description 1
- DLIVCJAYYLMSMA-UHFFFAOYSA-N (3-fluorophenyl)-[5-[2-(hydroxymethyl)-4-methoxyphenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound OCC1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 DLIVCJAYYLMSMA-UHFFFAOYSA-N 0.000 description 1
- PBEIKHCBTNOGLR-UHFFFAOYSA-N (3-fluorophenyl)-[5-[2-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C(=CC=CC=2)C(F)(F)F)=C1 PBEIKHCBTNOGLR-UHFFFAOYSA-N 0.000 description 1
- HIPNWVYARGFTDP-UHFFFAOYSA-N (3-fluorophenyl)-[5-[3-(hydroxymethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound OCC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 HIPNWVYARGFTDP-UHFFFAOYSA-N 0.000 description 1
- BIPQWDUPCSAXDK-UHFFFAOYSA-N (3-fluorophenyl)-[5-[3-(trifluoromethoxy)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(OC(F)(F)F)C=CC=2)=C1 BIPQWDUPCSAXDK-UHFFFAOYSA-N 0.000 description 1
- FOOBXYZVWKBFJR-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-(hydroxymethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(CO)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 FOOBXYZVWKBFJR-UHFFFAOYSA-N 0.000 description 1
- CHDURBULQFBCDZ-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CC(=CC=2)C(F)(F)F)=C1 CHDURBULQFBCDZ-UHFFFAOYSA-N 0.000 description 1
- AYOGAFLVQJXBNE-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-[(2-methylpropan-2-yl)oxy]phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=CC(OC(C)(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 AYOGAFLVQJXBNE-UHFFFAOYSA-N 0.000 description 1
- IUEUYBRTDMXLBL-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-methoxy-2-(trifluoromethoxy)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC(F)(F)OC1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 IUEUYBRTDMXLBL-UHFFFAOYSA-N 0.000 description 1
- DOHDBGXAPPXJFQ-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-methoxy-2-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound FC(F)(F)C1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 DOHDBGXAPPXJFQ-UHFFFAOYSA-N 0.000 description 1
- HICPARCXXZNDKA-UHFFFAOYSA-N (3-fluorophenyl)-[5-[4-methoxy-3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 HICPARCXXZNDKA-UHFFFAOYSA-N 0.000 description 1
- WDZFGCTZCSMWPK-UHFFFAOYSA-N (3-tert-butylphenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C(C)(C)C)CC1 WDZFGCTZCSMWPK-UHFFFAOYSA-N 0.000 description 1
- VBFVFAYOEWJVRR-UHFFFAOYSA-N (3-tert-butylphenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C(C)(C)C)CC1(C)C VBFVFAYOEWJVRR-UHFFFAOYSA-N 0.000 description 1
- CRLUASWLUVKHMI-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(Br)=CC=2)CC1 CRLUASWLUVKHMI-UHFFFAOYSA-N 0.000 description 1
- RKZMNUSUUCKTQW-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(Br)=CC=2)CC1(C)C RKZMNUSUUCKTQW-UHFFFAOYSA-N 0.000 description 1
- JGMQVBNVFDGPOY-UHFFFAOYSA-N (4-bromophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(Br)C=C1 JGMQVBNVFDGPOY-UHFFFAOYSA-N 0.000 description 1
- HUJQRKHULWSBJY-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(Cl)C(F)=C1 HUJQRKHULWSBJY-UHFFFAOYSA-N 0.000 description 1
- FXLLBGSVLZEWKY-UHFFFAOYSA-N (4-chlorophenyl)-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(Cl)C=C1 FXLLBGSVLZEWKY-UHFFFAOYSA-N 0.000 description 1
- AJGFZVPLUIUWOG-UHFFFAOYSA-N (6-bromo-1,3-benzodioxol-5-yl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=CC=3OCOC=3C=2)Br)CC1 AJGFZVPLUIUWOG-UHFFFAOYSA-N 0.000 description 1
- FZXUHOGBRXWGRC-UHFFFAOYSA-N (6-bromo-1,3-benzodioxol-5-yl)-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=CC=3OCOC=3C=2)Br)CC1(C)C FZXUHOGBRXWGRC-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- PZZHUDQKWSIBSK-UHFFFAOYSA-N (7-chloro-1,3-benzodioxol-5-yl)-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(Cl)C=3OCOC=3C=2)CC1 PZZHUDQKWSIBSK-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- GAZGOOCYTGBKCB-UHFFFAOYSA-N 1-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-2-(3-fluorophenyl)ethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)CC=2C=C(F)C=CC=2)CC1 GAZGOOCYTGBKCB-UHFFFAOYSA-N 0.000 description 1
- GBHPLEUCFJMMKZ-UHFFFAOYSA-N 1-[5-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CCN(C3=CC=2)C(C)=O)CC1 GBHPLEUCFJMMKZ-UHFFFAOYSA-N 0.000 description 1
- HDVTYDZFDUUXBA-UHFFFAOYSA-N 1-benzofuran-5-yl-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3C=COC3=CC=2)CC1 HDVTYDZFDUUXBA-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- DCAZXDCKDZFGGP-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-yl-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3OCCOC3=CC=2)CC1 DCAZXDCKDZFGGP-UHFFFAOYSA-N 0.000 description 1
- UQQUMJHJHIFUBT-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-yl-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3OCCOC3=CC=2)CC1(C)C UQQUMJHJHIFUBT-UHFFFAOYSA-N 0.000 description 1
- BSENVLDBHMQWBC-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-yl-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CCOC3=CC=2)CC1 BSENVLDBHMQWBC-UHFFFAOYSA-N 0.000 description 1
- JBZCZQLRICNWQT-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-yl-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CCOC3=CC=2)CC1(C)C JBZCZQLRICNWQT-UHFFFAOYSA-N 0.000 description 1
- YKNNVWBVDLNVPN-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-yl-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CCCC3=CC=2)CC1 YKNNVWBVDLNVPN-UHFFFAOYSA-N 0.000 description 1
- JXUYPRKMAYLCFW-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-yl-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CCCC3=CC=2)CC1(C)C JXUYPRKMAYLCFW-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
- CLPJHPLDPSLBNO-UHFFFAOYSA-N 2-(2,3-difluorophenyl)-1-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]ethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)CC=2C(=C(F)C=CC=2)F)CC1 CLPJHPLDPSLBNO-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- YCPSZGNFMWQPLJ-UHFFFAOYSA-N 2-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 YCPSZGNFMWQPLJ-UHFFFAOYSA-N 0.000 description 1
- ANHHNJPTQXFUAZ-UHFFFAOYSA-N 2-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]benzonitrile Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C(=CC=CC=2)C#N)=C1 ANHHNJPTQXFUAZ-UHFFFAOYSA-N 0.000 description 1
- GFXQBWUWIQBIKN-UHFFFAOYSA-N 2-[3-fluoro-n-(2-hydroxyethyl)anilino]ethanol Chemical compound OCCN(CCO)C1=CC=CC(F)=C1 GFXQBWUWIQBIKN-UHFFFAOYSA-N 0.000 description 1
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006026 2-methyl-1-butenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- UMMFNWCQDYDGJT-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-4,4-dimethyl-1,5-dihydropyrazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NNCC1(C)C UMMFNWCQDYDGJT-UHFFFAOYSA-N 0.000 description 1
- OPJMPIFJEWHDMD-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-[(3-fluorophenyl)methyl]-5,5-dimethyl-4h-pyrazole-1-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)NCC1=CC=CC(F)=C1 OPJMPIFJEWHDMD-UHFFFAOYSA-N 0.000 description 1
- BYTFPLSTWRQNPV-UHFFFAOYSA-N 3-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 BYTFPLSTWRQNPV-UHFFFAOYSA-N 0.000 description 1
- WLRHSMGGZMFVBU-UHFFFAOYSA-N 3-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 WLRHSMGGZMFVBU-UHFFFAOYSA-N 0.000 description 1
- XJRYEFAKIYHSCP-UHFFFAOYSA-N 3-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]benzonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C#N)CC1 XJRYEFAKIYHSCP-UHFFFAOYSA-N 0.000 description 1
- JKFYCUHNSJACOI-UHFFFAOYSA-N 3-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazole-2-carbonyl]benzonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C#N)CC1(C)C JKFYCUHNSJACOI-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical class OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- HRJTXKOBMFNJAG-UHFFFAOYSA-N 4-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 HRJTXKOBMFNJAG-UHFFFAOYSA-N 0.000 description 1
- CMGSALPCSFARGE-UHFFFAOYSA-N 4-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-2-methoxybenzonitrile Chemical compound C1=C(C#N)C(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 CMGSALPCSFARGE-UHFFFAOYSA-N 0.000 description 1
- VQOPHDWUWQGGSK-UHFFFAOYSA-N 4-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 VQOPHDWUWQGGSK-UHFFFAOYSA-N 0.000 description 1
- BVUPVFLBDVHOCN-UHFFFAOYSA-N 4-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-n,n-dimethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 BVUPVFLBDVHOCN-UHFFFAOYSA-N 0.000 description 1
- VTQFESLCNDHUSK-UHFFFAOYSA-N 4-[3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazole-1-carbonyl]benzonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(C#N)C=C1 VTQFESLCNDHUSK-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- CYHMDXAUUXFZAN-UHFFFAOYSA-N 5-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 CYHMDXAUUXFZAN-UHFFFAOYSA-N 0.000 description 1
- AJNVEPKHKLNXNO-UHFFFAOYSA-N 5-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]-1,3-dihydroindol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CC(=O)NC3=CC=2)CC1 AJNVEPKHKLNXNO-UHFFFAOYSA-N 0.000 description 1
- HECQJANLXIDAKU-UHFFFAOYSA-N 5-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]-2-methylisoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3C(=O)N(C)C(=O)C3=CC=2)CC1 HECQJANLXIDAKU-UHFFFAOYSA-N 0.000 description 1
- CCXXBUKDXVBBPU-UHFFFAOYSA-N 5-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3NC(=O)OC3=CC=2)CC1 CCXXBUKDXVBBPU-UHFFFAOYSA-N 0.000 description 1
- KUGUXZHRSYTCDN-UHFFFAOYSA-N 5-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazole-2-carbonyl]-1,3-dihydroindol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3CC(=O)NC3=CC=2)CC1(C)C KUGUXZHRSYTCDN-UHFFFAOYSA-N 0.000 description 1
- XUVCKOJYWMCTKP-UHFFFAOYSA-N 6-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]-1,3-dihydroindol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3NC(=O)CC3=CC=2)CC1 XUVCKOJYWMCTKP-UHFFFAOYSA-N 0.000 description 1
- OIFWXETXOXMZRG-UHFFFAOYSA-N 6-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]-2,3-dihydroisoindol-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3C(=O)NCC3=CC=2)CC1 OIFWXETXOXMZRG-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000017357 Glycoprotein hormone receptor Human genes 0.000 description 1
- 108050005395 Glycoprotein hormone receptor Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 238000003692 Hiyama coupling reaction Methods 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000023108 LH Receptors Human genes 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- FZJCPMKRTUTFRK-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(1,3-dioxol-4-yl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=COCO1 FZJCPMKRTUTFRK-UHFFFAOYSA-N 0.000 description 1
- FIBKRXUYKQIFGT-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(2-fluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC=C1F FIBKRXUYKQIFGT-UHFFFAOYSA-N 0.000 description 1
- GZJFBSRTWBVQDO-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(3-fluoro-4-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(C)C(F)=C1 GZJFBSRTWBVQDO-UHFFFAOYSA-N 0.000 description 1
- KVTDWGIIAZUYSY-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(3-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(C)=C1 KVTDWGIIAZUYSY-UHFFFAOYSA-N 0.000 description 1
- AZFLWFBKIONHEG-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(3-phenoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(OC=2C=CC=CC=2)=C1 AZFLWFBKIONHEG-UHFFFAOYSA-N 0.000 description 1
- VZMYPWQPSUNACJ-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)N1C(C)(C)CC(C=2C=C(OC)C(OC)=CC=2)=N1 VZMYPWQPSUNACJ-UHFFFAOYSA-N 0.000 description 1
- IEYAZNKQEUPZNZ-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-(4-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(C)C=C1 IEYAZNKQEUPZNZ-UHFFFAOYSA-N 0.000 description 1
- CJHITLKUFCDCBG-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(OC(F)(F)F)=C1 CJHITLKUFCDCBG-UHFFFAOYSA-N 0.000 description 1
- AZJUNEQAJYACHR-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC(C(F)(F)F)=C1 AZJUNEQAJYACHR-UHFFFAOYSA-N 0.000 description 1
- CRTDGROXTIBEFN-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-[4-fluoro-3-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=C(F)C(C(F)(F)F)=C1 CRTDGROXTIBEFN-UHFFFAOYSA-N 0.000 description 1
- HFWORVVUFUNXAS-UHFFFAOYSA-N [3-(3,4-dimethoxyphenyl)-5,5-dimethyl-4h-pyrazol-1-yl]-phenylmethanone Chemical compound C1=C(OC)C(OC)=CC=C1C(CC1(C)C)=NN1C(=O)C1=CC=CC=C1 HFWORVVUFUNXAS-UHFFFAOYSA-N 0.000 description 1
- KCNFNUAQDOBYFJ-UHFFFAOYSA-N [3-(difluoromethoxy)phenyl]-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC(F)F)C=CC=2)CC1 KCNFNUAQDOBYFJ-UHFFFAOYSA-N 0.000 description 1
- GTFCRQDBUSIRPA-UHFFFAOYSA-N [5-(1-benzofuran-2-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2OC3=CC=CC=C3C=2)=C1 GTFCRQDBUSIRPA-UHFFFAOYSA-N 0.000 description 1
- FIIMHDXAVLSQMT-UHFFFAOYSA-N [5-(1-benzofuran-5-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3C=COC3=CC=2)=C1 FIIMHDXAVLSQMT-UHFFFAOYSA-N 0.000 description 1
- YHPATXFQCVNQPZ-UHFFFAOYSA-N [5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3OCCOC3=CC=2)=C1 YHPATXFQCVNQPZ-UHFFFAOYSA-N 0.000 description 1
- WYIJKDLLLQYPLP-UHFFFAOYSA-N [5-(2,3-dihydro-1-benzofuran-5-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3CCOC3=CC=2)=C1 WYIJKDLLLQYPLP-UHFFFAOYSA-N 0.000 description 1
- LIKYEPRRQDPHNQ-UHFFFAOYSA-N [5-(2,3-dihydro-1h-inden-5-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3CCCC3=CC=2)=C1 LIKYEPRRQDPHNQ-UHFFFAOYSA-N 0.000 description 1
- PIWBGIFEPGRBQD-UHFFFAOYSA-N [5-(2,3-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound COC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1OC PIWBGIFEPGRBQD-UHFFFAOYSA-N 0.000 description 1
- FHLDYDGFDOYBGB-UHFFFAOYSA-N [5-(2,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound COC1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 FHLDYDGFDOYBGB-UHFFFAOYSA-N 0.000 description 1
- RKBLIGYZMMNNKD-UHFFFAOYSA-N [5-(2-aminophenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound NC1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 RKBLIGYZMMNNKD-UHFFFAOYSA-N 0.000 description 1
- LUHSJFHUYYTRSZ-UHFFFAOYSA-N [5-(2-aminopyrimidin-5-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=NC(N)=NC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 LUHSJFHUYYTRSZ-UHFFFAOYSA-N 0.000 description 1
- RVWXCBLUFMYGJF-UHFFFAOYSA-N [5-(2-chloro-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound ClC1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 RVWXCBLUFMYGJF-UHFFFAOYSA-N 0.000 description 1
- QNQUPUGDABZJDK-UHFFFAOYSA-N [5-(2-fluoro-3-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound COC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1F QNQUPUGDABZJDK-UHFFFAOYSA-N 0.000 description 1
- OSIIIYUGKDAPQL-UHFFFAOYSA-N [5-(2-fluoro-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 OSIIIYUGKDAPQL-UHFFFAOYSA-N 0.000 description 1
- KLTBFXMBXRFHEC-UHFFFAOYSA-N [5-(3,4-dihydro-2h-chromen-6-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3CCCOC3=CC=2)=C1 KLTBFXMBXRFHEC-UHFFFAOYSA-N 0.000 description 1
- CSPWRQHOZYQPNC-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(2,3,4-trifluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(F)=CC=2)F)CC1 CSPWRQHOZYQPNC-UHFFFAOYSA-N 0.000 description 1
- IURJXIQQXOFCPA-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-ethylphenyl)methanone Chemical compound CCC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(OC)C(OC)=CC=2)=C1 IURJXIQQXOFCPA-UHFFFAOYSA-N 0.000 description 1
- FCQKLCFHSDBMFZ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluoro-2-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)C)CC1 FCQKLCFHSDBMFZ-UHFFFAOYSA-N 0.000 description 1
- BUJHXSSOAOMENU-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluoro-4-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(C)=CC=2)CC1 BUJHXSSOAOMENU-UHFFFAOYSA-N 0.000 description 1
- QEBZGTASGZPIEL-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-hydroxy-4-methoxyphenyl)methanone Chemical compound C1=C(O)C(OC)=CC=C1C(=O)N1N=C(C=2C=C(OC)C(OC)=CC=2)CC1 QEBZGTASGZPIEL-UHFFFAOYSA-N 0.000 description 1
- ULZCTGHROREODO-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(OC)C(OC)=CC=2)=C1 ULZCTGHROREODO-UHFFFAOYSA-N 0.000 description 1
- WMXVPFFZGBUEBW-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C)C=CC=2)CC1 WMXVPFFZGBUEBW-UHFFFAOYSA-N 0.000 description 1
- FVPWRRFGYJXJGE-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-methylsulfonylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)S(C)(=O)=O)CC1 FVPWRRFGYJXJGE-UHFFFAOYSA-N 0.000 description 1
- QDYKQTQDUZWTGN-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-phenoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC=3C=CC=CC=3)C=CC=2)CC1 QDYKQTQDUZWTGN-UHFFFAOYSA-N 0.000 description 1
- RTLSXZWTKOAWCQ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-phenylmethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OCC=3C=CC=CC=3)C=CC=2)CC1 RTLSXZWTKOAWCQ-UHFFFAOYSA-N 0.000 description 1
- MVPSNMHEEPLEBD-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-phenylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C=2C=CC=CC=2)CC1 MVPSNMHEEPLEBD-UHFFFAOYSA-N 0.000 description 1
- JQBBUAHPBHJYGL-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC(C)C)C=CC=2)CC1 JQBBUAHPBHJYGL-UHFFFAOYSA-N 0.000 description 1
- RNXAVHVLUCMNTJ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(4-fluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC(F)=CC=2)CC1 RNXAVHVLUCMNTJ-UHFFFAOYSA-N 0.000 description 1
- ZOOXHPIQXYQRCU-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(4-hydroxy-3-methoxyphenyl)methanone Chemical compound C1=C(O)C(OC)=CC(C(=O)N2N=C(CC2)C=2C=C(OC)C(OC)=CC=2)=C1 ZOOXHPIQXYQRCU-UHFFFAOYSA-N 0.000 description 1
- REFDXXUZWYJXJK-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(6-nitro-1,3-benzodioxol-5-yl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=CC=3OCOC=3C=2)[N+]([O-])=O)CC1 REFDXXUZWYJXJK-UHFFFAOYSA-N 0.000 description 1
- QXOKSXVCSSOVKP-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-[3-(2-methyl-1,3-thiazol-4-yl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C=2N=C(C)SC=2)CC1 QXOKSXVCSSOVKP-UHFFFAOYSA-N 0.000 description 1
- RBUYGJPOOGZOEU-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)N(C)C)CC1 RBUYGJPOOGZOEU-UHFFFAOYSA-N 0.000 description 1
- VWCCMHAYFXCOCZ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC(F)(F)F)C=CC=2)CC1 VWCCMHAYFXCOCZ-UHFFFAOYSA-N 0.000 description 1
- RNZFNYGKCKBBRD-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 RNZFNYGKCKBBRD-UHFFFAOYSA-N 0.000 description 1
- WVXMBSPGKZOZFH-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-[3-fluoro-2-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)C(F)(F)F)CC1 WVXMBSPGKZOZFH-UHFFFAOYSA-N 0.000 description 1
- JNAXDVOOXPMJDD-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-[3-fluoro-4-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(=CC=2)C(F)(F)F)CC1 JNAXDVOOXPMJDD-UHFFFAOYSA-N 0.000 description 1
- QLVBRFLJUNRZAQ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazol-2-yl]-quinolin-6-ylmethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3C=CC=NC3=CC=2)CC1 QLVBRFLJUNRZAQ-UHFFFAOYSA-N 0.000 description 1
- AHLONMQYYXMOHK-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(2,3,4,5-tetrafluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(F)=C(F)C=2)F)CC1(C)C AHLONMQYYXMOHK-UHFFFAOYSA-N 0.000 description 1
- ZMJUKGGDXNFBSX-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(2,3,4-trifluorophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C(F)=CC=2)F)CC1(C)C ZMJUKGGDXNFBSX-UHFFFAOYSA-N 0.000 description 1
- BXWHYUIBWHCWOK-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-ethoxyphenyl)methanone Chemical compound CCOC1=CC=CC(C(=O)N2N=C(C(C)(C)C2)C=2C=C(OC)C(OC)=CC=2)=C1 BXWHYUIBWHCWOK-UHFFFAOYSA-N 0.000 description 1
- GGGFOCWBVHNDEH-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-fluoro-2-methoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)OC)CC1(C)C GGGFOCWBVHNDEH-UHFFFAOYSA-N 0.000 description 1
- OWZVEXXSXZIPQV-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-fluoro-2-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)C)CC1(C)C OWZVEXXSXZIPQV-UHFFFAOYSA-N 0.000 description 1
- YFWVLBJBHQHROL-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-fluoro-4-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(C)=CC=2)CC1(C)C YFWVLBJBHQHROL-UHFFFAOYSA-N 0.000 description 1
- WPIWGEOWGGHVQZ-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-hydroxy-4-methoxyphenyl)methanone Chemical compound C1=C(O)C(OC)=CC=C1C(=O)N1N=C(C=2C=C(OC)C(OC)=CC=2)C(C)(C)C1 WPIWGEOWGGHVQZ-UHFFFAOYSA-N 0.000 description 1
- UKGQUCUOWJLZDC-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)N2N=C(C(C)(C)C2)C=2C=C(OC)C(OC)=CC=2)=C1 UKGQUCUOWJLZDC-UHFFFAOYSA-N 0.000 description 1
- XMLTVKRQWSPONU-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-methylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C)C=CC=2)CC1(C)C XMLTVKRQWSPONU-UHFFFAOYSA-N 0.000 description 1
- BBKKVKJATPVLGT-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-methylsulfonylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)S(C)(=O)=O)CC1(C)C BBKKVKJATPVLGT-UHFFFAOYSA-N 0.000 description 1
- LECLPRDFDQKQSN-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-phenoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC=3C=CC=CC=3)C=CC=2)CC1(C)C LECLPRDFDQKQSN-UHFFFAOYSA-N 0.000 description 1
- GIPRWORTNPFYCT-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-phenylmethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OCC=3C=CC=CC=3)C=CC=2)CC1(C)C GIPRWORTNPFYCT-UHFFFAOYSA-N 0.000 description 1
- OKTKIWLCVDUBOM-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-phenylphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C=2C=CC=CC=2)CC1(C)C OKTKIWLCVDUBOM-UHFFFAOYSA-N 0.000 description 1
- GIHCMPKTKLBQPI-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-(3-propan-2-yloxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC(C)C)C=CC=2)CC1(C)C GIHCMPKTKLBQPI-UHFFFAOYSA-N 0.000 description 1
- HWWXCCXESOKIMG-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-[3-(dimethylamino)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)N(C)C)CC1(C)C HWWXCCXESOKIMG-UHFFFAOYSA-N 0.000 description 1
- QVJCBCLRADKXQB-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(OC(F)(F)F)C=CC=2)CC1(C)C QVJCBCLRADKXQB-UHFFFAOYSA-N 0.000 description 1
- VABZMHMRNYQQGN-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1(C)C VABZMHMRNYQQGN-UHFFFAOYSA-N 0.000 description 1
- WMYVMIHRMQSPHB-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-[3-fluoro-2-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C(=C(F)C=CC=2)C(F)(F)F)CC1(C)C WMYVMIHRMQSPHB-UHFFFAOYSA-N 0.000 description 1
- WKXRJEAVODQZME-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-[3-fluoro-4-(trifluoromethyl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C(=CC=2)C(F)(F)F)CC1(C)C WKXRJEAVODQZME-UHFFFAOYSA-N 0.000 description 1
- NNZFKXUVXLJRQI-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-phenylmethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=CC=CC=2)CC1(C)C NNZFKXUVXLJRQI-UHFFFAOYSA-N 0.000 description 1
- FVBRDTHSGLLWDP-UHFFFAOYSA-N [5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazol-2-yl]-quinolin-6-ylmethanone Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C3C=CC=NC3=CC=2)CC1(C)C FVBRDTHSGLLWDP-UHFFFAOYSA-N 0.000 description 1
- KDGKSYWIIFCLTA-UHFFFAOYSA-N [5-(3,5-dimethyl-1,2-oxazol-4-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound CC1=NOC(C)=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 KDGKSYWIIFCLTA-UHFFFAOYSA-N 0.000 description 1
- ZJGUUBRLUBCWMX-UHFFFAOYSA-N [5-(3-amino-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(N)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 ZJGUUBRLUBCWMX-UHFFFAOYSA-N 0.000 description 1
- DOGHYHBPKBPWTK-UHFFFAOYSA-N [5-(3-aminophenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound NC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 DOGHYHBPKBPWTK-UHFFFAOYSA-N 0.000 description 1
- LJAOMVRYJHJJEI-UHFFFAOYSA-N [5-(3-chloro-2-methoxypyridin-4-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound COC1=NC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1Cl LJAOMVRYJHJJEI-UHFFFAOYSA-N 0.000 description 1
- MSTNDXRSBCZZPQ-UHFFFAOYSA-N [5-(3-chloro-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(Cl)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 MSTNDXRSBCZZPQ-UHFFFAOYSA-N 0.000 description 1
- HUUSTUALCKTAJQ-UHFFFAOYSA-N [5-(3-cyclopentyloxy-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound COC1=CC=C(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)C=C1OC1CCCC1 HUUSTUALCKTAJQ-UHFFFAOYSA-N 0.000 description 1
- VNPRKJWPYMMFNX-UHFFFAOYSA-N [5-(3-ethoxy-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(OC)C(OCC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 VNPRKJWPYMMFNX-UHFFFAOYSA-N 0.000 description 1
- QSSZBSVDEAXSCC-UHFFFAOYSA-N [5-(3-ethoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound CCOC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 QSSZBSVDEAXSCC-UHFFFAOYSA-N 0.000 description 1
- PWKZUEUVUIBRBK-UHFFFAOYSA-N [5-(3-fluoro-4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(F)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 PWKZUEUVUIBRBK-UHFFFAOYSA-N 0.000 description 1
- CBGJAOZYIZHEQA-UHFFFAOYSA-N [5-(4-chloro-3-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(Cl)C(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 CBGJAOZYIZHEQA-UHFFFAOYSA-N 0.000 description 1
- LQBJAQFOGWNCNY-UHFFFAOYSA-N [5-(4-ethenylphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=CC(C=C)=CC=2)=C1 LQBJAQFOGWNCNY-UHFFFAOYSA-N 0.000 description 1
- QQFDFSISKOBCHJ-UHFFFAOYSA-N [5-(4-ethylphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=CC(CC)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 QQFDFSISKOBCHJ-UHFFFAOYSA-N 0.000 description 1
- HSBFJOJUURSSHM-UHFFFAOYSA-N [5-(4-fluoro-3-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(F)C(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 HSBFJOJUURSSHM-UHFFFAOYSA-N 0.000 description 1
- QZVRWYVTKMKYPD-UHFFFAOYSA-N [5-(4-tert-butylphenyl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 QZVRWYVTKMKYPD-UHFFFAOYSA-N 0.000 description 1
- OGJXFHMPQGVISP-UHFFFAOYSA-N [5-(5-chloro-2-methoxypyridin-3-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound COC1=NC=C(Cl)C=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 OGJXFHMPQGVISP-UHFFFAOYSA-N 0.000 description 1
- HGFJYHLTUVPKTF-UHFFFAOYSA-N [5-(5-chloro-6-methoxypyridin-3-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=C(Cl)C(OC)=NC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 HGFJYHLTUVPKTF-UHFFFAOYSA-N 0.000 description 1
- HYCXAOVCRLPYRX-UHFFFAOYSA-N [5-(5-fluoro-2-methoxypyridin-4-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=NC(OC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1F HYCXAOVCRLPYRX-UHFFFAOYSA-N 0.000 description 1
- RQXQJSBNITWXFZ-UHFFFAOYSA-N [5-(6-aminopyridin-3-yl)-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=NC(N)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 RQXQJSBNITWXFZ-UHFFFAOYSA-N 0.000 description 1
- HPJKUKIQHNLDGC-UHFFFAOYSA-N [5-[(2,4-difluorophenyl)methylamino]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(NCC=3C(=CC(F)=CC=3)F)CC2)=C1 HPJKUKIQHNLDGC-UHFFFAOYSA-N 0.000 description 1
- NMXUULHWDOVFMN-UHFFFAOYSA-N [5-[(3,4-difluorophenyl)methylamino]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(NCC=3C=C(F)C(F)=CC=3)CC2)=C1 NMXUULHWDOVFMN-UHFFFAOYSA-N 0.000 description 1
- RAOJNEFHXRAUSL-UHFFFAOYSA-N [5-[1-(benzenesulfonyl)indol-6-yl]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C3N(C=CC3=CC=2)S(=O)(=O)C=2C=CC=CC=2)=C1 RAOJNEFHXRAUSL-UHFFFAOYSA-N 0.000 description 1
- MMCYVULQQGEEQW-UHFFFAOYSA-N [5-[2-(dimethylamino)phenyl]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound CN(C)C1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 MMCYVULQQGEEQW-UHFFFAOYSA-N 0.000 description 1
- PWWWIOTVFQAKGZ-UHFFFAOYSA-N [5-[2-(dimethylamino)pyrimidin-5-yl]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=NC(N(C)C)=NC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 PWWWIOTVFQAKGZ-UHFFFAOYSA-N 0.000 description 1
- BGNWLDUZJJSWRY-UHFFFAOYSA-N [5-[3-(dimethylamino)phenyl]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound CN(C)C1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 BGNWLDUZJJSWRY-UHFFFAOYSA-N 0.000 description 1
- RIZPZVRMQAZYBN-UHFFFAOYSA-N [5-[4-[(dimethylamino)methyl]phenyl]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=CC(CN(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 RIZPZVRMQAZYBN-UHFFFAOYSA-N 0.000 description 1
- BXVNYILNDLWXJF-UHFFFAOYSA-N [5-[6-(dimethylamino)pyridin-3-yl]-3,4-dihydropyrazol-2-yl]-(3-fluorophenyl)methanone Chemical compound C1=NC(N(C)C)=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 BXVNYILNDLWXJF-UHFFFAOYSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000011872 anthropometric measurement Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- NJYKPYJDYQLJIL-UHFFFAOYSA-N boronoformic acid Chemical compound OB(O)C(O)=O NJYKPYJDYQLJIL-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Chemical class 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- HZXXSCOUSGLRRX-UHFFFAOYSA-N cyanoboronic acid Chemical compound OB(O)C#N HZXXSCOUSGLRRX-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LLTVGKHHDXGLMR-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.OC.ClCCl LLTVGKHHDXGLMR-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- UTXVCHVLDOLVPC-UHFFFAOYSA-N ethyl 3-methylbut-2-enoate Chemical compound CCOC(=O)C=C(C)C UTXVCHVLDOLVPC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- FOHAUVGMODKVMD-UHFFFAOYSA-N n,n-diethyl-5-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]-2-methoxybenzenesulfonamide Chemical compound C1=C(OC)C(S(=O)(=O)N(CC)CC)=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 FOHAUVGMODKVMD-UHFFFAOYSA-N 0.000 description 1
- IVIVXEBFYPTYEW-UHFFFAOYSA-N n-[2-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC=C1C1=NN(C(=O)C=2C=C(F)C=CC=2)CC1 IVIVXEBFYPTYEW-UHFFFAOYSA-N 0.000 description 1
- ZJBFZELSXJCBDA-UHFFFAOYSA-N n-[3-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2CCN(N=2)C(=O)C=2C=C(F)C=CC=2)=C1 ZJBFZELSXJCBDA-UHFFFAOYSA-N 0.000 description 1
- IVJPCMCYWGESHJ-UHFFFAOYSA-N n-[3-[5-(3,4-dimethoxyphenyl)-3,4-dihydropyrazole-2-carbonyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(NC(C)=O)C=CC=2)CC1 IVJPCMCYWGESHJ-UHFFFAOYSA-N 0.000 description 1
- YQZFHQUQUWASBL-UHFFFAOYSA-N n-[3-[5-(3,4-dimethoxyphenyl)-4,4-dimethyl-3h-pyrazole-2-carbonyl]phenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN(C(=O)C=2C=C(NC(C)=O)C=CC=2)CC1(C)C YQZFHQUQUWASBL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XXAVTOUDQNQNSV-UHFFFAOYSA-N n-cyclopentyl-3-[2-(3-fluorobenzoyl)-3,4-dihydropyrazol-5-yl]benzamide Chemical compound FC1=CC=CC(C(=O)N2N=C(CC2)C=2C=C(C=CC=2)C(=O)NC2CCCC2)=C1 XXAVTOUDQNQNSV-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 229940127264 non-peptide agonist Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000001282 organosilanes Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
驚いたことに、本発明による化合物とその塩が、非常に有益な薬理特性を有すると同時に、良好な耐容性を示すことがわかった。特に、それらはFSHR作動薬として機能する。本発明は、式(I)
R、Lは、Ar1又はHet1であり;
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、NHCOY、CN、SO2Y、-E-(CY2)p-Ar2、-E-(CY2)p-Het1又は-E-(CY2)p-Het3であり;
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、-CONY-Cyc、NO2、CN、SY、SOY、SO2Y、SO2NY2、NHSO2Y、アルケニル又は-E-(CY2)p-Ar2であり;
R3、R4、R5、R6は、互いに独立してH、A又はAr2であり;
R7は、Y、OY又はNY2であり;
X1、X2、X3、X4は、互いに独立してO、NY又は単結合であり、但し、X1及びX2が単結合の場合、mは0であり;
Eは、-C≡C-、SO2、-SO2-NY-、O、NY又は単結合であり;
Yは、H又はAであり;
Cycは、3-7個の炭素原子を有するシクロアルキルであると共に、1-4個の水素原子は互いに独立してHal又はAと置換可能であり;
Ar1は、飽和、不飽和又は芳香族の、3-10個の炭素原子を有する単環又は二環式の炭素環であると共に、R1、R2、及び-C≡C-C(A)2OHの群から選択される少なくとも1つの置換基によって置換可能であるか、又はCyc、Het1又はHet3に融合可能であり;
Ar2は、芳香族の、6-10個の炭素原子を有する単環又は二環式の炭素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり;
Het2は、5-7個の炭素原子及び1-3個の窒素原子を有する芳香族単環式複素環であると共に、Hal、A、及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり;
Het3は、3-7個の炭素原子及び1-4個のN、O、及び/又はS原子を有する飽和単環式複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、COY、-CONY2、=O、及びCNの群から選択される少なくとも1つの置換基によって置換可能であり;
Halは、F、Cl、Br又はIであり;
m、n、pは、互いに独立して0、1、2、3又は4である)
の化合物、及び/又は生理的に許容されるその塩に関する。
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、CONY2、NHCOA、CN、SO2A、-E-(CY2)p-Ar2、Het1又は-E-Het3であり;
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、CONY2、-CONH-Cyc、NO2、CN、SA、SOA、SO2A、SO2NY2、NHSO2A、アルケニル、-E-(CY2)p-Ar2又はHet1であり;
R3、R4、R5、R6は、互いに独立してH又はAであり;
R7は、H、OA又はNA2であり;
Eは、-C≡C-、SO2、-SO2-NH-、O又は単結合であり;
Yは、H又はAであり;
Cycは、3-5個の炭素原子を有するシクロアルキルであり;
Ar1は、5-8個の炭素原子を有する芳香族の単環式炭素環であり;
Ar2は、フェニルであり;
Het1は、3-6個の炭素原子及び1-3個のN、O、及び/又はS原子を有する不飽和又は芳香族の単環式複素環であると共に、Hal、A、及びOAの群から選択される少なくとも1個の置換基によって置換可能であり;
Het3は、3-6個の炭素原子及び1-2個のN、及び/又はO原子を有する飽和単環式複素環であると共に、Hal、COA、及び=Oの群から選択される少なくとも1個の置換基によって置換可能であり;
m、p、qは、互いに独立して0、1、2又は3である)
のジヒドロピラゾール誘導体、及び/又は生理的に許容されるその塩が提供される。
本発明のより好ましい実施形態において、部分式(I-B)
R1は、Hal、A、CN、-E-フェニル又はHet3であり;
R2は、Hal、A、OA、NH2、CN、SA、SO2A、SO2NH2、O-フェニル又はHet1であり;
R3、R4は、Hであり、且つ
R5、R6は、Aであるか、又は逆もまた同様であり;
Eは、O又は単結合であり;
Aは、1-5個の炭素原子を有する非分岐又は分岐のアルキルであり;
Het3は、ピロリジニル、テトラヒドロフリル、オキサゾリジニル、ジオキサラニル、ピペラジニル、モルホリニル又はジオキサニルであると共にHal、COA、及び=Oの群から選択される少なくとも1個の置換基によって一又は二置換されることができ;
Halは、F、Cl又はBrであり;
mは、0又は1である)
のジヒドロピラゾール誘導体、及び/又は生理的に許容されるその塩を提供する。
(a)式(II)
を含む方法にも関する。
R、Lは、互いに独立してAr1、Het1、A又はOYであり、
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、NHCOY、CN、SO2Y、-E-(CY2)p-Ar2、-E-(CY2)p-Het1又は-E-(CY2)p-Het3であり、
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COY、COOY、CONY2、-CONY-Cyc、-O-Cyc、NO2、CN、SY、SOY、SO2Y、SO2NY2、NHSO2Y、アルケニル又は-E-(CY2)p-Ar2であり、
R3、R4、R5、R6は、互いに独立してH、A又はAr2であり、
R7は、Y、OY又はNY2であり、
X1、X2、X3、X4は、互いに独立してO、NY又は単結合であり、
Eは、-C≡C-、SO2、-SO2-NY-、O、NY又は単結合であり、
Yは、H又はAであり、
Cycは、3-7個の炭素原子を有するシクロアルキルであると共に、1-4個の水素原子は互いに独立してHal又はAと置換可能であり、
Ar1は、3-10個の炭素原子を有する飽和、不飽和又は芳香族の、単環又は二環式の炭素環であると共に、R1、R2及び-C≡C-C(A)2OHの群から選択される少なくとも1つの置換基によって置換可能であり、且つ/又はCyc、Het1又はHet3に融合可能であり、
Ar2は、6-10個の炭素原子を有する芳香族の、単環又は二環式の炭素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het2は、5-7個の炭素原子及び1-3個のN原子を有する芳香族単環式複素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het3は、3-7個の炭素原子及び1-4個のN、O及び/又はS原子を有する飽和単環式複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、COY、-CONY2、=O及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Halは、F、Cl、Br又はIであり、
m、n、pは、互いに独立して0、1、2、3又は4である)
の化合物、及び/又は生理的に許容されるその塩と接触させることを含む方法に関する。
R、Lは、互いに独立してAr1、Het1、A又はOYであり;
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、NHCOY、CN、SO2Y、-E-(CY2)p-Ar2、-E-(CY2)p-Het1又は-E-(CY2)p-Het3であり;
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COY、COOY、CONY2、-CONY-Cyc、-O-Cyc、NO2、CN、SY、SOY、SO2Y、SO2NY2、NHSO2Y、アルケニル又は-E-(CY2)p-Ar2であり;
R3、R4、R5、R6は、互いに独立してH、A又はAr2であり;
R7は、Y、OY又はNY2であり;
X1、X2、X3、X4は、互いに独立してO、NY又は単結合であり;
Eは、-C≡C-、SO2、-SO2-NY-、O、NY又は単結合であり;
Yは、H又はAであり;
Cycは、3-7個の炭素原子を有するシクロアルキルであると共に、1-4個の水素原子は互いに独立してHal又はAと置換可能であり;
Ar1は、飽和、不飽和又は芳香族の、3-10個の炭素原子を有する単環又は二環式の炭素環であると共に、R1、R2及び-C≡C-C(A)2OHの群から選択される少なくとも1つの置換基によって置換可能であり、且つ/又はCyc、Het1又はHet3に融合可能であり;
Ar2は、6-10個の炭素原子を有する芳香族の、単環又は二環式の炭素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり;
Het2は、5-7個の炭素原子及び1-3個のN原子を有する芳香族単環式複素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり;
Het3は、3-7個の炭素原子及び1-4個のN、O及び/又はS原子を有する飽和単環式複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、COY、-CONY2、=O及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Halは、F、Cl、Br又はIであり;
m、n、pは、互いに独立して0、1、2、3又は4である)
の化合物、及び/又は生理的に許容されるその塩に関係する。
NMRスペクトルは、Automation Triple Broadband(ATB)プローブを備えたVarian Unity Inova400MHzのNMR分光計で得た。ATBプローブは、1H、19F及び13Cに同時に調整されていた。典型的1H NMRスペクトルについて、パルス角は45度であり、8回のスキャンを合計し、スペクトル幅は16ppm(−2ppmから14ppm)であった。合計32768の複合ポイントを5.1秒の取得時間内に収集し、リサイクル遅延は1秒に設定した。スペクトルは25℃で収集し、1H NMRスペクトルは典型的には、フーリエ変換の前に、0.2Hzの線幅拡大及び131072点でのゼロ充填によって処理した。
島津Shin-pack XR-ODS、3.0×30mm、2.2μmを、温度50℃及び流量1.5mL/分、2μLの注入で使用した、移動相:(A)水に0.1%ギ酸及び1%アセトニトリル、移動相(B)メタノールに0.1%ギ酸;保持時間は分の単位で与える。方法の詳細:(I)バイナリポンプG1312B、UV/Visダイオードアレイ検出器G1315C、及びAgilent6130質量分析計の正及び負のイオンエレクトロスプレーモード、220nm及び254nmでのUV検出において、2.2分の直線勾配で15〜95%(B)の勾配にて走行、(II)95%(B)で0.8分保持、(III)0.1分の直線勾配で95%〜15%(B)で減少、(IV)15%(B)で0.29分保持。
Aglient Zorbax Bonus RP、2.1×50mm、3.5μmを、温度50℃及び流量0.8mL/分、2μLの注入で使用した、移動相:(A)水に0.1%ギ酸%及び1%アセトニトリル、移動相(B)メタノールに0.1%ギ酸;保持時間は分の単位で与える。方法の詳細:(I)バイナリポンプG1312B、UV/Visダイオードアレイ検出器G1315C及びAgilent6130質量分析計の正及び負のイオンエレクトロスプレーモード、220nm及び254nmでのUV検出において、2.5分の直線勾配で5〜95%(B)の勾配にて走行、(II)95%(B)で0.5分保持、(III)0.1分の直線勾配で95%〜5%(B)で減少、(IV)5%(B)で0.29分保持。
スキーム1
工程1
撹拌子と窒素入口を備えた丸底フラスコに、ベラトロール(2.5mL、20mmol)、3.3-ジメチルアクリロイルクロライド(2.2mL、20mmol)及び無水CH2Cl2(100mL)を入れた。その溶液を、0℃に冷やし、そして、AlCl3(2.6g、20mmol)を分割して加えた。添加完了時に、冷却浴を取り外し、3時間反応させた。TLCはSMの消費を示した。それを飽和NH4Cl(100mL)に加え、そして、15分間強く撹拌した。相を分離し、そして、CH2Cl2相を、飽和Na2CO3(100mL)で洗浄し、塩水(100mL)で洗浄し、乾燥させ(Na2SO4)、そして、溶媒を減圧下で留去した。その物質を、次の工程でそのままで使用した。得られた量:19.5mmol、4.3g、98%の収率。LC-MS(ESI)m/e 221(M+H). 1H NMR(400 MHz, CHLOROFORM-d)δ ppm 2.02(s, 3H)2.20(s, 3H)3.96(s, 6H)6.73(s, 1H)6.89(d, J=8.20 Hz, 1H)7.53 - 7.60(m, 2H)。
撹拌子、Vigreuxカラム及び窒素入口を備えた100mL容の丸底フラスコに、1-(3,4-ジメトキシ-フェニル)-3-メチル-ブタ-2-エン-1-オン(1.4g、10mmol)、EtOH(40mL)、及びヒドラジン一水和物(0.58mL、12mmol)を入れた。その混合物を、80℃にて2時間加熱した。LC-MS及びTLC分析はSMの消費を示した。溶媒を減圧下で留去し、そして、微量のヒドラジン及びEtOHを、高真空下で30分間取り除いた。その物質を、次の工程に使用した。得られた量:2.3g、10mmol、100%の収率。LC-MS(ESI)m/e 235(M+H)。
撹拌子を備えたシンチレーションバイアルに、3-(3,4-ジメトキシ-フェニル)-5,5-ジメチル-4,5-ジヒドロ-1H-ピラゾール(469mg、2mmol)、ヒューニッヒ塩基(1mL、6mmol)及び無水CH2Cl2(10mL)を入れた。この混合物に、3-フルオロベンゾイルクロライド(0.23mL、2mmol)を加え、そして、その反応物を室温にて3時間撹拌した。LC-MSはSMの消費を示した。その混合物を、CH2Cl2(50mL)で希釈し、そして、水(50mL)に加えた。相を分離し、そして、CH2Cl2相を、飽和Na2CO3(50mL)、塩水(50mL)で洗浄し、乾燥させ(Na2SO4)、そして、溶媒を減圧下で留去した。その物質を、ヘプタン-EtOAcの0から50% EtOAcへのグラジエントを用いて溶出する40gのシリカカートリッジを使用することで精製した。得られた量:350mg、1mmol、50%の収率。LC-MS(ESI)m/e 357(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 1.79(s, 6H)3.17(s, 2 H)3.88(s, 3H)3.93(s, 3H)6.87(d, J=8.35 Hz, 1H)7.10(dd, J=8.32, 1.83 Hz, 1H)7.15(td, J=8.33, 2.03 Hz, 1H)7.28(d, J=1.76 Hz, 1H)7.38(td, J=7.92, 5.88 Hz, 1H)7.62 - 7.69(m, 2 H)。
スキーム2
撹拌子、Vigreuxカラム及び窒素入口を備えた100mL容の丸底フラスコに、3-メチル-ブタ-2-エン酸エチルエステル(1.4mL、10mmol)、EtOH(10mL)及びヒドラジン一水和物(0.58mL、12mmol)を入れた。その混合物を80℃にて2時間加熱した。LC-MS及びTLC分析はSMの消費を示した。溶媒を減圧下で留去し、そして、微量のヒドラジン及びEtOHを高真空下で30分間取り除いた。その物質を、次の工程に使用した。得られた量:1.1g、10mmol、100%の収率。LC-MS(ESI)m/e 115(M+H)。
工程2
撹拌子を備えたシンチレーションバイアルに、5,5-ジメチル-ピラゾリジン-3-オン(228mg、2.0mmol)を入れ、そして、Et2O(2mL)中の2.0M HClを加えた。白色のPPTを形成した。これを、濾過し、そして、更なるEt2O(20mL)で洗浄した。得られた量:300mg、2.0mmol、100%の収率。
工程3
撹拌子、Vigreuxカラム及び窒素入口を備えた丸い50mL容の丸底フラスコに5,5-ジメチル-ピラゾリジン-3-オン塩酸塩(300mg、2.0mmol)及びPOCl3(4mL)を入れた。その混合物を90℃にて3時間加熱した。LC-MSはSMの消費を示した。POCl3を減圧下で留去し、そして、微量のPOCl3を高真空下で30分間取り除いた。得られた量:336mg、2.0mmol、100%の収率。その物質を、次の工程に使用した。
工程4
撹拌子及び窒素入口を備えた250mL容の丸底フラスコに、無水CH2Cl2(100mL)、ヒューニッヒ塩基(7.8mL、45mmol)、DMAP(5mg)及び3-フルオロベンゾイルクロライド(1.8mL15mmol)を入れた。混合物を0℃に冷やした。この混合物に、分割して3-クロロ-5,5-ジメチル4,5は-ジヒドロ-1H-ピラゾール塩酸塩(1.68g、10mmol)を加え、そして、反応物を、一晩室温まで加熱した。LC-MSはSMの消費を示した。反応物を水(100mL)に加え、相を分離し、そして、有機相を、NaHCO3(100mL)で洗浄し、乾燥させ(Na2SO4)そして、溶媒を減圧下で留去した。その物質を、ヘプタン-EtOAcの0から20% EtOAcへのグラジエントを用いて溶出する40gのシリカカートリッジを使用したクロマトグラフィーで精製した。得られた量:3.7mmol、0.9g、37%の収率。LC-MS(ESI)m/e 255(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 1.76(s, 6H)3.03(s, 2 H)7.14(td, J=8.36, 1.98 Hz, 1H)7.36(td, J=7.96, 5.71 Hz, 1H)7.43(dd, J=9.57, 2.25 Hz, 1H)7.51(d, J=7.76 Hz, 1H)。
撹拌子を備えたシンチレーションバイアルに、3-クロロ-5,5-ジメチル-4,5-ジヒドロ-ピラゾール-1-イル)-(3-フルオロフェニル)-メタノン(64mg、0.25mmol)、3,4-ジメトキシボロン酸(40mg、0.3mmol)、Cs2CO3(162mg、0.5mmol)及びDMF(5mL)を入れた。この混合物を、窒素で15分間脱気し、そして、Pd(PPh3)4(60mg、0.05mmol)を加えた。その溶液を、さらに15分間脱気し、そして、次に、それを80℃にて2時間加熱した。LC-MSはSMの消費を示した。その混合物を、水(50mL)に加え、EtOAc(50mL)で抽出し、有機相を、LiCl溶液(50mL)で洗浄し、乾燥させ(Na2SO4)、そして、溶媒を減圧下で留去した。その物質を、ヘプタン-EtOAcの0から30% EtOAcへのグラジエントを用いて溶出する12gのシリカカートリッジを使用したクロマトグラフィーによって精製した。得られた量:59 mg、0.19mmol、76%の収率。LC-MS(ESI)m/e 311(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 1.57(s, 6H)1.95(s, 1H)3.77(s, 3H)3.82(s, 3H)4.16(dd, J=12.25, 4.98 Hz, 1H)4.57(t, J=11.91 Hz, 1H)4.68(dd, 1H)6.68(d, J=8.39 Hz, 1H)6.98(dd, J=8.35, 1.85 Hz, 1H)7.13 - 7.22(m, 4H)7.36(d, J=8.20 Hz, 2H)7.42(td, J=8.07, 5.78 Hz, 1H)7.81 - 7.87(m, 2H)。
スキーム3
撹拌子を備えた50mL容の丸底フラスコに、ベラトロール(1.3mL、10mmol)及び3-クロロピバロイルクロライド(1.4g、10mmol)を入れた。この混合物に、ポリリン酸(20g)を加えた。その混合物を70℃にて2時間加熱した。[反応の経過のあとに続いて、ミニワークアップ及びNMR分析のためにアリコートを取り出した。]その物質を、氷水(100mL)/EtOAc(100mL)の混合物に加え、そして、ポリリン酸が溶解するまで撹拌した。相を分離し、そして、EtOAc相を飽和NaHCO3(100mL)で洗浄し、乾燥させ(Na2SO4)、そして、溶媒を減圧下で留去した。その物質を、次の工程でそのままで使用した。得られた量:9.3mmol、2.4g、93%の収率。LC-MS(ESI)m/e 257(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 1.51(s, 6H)3.83(s, 2H)3.93(s, 3H)3.95(s, 3H)6.87(d, J=8.44 Hz, 1H)7.37(d, J=1.95 Hz, 1H)7.48(dd, J=8.42, 1.98 Hz, 1H)。
工程2
撹拌子、Vigreuxカラム、及び窒素入口を備えた100mL容の丸底フラスコに、3-クロロ-1-(3,4-ジメトキシ-フェニル)-2,2-ジメチル-プロパン-1-オン(1.3g、5mmol)、EtOH(20mL)及びヒドラジン一水和物(0.3mL、6mmol)を入れた。その混合物を80℃にて2時間加熱した。LC-MS及びTLC分析はSMの消費を示した。溶媒を減圧下で留去し、そして、微量のヒドラジン及びEtOHを高真空下で30分間取り除いた。その物質を、次の工程に使用した。得られた量:1170mg、5mmol、100%の収率。LC-MS(ESI)m/e 235(M+H)。
工程3
撹拌子を備えたシンチレーションバイアルに、3-クロロ-1-(3,4-ジメトキシ-フェニル)-2,2-ジメチル-プロパン-1-オン(469mg、2mmol)、ヒューニッヒ塩基(1mL、6mmol)及び無水CH2Cl2(10mL)を入れた。この混合物に3-フルオロベンゾイルクロライド(0.23mL、2mmol)を加え、そして、その反応物を室温にて3時間撹拌した。LC-MSはSMの消費を示した。その混合物をCH2Cl2(50mL)で希釈し、そして、水(50mL)に加えた。相を分離し、そして、CH2Cl2相を、飽和Na2CO3(50mL)で洗浄し、乾燥させ(Na2SO4)、そして、溶媒を減圧下で留去した。その物質を、ヘプタン-EtOAcの0から50% EtOAcへのグラジエントを用いて溶出する40gのシリカカートリッジを使用することで精製した。得られた量:350mg、1mmol、50%の収率。LC-MS(ESI)m/e 357(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 1.58(s, 6H)3.89(s, 3H)3.93(s, 3H)4.05(s, 2H)6.87(d, J=8.39 Hz, 1H)7.18(td, J=8.31, 1.98 Hz, 1H)7.30 - 7.43(m, 3H)7.80(t, J=7.00 Hz, 2H)。
(3-ブロモ-フェニル)-[3-(3, 4-ジメトキシ-フェニル)-4, 4-ジメチル-4, 5-ジヒドロ-ピラゾール-1-イル]-メタノン
LC-MS: 質量の実測値(M+, 419)。Rt(分): 4.97; 面積比(%): 95.97(最大), 95.63(220 nm)。
HPLC - Rt(分): 4.94; 面積比(%): 98.17(最大), 97.86(254 nm)。
400 MHz, DMSO-d6: δ 8.12(s, 1H), 7.85-7.83(m, 1H), 7.73-7.71(m, 1H), 7.44(t, J = 8.00 Hz, 1H), 7.35-7.33(m, 1H), 7.27-7.26(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.92(s, 2H), 3.78(s, 3H), 3.76(s, 3H), 1.48(s, 6H)。
LC-MS: 質量の実測値(M+, 373)。Rt(分): 4.88; 面積比(%): 96.54(最大), 96.77(254 nm)。
HPLC - Rt(分): 4.87; 面積比(%): 98.76(最大), 99.01(254 nm)。
400 MHz, DMSO-d6: δ 7.96(s, 1H), 7.81-7.79(m, 1H), 7.60-7.58(m, 1H), 7.50(t, J = 8.00 Hz, 1H), 7.35-7.32(m, 1H), 7.26-7.25(m, 1H), 6.99(d, J = 12.00 Hz, 1H), 3.93(s, 2H), 3.78(s, 3H), 3.74(s, 3H), 1.48(s, 6H)。
LC-MS: 質量の実測値(M+, 369.3)。Rt(分): 4.42; 面積比(%): 95.08(最大), 96.50(254 nm)。
HPLC-Rt(分): 4.39; 面積比(%): 98.94(最大), 98.15(254 nm)。
400 MHz, DMSO-d6: δ 7.44-7.42(m, 2H), 7.38-7.31(m, 2H), 7.23(d, J = 4.00 Hz, 1H), 7.09-7.06(m, 1H), 6.99(d, J = 8.00 Hz, 1H), 3.91(s, 2H), 3.78(s, 6H), 3.73(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 383.3)。Rt(分): 4.71; 面積比(%): 97.98(最大), 98.48(220 nm)。
HPLC - Rt(分): 4.7; 面積比(%): 98.82(最大), 98.31(254 nm)。
400 MHz, DMSO-d6: δ 7.42-7.40(m, 2H), 7.37-7.31(m, 2H), 7.24(d, J = 4.00 Hz, 1H), 7.07-7.04(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 4.07-4.02(m, 2H), 3.91(s, 2H), 3.78(s, 3H), 3.73(s, 3H), 1.47(s, 6H), 1.31(t, J = 8.00 Hz, 3H)。
LC-MS: 質量の実測値(M+, 407.3)。Rt(分): 5.12; 面積比(%): 96.50(最大), 97.34(254 nm)。
HPLC - Rt(分): 5.3; 面積比(%): 98.42(最大), 98.15(254 nm)。
400 MHz, DMSO-d6: δ 8.29(s, 1H), 8.15-8.13(m, 1H), 7.91-7.89(m, 1H), 7.72(t, J = 8.00 Hz, 1H), 7.36(dd, J = 8.00, 4.00 Hz, 1H), 7.25(d, J = 4.00 Hz, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.96(s, 2H), 3.78(s, 3H), 3.71(s, 3H), 1.50(s, 6H)。
LC-MS: 質量の実測値(M+, 353.3)。Rt(分): 4.66; 面積比(%): 91.12(最大), 92.42(254 nm)。
HPLC - Rt(分): 4.64; 面積比(%): 94.23(最大), 95.13(254 nm)。
400 MHz, DMSO-d6: δ 7.71(s, 1H), 7.64-7.62(m, 1H), 7.35-7.31(m, 3H), 7.25-7.24(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.91(s, 2H), 3.78(s, 3H), 3.73(s, 3H), 2.35(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 364.3)。Rt(分): 4.36; 面積比(%): 96.95(最大), 96.43(254 nm)。
HPLC - Rt(分): 4.34; 面積比(%): 97.62(最大), 95.87(254 nm)。
400 MHz, DMSO-d6: δ 8.36(s, 1H), 8.15-8.13(m, 1H), 8.00-7.98(m, 1H), 7.69(t, J = 8.00 Hz, 1H), 7.35-7.33(m, 1H), 7.26-7.25(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.94(s, 2H), 3.78(s, 3H), 3.75(s, 3H), 1.49(s, 6H)。
LC-MS: 質量の実測値(M+, 423.3)。Rt(分): 5.24; 面積比(%): 99.09(最大), 98.87(254 nm)。
HPLC - Rt(分): 5.23; 面積比(%): 99.18(最大), 99.10(254 nm)。
400 MHz, DMSO-d6: δ 7.90-7.88(m, 2H), 7.61(t, J = 8.00 Hz, 1H), 7.55-7.53(m, 1H), 7.35(dd, J = 12.00, 4.00 Hz, 1H), 7.24-7.23(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.94(s, 2H), 3.78(s, 3H), 3.72(s, 3H), 1.49(s, 6H)。
LC-MS: 質量の実測値(M+, 382.3)。Rt(分): 3.22; 面積比(%): 91.47(最大), 92.60(254 nm)。
HPLC - Rt(分): 3.18; 面積比(%): 91.78(最大), 91.41(254 nm)。
400 MHz, DMSO-d6: δ 7.33(dd, J = 8.00, 4.00 Hz, 1H), 7.26-7.22(m, 3H), 7.14-7.12(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 6.87-6.84(m, 1H), 3.90(s, 2H), 3.78(s, 3H), 3.72(s, 3H), 2.91(s, 6H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 445.3)。Rt(分): 5.29; 面積比(%): 96.04(最大), 96.50(254 nm)。
HPLC - Rt(分): 5.49; 面積比(%): 98.40(最大), 97.32(254 nm)。
400 MHz, DMSO-d6: δ 7.53-7.52(m, 1H), 7.46-7.43(m, 3H), 7.39-7.35(m, 3H), 7.33-7.30(m, 2H), 7.24(s, 1H), 7.17(dd, J = 8.00, 4.00 Hz, 1H), 6.98(d, J = 12.00 Hz, 1H), 5.13(s, 2H), 3.91(s, 2H), 3.78(s, 3H), 3.67(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 397.3)。Rt(分): 4.45; 面積比(%): 95.91(最大), 96.11(254 nm)。
HPLC - Rt(分): 5.11; 面積比(%): 97.30(最大), 96.48(254 nm)。
400 MHz, DMSO-d6: δ 7.40-7.31(m, 4H), 7.24(d, J = 4.00 Hz, 1H), 7.06-7.03(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 4.65-4.59(m, 1H), 3.91(s, 2H), 3.78(s, 3H), 3.73(s, 3H), 1.47(s, 6H), 1.25(d, J = 8.00 Hz, 6H)。
LC-MS: 質量の実測値(M+, 431.3)。Rt(分): 5.29; 面積比(%): 98.33(最大), 98.71(254 nm)。
HPLC - Rt(分): 5.47; 面積比(%): 98.66(最大), 99.24(254 nm)。
400 MHz, DMSO-d6: δ 7.65(d, J = 8.00 Hz, 1H), 7.51-7.47(m, 2H), 7.39-7.35(m, 2H), 7.28(d, J = 8.00 Hz, 1H), 7.21-7.12(m, 3H), 7.03(d, J = 8.00 Hz, 2H), 6.97(d, J = 8.00 Hz, 1H), 3.90(s, 2H), 3.79(s, 3H), 3.69(s, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 415.3)。Rt(分): 5.23; 面積比(%): 97.14(最大), 98.20(254 nm)。
HPLC - Rt(分): 5.22; 面積比(%): 98.53(最大), 98.97(254 nm)。
400 MHz, DMSO-d6: δ 8.20(s, 1H), 7.83-7.79(m, 2H), 7.69(d, J = 8.00 Hz, 2H), 7.56(t, J = 8.00 Hz, 1H), 7.48(t, J = 4.00 Hz, 2H), 7.41-7.33(m, 2H), 7.20(s, 1H), 6.97(d, J = 12.00 Hz, 1H), 3.96(s, 2H), 3.77(s, 3H), 3.50(s, 3H), 1.50(s, 6H)。
LC-MS: 質量の実測値(M+, 395.3)。Rt(分): 5.39; 面積比(%): 96.81(最大), 96.96(220 nm)。
HPLC - Rt(分): 5.57; 面積比(%): 97.60(最大), 97.74(254 nm)。
400 MHz, DMSO-d6: δ 7.91(s, 1H), 7.66-7.64(m, 1H), 7.56-7.53(m, 1H), 7.40-7.34(m, 2H), 7.24(d, J = 4.00 Hz, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.92(s, 2H), 3.78(s, 3H), 3.71(s, 3H), 1.48(s, 6H), 1.30(s, 9H)。
LC-MS: 質量の実測値(M+, 417.3)。Rt(分): 3.89; 面積比(%): 96.94(最大), 96.17(220 nm)。
HPLC - Rt(分): 4.07; 面積比(%): 98.57(最大), 97.36(254 nm)。
400 MHz, DMSO-d6: δ 8.56(s, 1H), 8.19-8.17(m, 1H), 8.09-8.06(m, 1H), 7.76(t, J = 8.00 Hz, 1H), 7.38(dd, J = 8.00, 4.00 Hz, 1H), 7.30(d, J = 4.00 Hz, 1H), 6.97(d, J = 8.00 Hz, 1H), 3.97(s, 2H), 3.78(s, 3H), 3.75(s, 3H), 3.25(s, 3H), 1.50(s, 6H)。
LC-MS: 質量の実測値(M+, 396.3)。Rt(分): 3.62; 面積比(%): 98.93(最大), 99.25(254 nm)。
HPLC - Rt(分): 3.77; 面積比(%): 99.61(最大), 99.39(254 nm)。
400 MHz, DMSO-d6: δ 10.07(s, 1H), 8.19(s, 1H), 7.69-7.67(m, 1H), 7.51-7.49(m, 1H), 7.38-7.33(m, 2H), 7.30(d, J = 4.00 Hz, 1H), 6.97(d, J = 8.00 Hz, 1H), 3.92(s, 2H), 3.78(s, 3H), 3.74(s, 3H), 2.03(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 357.2)。Rt(分): 4.63; 面積比(%): 97.62(最大), 95.61(254 nm)。
HPLC - Rt(分): 4.56; 面積比(%): 96.57(最大), 95.51(254 nm)。
400 MHz, DMSO-d6: δ 7.97-7.94(m, 2H), 7.34-7.27(m, 3H), 7.23(d, J = 4.00 Hz, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.91(s, 2H), 3.78(s, 3H), 3.74(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 375)。Rt(分): 4.80; 面積比(%): 99.11(最大), 99.31(254 nm)。
HPLC - Rt(分): 4.82; 面積比(%): 97.49(最大), 98.77(254 nm)。
400 MHz, DMSO-d6: δ 7.98-7.93(m, 1H), 7.80-7.77(m, 1H), 7.57-7.51(m, 1H), 7.35(dd, J = 8.00, 4.00 Hz, 1H), 7.25(d, J = 4.00 Hz, 1H), 7.00(d, J = 12.00 Hz, 1H), 3.92(s, 2H), 3.78(s, 3H), 3.74(s, 3H), 1.48(s, 6H)。
LC-MS: 質量の実測値(M+, 425)。Rt(分): 5.35; 面積比(%): 99.05(最大), 99.46(254 nm)。
HPLC - Rt(分): 5.34; 面積比(%): 98.71(最大), 98.93(254 nm)。
400 MHz, DMSO-d6: δ 7.84-7.79(m, 2H), 7.35(dd, J = 8.00, 4.00 Hz, 1H), 7.27-7.22(m, 2H), 7.00(d, J = 8.00 Hz, 1H), 3.90(s, 2H), 3.79(s, 3H), 3.76(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 371.3)。Rt(分): 4.87; 面積比(%): 93.26(最大), 94.56(254 nm)。
HPLC - Rt(分): 4.86; 面積比(%): 95.35(最大), 94.94(254 nm)。
400 MHz, DMSO-d6: δ 7.68-7.65(m, 2H), 7.39-7.32(m, 2H), 7.25(d, J = 4.00 Hz, 1H), 6.99(d, J = 8.00 Hz, 1H), 3.91(s, 2H), 3.78(s, 3H), 3.75(s, 3H), 2.29(d, J = 4.00 Hz, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 387.3)。Rt(分): 4.53; 面積比(%): 98.58(最大), 99.07(254 nm)。
HPLC - Rt(分): 4.54; 面積比(%): 98.67(最大), 99.14(254 nm)。
400 MHz, DMSO-d6: δ 7.84-7.79(m, 2H), 7.35(dd, J = 8.00, 4.00 Hz, 1H), 7.27-7.22(m, 2H), 7.00(d, J = 8.00 Hz, 1H), 3.90(d, J = 4.00 Hz, 5H), 3.79(s, 3H), 3.76(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 437)。Rt(分): 5.12; 面積比(%): 97.72(最大), 98.70(254 nm)。
HPLC - Rt(分): 5.11; 面積比(%): 98.7(最大), 98.93(254 nm)。
400 MHz, DMSO-d6: δ 7.87-7.81(m, 2H), 7.69-7.67(m, 1H), 7.34(dd, J = 8.00, 4.00 Hz, 1H), 7.24(d, J = 4.00 Hz, 1H), 6.99(d, J = 8.00 Hz, 1H), 3.92(s, 2H), 3.78(s, 3H), 3.75(s, 3H), 1.48(s, 6H)。
LC-MS: 質量の実測値(M+, 375)。Rt(分): 4.55; 面積比(%): 97.31(最大), 97.42(254 nm)。
HPLC - Rt(分): 4.54; 面積比(%): 98.87(最大), 99.13(254 nm)。
400 MHz, DMSO-d6: δ 7.59-7.52(m, 1H), 7.38-7.35(m, 1H), 7.31-7.28(m, 1H), 7.25(dd, J = 8.00, 4.00 Hz, 1H), 7.10(d, J = 4.00 Hz, 1H), 6.97(d, J = 12.00 Hz, 1H), 3.93(s, 2H), 3.76(s, 3H), 3.67(s, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 371.3)。Rt(分): 4.60; 面積比(%): 92.64(最大), 94.86(254 nm)。
HPLC - Rt(分): 4.61; 面積比(%): 95.70(最大), 96.29(254 nm)。
400 MHz, DMSO-d6: δ 7.28-7.17(m, 4H), 7.04(d, J = 4.00 Hz, 1H), 6.95(d, J = 8.00 Hz, 1H), 3.93(s, 2H), 3.75(s, 3H), 3.66(s, 3H), 2.15(d, J = 4.00 Hz, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 425.3)。Rt(分): 4.89; 面積比(%): 91.76(最大), 93.89(254 nm)。
HPLC - Rt(分): 4.89; 面積比(%): 93.92(最大), 94.22(254 nm)。
400 MHz, DMSO-d6: δ 7.83-7.80(m, 1H), 7.61-7.56(m, 1H), 7.40-7.38(m, 1H), 7.20(dd, J = 8.00, 4.00 Hz, 1H), 7.01(d, J = 4.00 Hz, 1H), 6.95(d, J = 8.00 Hz, 1H), 3.88(s, 2H), 3.75(s, 3H), 3.63(s, 3H), 1.45(s, 6H)。
LC-MS: 質量の実測値(M+, 387.3)。Rt(分): 4.40; 面積比(%): 92.17(最大), 92.25(254 nm)。
HPLC - Rt(分): 4.55; 面積比(%): 93.05(最大), 93.51(254 nm)。
400 MHz, DMSO-d6: δ 7.37-7.31(m, 1H), 7.23(dd, J = 8.00, 4.00 Hz, 1H), 7.17-7.13(m, 2H), 7.06(s, 1H), 6.96(d, J = 12.00 Hz, 1H), 3.91(s, 2H), 3.80(s, 3H), 3.76(s, 3H), 3.66(s, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 435)。Rt(分): 4.62; 面積比(%): 98.72(最大), 98.38(220 nm)。
HPLC - Rt(分): 4.78; 面積比(%): 98.25(最大), 98.99(254 nm)。
400 MHz, DMSO-d6: δ 7.52-7.40(m, 2H), 7.30(dd, J = 6.00, 0.00 Hz, 1H), 7.20(dd, J = 8.00, 4.00 Hz, 1H), 7.04(d, J = 4.00 Hz, 1H), 6.96(d, J = 12.00 Hz, 1H), 3.92(s, 2H), 3.75(s, 3H), 3.66(s, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 391.3)。Rt(分): 4.62; 面積比(%): 93.71(最大), 94.18(220 nm)。
HPLC - Rt(分): 4.77; 面積比(%): 96.56(最大), 96.01(254 nm)。
400 MHz, DMSO-d6: δ 7.51-7.45(m, 2H), 7.36-7.33(m, 1H), 7.21(dd, J = 8.00, 4.00 Hz, 1H), 7.04(d, J = 4.00 Hz, 1H), 6.96(d, J = 12.00 Hz, 1H), 3.93(s, 2H), 3.75(s, 3H), 3.65(s, 3H), (s, 6H)。
LC-MS: 質量の実測値(M+, 393.3)。Rt(分): 4.77; 面積比(%): 94.01(最大), 93.90(254 nm)。
HPLC - Rt(分): 4.78; 面積比(%): 95.89(最大), 95.68(254 nm)。
400 MHz, DMSO-d6: δ 7.46-7.40(m, 2H), 7.27(dd, J = 8.00, 4.00 Hz, 1H), 7.11(d, J = 4.00 Hz, 1H), 6.97(d, J = 8.00 Hz, 1H), 3.92(s, 2H), 3.77(s, 3H), 3.69(s, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 389.3)。Rt(分): 4.79; 面積比(%): 97.73(最大), 97.21(254nm)。
HPLC - Rt(分): 4.95; 面積比(%): 97.84(最大), 97.61(254 nm)。
400 MHz, DMSO-d6: δ 7.27-7.22(m, 2H), 7.19-7.15(m, 1H), 7.10(d, J = 4.00 Hz, 1H), 6.97(d, J = 8.00 Hz, 1H), 3.91(s, 2H), 3.76(s, 3H), 3.69(s, 3H), 2.32(d, J = 4.00 Hz, 3H), 1.45(s, 6H)。
LC-MS: 質量の実測値(M+, 411.2)。Rt(分): 5.04; 面積比(%): 98.62(最大), 98.04(254 nm)。
HPLC - Rt(分): 5.04; 面積比(%): 98.61(最大), 98.88(254 nm)。
400 MHz, DMSO-d6: δ 7.70-7.66(m, 1H), 7.28(dd, J = 8.00, 4.00 Hz, 1H), 7.12(d, J = 4.00 Hz, 1H), 6.97(d, J = 8.00 Hz, 1H), 3.92(s, 2H), 3.77(s, 3H), 3.70(s, 3H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 463)。Rt(分): 4.49; 面積比(%): 95.76(最大), 96.08(254 nm)。
HPLC - Rt(分): 4.50; 面積比(%): 98.26(最大), 97.72(254 nm)。
400 MHz, DMSO-d6: δ 7.24-7.22(m, 1H), 7.21-7.20(m, 1H), 7.10(d, J = 4.00 Hz, 1H), 7.05(s, 1H), 6.97(d, J = 12.00 Hz, 1H), 6.10(s, 2H), 3.86(s, 2H), 3.76(s, 3H), 3.69(s, 3H), 1.44(s, 6H)。
LC-MS: 質量の実測値(M+, 419)。Rt(分): 5.17; 面積比(%): 96.44(最大), 97.53(254nm)。
HPLC - Rt(分): 5.18; 面積比(%): 97.36(最大), 97.67(254 nm)。
400 MHz, DMSO-d6: δ 7.90(s, 1H), 7.79(d, J = 8.00 Hz, 1H), 7.51(d, J = 12.00 Hz, 1H), 7.34(dd, J = 8.00, 4.00 Hz, 1H), 7.24-7.23(m, 1H), 7.00(d, J = 12.00 Hz, 1H), 3.92(s, 2H), 3.79(s, 3H), 3.75(s, 3H), 1.48(s, 6H)。
LC-MS: 質量の実測値(M+, 399.3)。Rt(分): 4.14; 面積比(%): 95.01(最大), 96.10(254 nm)。
HPLC - Rt(分): 4.14; 面積比(%): 95.86(最大), 95.86(254 nm)。
400 MHz, DMSO-d6: δ 7.20(dd, J = 12.00, 4.00 Hz, 1H), 7.05(d, J = 4.00 Hz, 1H), 7.02-6.99(m, 1H), 6.97-6.96(m, 1H), 6.95-6.94(m, 1H), 6.87(d, J = 4.00 Hz, 1H), 3.86(s, 2H), 3.76(s, 3H), 3.71(s, 3H), 3.68(s, 3H), 3.67(s, 3H), 1.44(s, 6H)。
LC-MS: 質量の実測値(M+, 385.3)。Rt(分): 3.78; 面積比(%): 97.28(最大), 96.55(254 nm)。
HPLC - Rt(分): 3.75; 面積比(%): 98.10(最大), 98.01(254 nm)。
400 MHz, DMSO-d6: δ 7.45(s, 1H), 7.43(d, J = 4.00 Hz, 1H), 7.35(dd, J = 8.00, 4.00 Hz, 1H), 7.28(d, J = 4.00 Hz, 1H), 6.99(d, J = 8.00 Hz, 1H), 6.97(d, J = 4.00 Hz, 1H), 3.88(s, 2H), 3.81(s, 3H), 3.79(s, 3H), 3.76(s, 3H), 1.46(s, 6H)。
LC-MS: 質量の実測値(M+, 381.3)。Rt(分): 4.34; 面積比(%): 96.80(最大), 97.33(220 nm)。
HPLC - Rt(分): 4.51; 面積比(%): 96.93(最大), 96.36(254 nm)。
400 MHz, DMSO-d6: δ 7.86(s, 1H), 7.75-7.82(m, 1H), 7.33(d, J = 8.00 Hz, 1H), 7.27(d, J = 4.00 Hz, 1H), 6.99(d, J = 8.00 Hz, 1H), 6.81(d, J = 8.00 Hz, 1H), 4.60(t, J = 8.00 Hz, 2H), 3.89(s, 2H), 3.79(s, 3H), 3.76(s, 3H), 3.12(t, J = 8.00 Hz, 2H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 379.3)。Rt(分): 5.00; 面積比(%): 97.76(最大), 97.82(254 nm)。
HPLC - Rt(分): 5.16; 面積比(%): 98.08(最大), 97.80(254 nm)。
400 MHz, DMSO-d6: δ 7.76(s, 1H), 7.64(d, J = 8.00 Hz, 1H), 7.33-7.24(m, 3H), 6.97(d, J = 4.00 Hz, 1H), 3.90(s, 2H), 3.78(s, 3H), 3.75(s, 3H), 2.91-2.87(m, 4H), 2.05(q, J = 8.00 Hz, 2H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 422.2)。Rt(分): 4.22; 面積比(%): 99.08(最大), 98.59(254 nm)。
HPLC - Rt(分): 4.21; 面積比(%): 99.27(最大), 98.91(254 nm)。
400 MHz, DMSO-d6: δ 8.34(s, 1H), 8.23(d, J = 8.00 Hz, 1H), 7.95(d, J = 8.00 Hz, 1H), 7.34(d, J = 8.00 Hz, 1H), 7.26(d, J = 4.00 Hz, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.97(s, 2H), 3.79(s, 3H), 3.74(s, 3H), 3.05(s, 3H), 1.51(s, 6H)。
LC-MS: 質量の実測値(M+, 394.3)。Rt(分): 2.94; 面積比(%): 94.48(最大), 95.26(254 nm)。
HPLC - Rt(分): 3.47; 面積比(%): 95.98(最大), 95.74(254 nm)。
400 MHz, DMSO-d6: δ 10.62(s, 1H), 7.82(s, 1H), 7.81(d, J = 8.00 Hz, 1H), 7.34(dd, J = 8.00, 4.00 Hz, 1H), 7.26(s, 1H), 6.98(d, J = 8.00 Hz, 1H), 6.87(d, J = 8.00 Hz, 1H), 3.90(s, 2H), 3.79(s, 3H), 3.76(s, 3H), 3.52(s, 2H), 1.47(s, 6H)。
LC-MS: 質量の実測値(M+, 379.3)。Rt(分): 4.56; 面積比(%): 93.42(最大), 95.41(254 nm)。
HPLC - Rt(分): 4.56; 面積比(%): 96.17(最大), 96.21(254 nm)。
400 MHz, DMSO-d6: δ 8.25(s, 1H), 8.07(d, J = 4.00 Hz, 1H), 7.85(d, J = 8.00 Hz, 1H), 7.66(d, J = 8.00 Hz, 1H), 7.33(d, J = 8.00 Hz, 1H), 7.25(s, 1H), 7.07-7.06(m, 1H), 6.98(d, J = 8.00 Hz, 1H), 3.95(s, 2H), 3.78(s, 3H), 3.73(s, 3H), 1.49(s, 6H)。
LC-MS: 質量の実測値(M+, 390)。Rt(分): 3.11; 面積比(%): 98.54(最大), 98.14(254 nm)。
HPLC - Rt(分): 3.08; 面積比(%): 99.10(最大), 98.28(254 nm)。
400 MHz, DMSO-d6: δ 8.99-8.97(m, 1H), 8.59(s, 1H), 8.52(d, J = 8.00 Hz, 1H), 8.18(d, J = 12.00 Hz, 1H), 8.07(d, J = 8.00 Hz, 1H), 7.61-7.58(m, 1H), 7.36(dd, J = 8.00, 4.00 Hz, 1H), 7.28(s, 1H), 6.98(d, J = 8.00 Hz, 1H), 4.00(s, 2H), 3.78(s, 3H), 3.71(s, 3H), 1.52(s, 6H)。
LC-MS: 質量の実測値(M+, 397.3)。Rt(分): 4.31; 面積比(%): 91.44(最大), 93.57(254 nm)。
HPLC - Rt(分): 4.32; 面積比(%): 91.86(最大), 92.68(254 nm)。
400 MHz, DMSO-d6: δ 7.49-7.45(m, 2H), 7.34-7.31(m, 1H), 7.26(d, J = 4.00 Hz, 1H), 7.00(d, J = 8.00 Hz, 1H), 6.91(d, J = 8.00 Hz, 1H), 4.30-4.25(m, 4H), 3.89(s, 2H), 3.79(s, 3H), 3.76(s, 3H), 1.46(s, 6H)。
スキーム4
撹拌子、Vigreuxカラム及び窒素入口を備えた丸底フラスコに、1-(3,4-ジメトキシ-フェニル)-エタノン(18.0g、100mmol)、パラホルムアルデヒド(6g、200mmol)、ジメチルアミン.HCl(8.2g、100mL)及びEtOH(50mL)を入れた。この混合物にconc. HClを20滴加え、そして、その反応物を80℃にて18時間加熱した。TLCはまだSMの消費を示していた。それをEt2Oに加え、そして、pptの形成を引き起こした。これを濾過し、そして、Et2Oで洗浄した。得られたHCl塩の量:3.98g、13mmol、88%の収率。その物質を、次の工程でそのままで使用した。LC-MS(ESI)m/e 238(M+H)。
工程2
撹拌子、Vigreuxカラム及び窒素入口を備えた100mL容の丸底フラスコに、1-(3,4-ジメトキシ-フェニル)-3-ジメチルアミノ-プロパン-1-オン.HCl(1.4g、5mmol)、EtOH(20mL)及びヒドラジン一水和物(0.3mL、6mmol)を入れた。その混合物を80℃にて2時間加熱した。LC-MS及びTLC分析はSMの消費を示した。溶媒を減圧下で留去し、そして、微量のヒドラジン及びEtOHを高真空下で30分間取り除いた。その物質を、次の工程に使用した。得られた量: 1030mg、5mmol、100%の収率。LC-MS(ESI)m/e 207(M+H)。
工程3
撹拌子を備えたシンチレーションバイアルに、3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-1H-ピラゾール(412mg、2mmol)、ヒューニッヒ塩基(1mL、6mmol)及び無水CH2Cl2(10mL)を入れた。この混合物にフェニル酢酸クロライド(0.27mL、2mmol)を加え、そして、その反応物を室温にて3時間撹拌した。LC-MSはSMの消費を示した。その混合物を、CH2Cl2(50mL)で希釈し、そして、水(50mL)に加えた。相を分離し、そして、CH2Cl2相を、飽和Na2CO3(50mL)で洗浄し、乾燥させ(Na2SO4)、そして、溶媒を減圧下で留去した。その物質を、ヘプタン-EtOAcの0から100% EtOAcへのグラジエントを用いて溶出する40gのシリカカートリッジを使用することで精製した。得られた量:123mg、0.37mmol、19%の収率。LC-MS(ESI)m/e 325(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 3.21(t, J=10.03 Hz, 2H)3.94(s, 3H)3.98(s, 3H)4.04(t, J=10.03 Hz, 2H)4.11(s, 2H)6.90(d, J=8.35 Hz, 1H)7.16(dd, J=8.27, 1.88 Hz, 1H)7.21 - 7.26(m, 1H)7.31(t, J=7.42 Hz, 2H)7.40 - 7.44(m, 3H)。
スキーム5
1-(3-ブロモ-フェニル)エタノンで開始し、1-[3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-2-フェニルエタノン(29)と同じ手順に従って調製した。LC-MS(ESI)m/e 347 & 349(M+H)。1H NMR(CHLOROFORM-d)δ: 7.76 - 7.82(m, 2H), 7.71(d, J = 9.7 Hz, 1H), 7.65(d, J = 7.8 Hz, 1H), 7.56(d, J = 8.0 Hz, 1H), 7.44(td, J = 8.0, 5.8 Hz, 1H), 7.30(t, J = 8.0 Hz, 1H), 7.22(td, J = 8.3, 2.1 Hz, 1H), 4.29(t, 2H), 3.27(t, 1H)。
工程1
撹拌子を備えたシンチレーションバイアルに、[3-(3-ブロモ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-(3-フルオロ-フェニル)-メタノン(347mg、1.0mmol)、Zn(CN)2(234mg、2.0mmol)、Zn粉末(65mg、1.0mmol)及びDMA(10mL)を入れた。その混合物を脱気し、次に、Pd(t-Bu3P)2(51mg、0.1mmol)を加えた。その混合物を80℃にて4時間加熱した。LC-MSはSMの消費を示した。その物質を、Fluorosilのパッドを通して濾過し、そして、溶媒を減圧下で留去した。それを、ヘプタン-EtOAcの30から100% EtOAcへのグラジエントを用いて溶出する12gのシリカカートリッジを使用したクロマトグラフィーで精製した。得られた量:225mg、0.76mmol、76%の収率。LC-MS(ESI)m/e 294(M+H)。1H NMR(CHLOROFORM-d)δ: 7.92 - 7.97(m, 2H), 7.76(d, J = 7.8 Hz, 1H), 7.66 - 7.74(m, 2H), 7.52 - 7.59(m, 1H), 7.45(td, J = 8.0, 5.8 Hz, 1H), 7.20 - 7.30(m, 1H), 4.32(t, J = 10.1 Hz, 2H), 3.26 - 3.34(m, 2H)。
工程2
EtOH(10mL)及びEtOAc(10mL)中に溶解した3[1-(3-フルオロ-ベンゾイル)-4,5-ジヒドロ-1H-ピラゾール-3-イル]ベンゾニトリル(88mg、0.30mmol)を、10%のPd/Cカートリッジを備えたH-キューブに通した。温度80℃、50bar、流量1mL/分。LC-MSはSMの消費を示した。溶媒を圧力下で留去し、そして、その物質を、ヘプタン-EtOAcの0から50% EtOAcへのグラジエントを用いて溶出する12gのシリカカートリッジを使用したクロマトグラフィーで精製した。得られた量:30mg、0.11mmol、35%の収率。LC-MS(ESI)m/e 283(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 2.40(s, 3H)3.26 - 3.33(m, 2 H)4.27(t, J=9.96 Hz, 2 H)7.17 - 7.26(m, 2 H)7.32(t, J=7.81 Hz, 1H)7.43(td, J=7.98, 5.81 Hz, 1H)7.49 - 7.54(m, 2 H)7.73 - 7.84(m, 2 H)。
(3-フルオロ-フェニル)-(3-m-トリル-4,5-ジヒドロ-ピラゾール-1-イル)-メタノン(29)と同じ手順によって調製した。得られた量:33mg、0.12mmol、39%の収率。LC-MS(ESI)m/e 283(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 2.53(s, 3H)3.36(t, 2 H)4.22(t, J=9.96 Hz, 2 H)7.18(td, J=8.36, 2.03 Hz, 1H)7.28 - 7.34(m, 3H)7.36 - 7.41(m, 1H)7.41 - 7.45(m, 1H)7.72(d, J=9.81 Hz, 1H)7.77(d, J=7.76 Hz, 1H)。
スキーム6
[3-(3-ブロモ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-(3-フルオロ-フェニル)-メタノンを、1-(3-ブロモ-フェニル)エタノンから開始し、1-[3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-2-フェニル-エタノン(29)と同じ手順に従って調製した。撹拌子を備えたシンチレーションバイアルに、[3-(3-ブロモ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-(3-フルオロ-フェニル)-メタノン(138mg、0.40mmol)、フェニルアセチレン(0.09mL、0.80mmol)、CuI(15mg、0.08mmol)、トリエチルアミン(0.28mL、2.00mmol)及びアセトニトリル(4mL)を入れた。その混合物を、窒素で脱気し、そして、PdCl2(PPh3)2(56mg、0.08mmol)を加えた。その反応物を窒素雰囲気下で80℃にて5時間加熱した。LC-MSはSMの消費を示した。溶媒を減圧下で留去した。その物質を、CH2Cl2(50mL)中で溶解し、そして、Fluorosilのパッドを通した。溶媒を留去し、そして、その物質を、ヘプタン-EtOAcの0〜から50% EtOAcへのグラジエントを用いて溶出する12gのシリカカートリッジを使用したクロマトグラフィーで精製した。得られた量:13mg、0.04mmol、10%の収率。LC-MS(ESI)m/e 369(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 3.31(t, J=10.01 Hz, 2H)4.29(t, J=10.01 Hz, 2H)7.22(td, J=8.32, 2.00 Hz, 1H)7.36 - 7.48(m, 5H)7.54 - 7.62(m, 3H)7.70 - 7.77(m, 2 H)7.79 - 7.83(m, 2H)。
1-(4-トリフルオロメトキシ-フェニル)-エタノンから開始し、1-[3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-2-フェニル-エタノン(29)と同じ手順に従って調製した。得られた量:103mg、0.29mmol、12%の収率。LC-MS(ESI)m/e 353(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 3.29(t, 2H)4.30(t, 2 H)7.18 - 7.25(m, 1H)7.25 - 7.30(m, 2H)7.43(td, J=7.99, 5.78 Hz, 1H)7.66 - 7.85(m, 4H)。
1-(4-トリフルオロメトキシ-フェニル)-エタノンから開始し、1-[3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-2-フェニル-エタノン(29)と同じ手順に従って調製した。得られた量:180mg、0.48mmol、19%の収率。LC-MS(ESI)m/e 379(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 3.25(t, J=10.08 Hz, 2 H)4.27(t, J=10.08 Hz, 2 H)6.05(s, 2 H)6.88(d, J=8.20 Hz, 1H)7.25 - 7.29(m, 2 H)7.55(d, J=1.46 Hz, 1H)7.64(dd, J=8.17, 1.54 Hz, 1H)7.75(d, J=8.79 Hz, 2 H)。
1-(4-メチルスルファニル-フェニル)-エタノンから開始し、1-[3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-2-フェニル-エタノン(29)と同じ手順に従って調製した。得られた量:178mg、0.57mmol、23%の収率。LC-MS(ESI)m/e 315(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 2.52(s, 3H)3.27(t, J=9.96 Hz, 2 H)4.27(t, J=9.96 Hz, 2 H)7.20(td, J=8.27, 2.34 Hz, 1H)7.25(s, 1H)7.42(td, J=7.97, 5.83 Hz, 2 H)7.62(d, J=8.44 Hz, 2 H)7.75(d, J=9.81 Hz, 1H)7.80(d, J=7.76 Hz, 1H)。
1-(4-メチルスルファニル-フェニル)-エタノンから開始し、1-[3-(3,4-ジメトキシ-フェニル)-4,5-ジヒドロ-ピラゾール-1-イル]-2-フェニル-エタノン(29)と同じ手順に従って調製した。得られた量:53mg、0.16mmol、6%の収率。LC-MS(ESI)m/e 341(M+H)。1H NMR(400 MHz, CHLOROFORM-d)δ ppm 2.52(s, 3H)3.23(t, J=10.01 Hz, 2 H)4.24(t, J=10.01 Hz, 2 H)6.05(s, 2 H)6.88(d, J=8.20 Hz, 1H)7.25(s, 1H)7.27(s, 1H)7.58(d, J=1.27 Hz, 1H)7.63(d, J=8.44 Hz, 2 H)7.67(dd, J=8.20, 1.37 Hz, 1H)。
スキーム7
Rf=0.15
緑色の油状液体;73%の収率
LC-MS:質量の実測値(M+、238.2)
方法:A-:0.1%のHCOOH、B-:MeOH、流量-1ml/分。Atlantis dC18(50 X 4.6mm、5μm)。Rt(分):0.946;面積比(%):96.97。
HPLC-方法:A-:水中に0.1%のTFA、B-:CAN中に0.1%のTFA:流量-1ml/分。カラム:Xbridge C8(50 X 4.6mm、3.5μm)。Rt(分):1.76;面積比(%):95.21(最大)、91.73(254nm)。
1H NMR 400 MHz, DMSO-d6: δ 7.65(dd, J = 8.00, 4.00 Hz, 1H), 7.44(d, J = 4.00 Hz, 1H), 7.04(d, J = 8.00 Hz, 1H), 3.85(s, 3H), 3.80(s, 3H), 3.07(t, J = 8.00 Hz, 2H), 2.57(t, J = 8.00 Hz, 2H), 2.14(s, 6H)。
Rf=0.2
白色の固体;95%の収率
LC-MS:質量の実測値(M+、207)
方法:A-:水中に0.1%のTFA、B-:ACN中に0.1%のTFA:流量-0.6ml/分。カラム:Xbridge C8(50 X 4.6mm、3.5μm)。Rt(分):1.49;面積比(%):58.00。
1H NMR 400 MHz, DMSO-d6: δ 7.25(d, J = 4.00 Hz, 1H), 7.04(d, J = 8.00 Hz, 1H), 6.93(d, J = 8.00 Hz, 1H), 3.83-3.80(m, 1H), 3.75(s, 6H), 3.31(t, J = 8.00 Hz, 2H), 2.82(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 389)。Rt(分): 4.44; 面積比(%): 99.16(最大), 99.30(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 4.50; 面積比(%): 99.68(最大), 99.20(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.29(s, 1H), 7.94(d, J = 8.00 Hz, 1H), 7.62(td, J = 2.00, 1.20 Hz, 1H), 7.40(d, J = 4.00 Hz, 1H), 7.33(t, J = 8.00 Hz, 1H), 7.14(dd, J = 8.40, 2.00 Hz, 1H), 6.89(d, J = 12.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.93(s, 6H), 3.28(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 345)。Rt(分): 4.36; 面積比(%): 99.73(最大), 99.54(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 4.44; 面積比(%): 98.76(最大), 98.44(254 nm)。
1H NMR 400 MHz, DMSO-d6: δ 7.95(s, 1H), 7.83(d, J = 8.00 Hz, 1H), 7.61-7.58(m, 1H), 7.51(t, J = 8.00 Hz, 1H), 7.25-7.04(m, 2H), 7.03(d, J = 8.00 Hz, 1H), 4.09(t, J = 12.00 Hz, 2H), 3.79(s, 3H), 3.76(s, 3H), 3.33(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 341)。Rt(分): 3.87; 面積比(%): 96.42(最大), 96.54(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 3.88; 面積比(%): 96.96(最大), 95.83(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.62-7.58(m, 2H), 7.37-7.33(m, 2H), 7.18(d, J = 8.00 Hz, 1H), 7.06-7.03(m, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.26(t, J = 12.00 Hz, 2H), 3.95(s, 3H), 3.93(s, 3H), 3.90(s, 3H), 3.26(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 355)。Rt(分): 4.21; 面積比(%): 95.38(最大), 94.61(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 4.21; 面積比(%): 95.51(最大), 93.71(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.60-7.58(m, 2H), 7.35-7.32(m, 2H), 7.17(dd, J = 8.00, 4.00 Hz, 1H), 7.03(td, J = 5.00, 1.20 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 4.09(q, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.90(s, 3H), 3.26(t, J = 8.00 Hz, 2H), 1.42(t, J = 8.00 Hz, 3H)。
LC-MS: 質量の実測値(M+, 379)。Rt(分): 4.63; 面積比(%): 99.37(最大), 99.73(254 nm)。
HPLC - Rt(分): 4.64; 面積比(%): 98.52(最大), 98.24(254 nm)。
1H NMR 400 MHz, DMSO-d6: δ 8.31(d, J = 8.00 Hz, 1H), 8.15(d, J = 8.00 Hz, 1H), 7.90(d, J = 8.00 Hz, 1H), 7.73(t, J = 8.00 Hz, 1H), 7.26-7.21(m, 2H), 7.03(d, J = 8.00 Hz, 1H), 4.12(t, J = 12.00 Hz, 2H), 3.79(s, 3H), 3.74(s, 3H), 3.31(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 325)。Rt(分): 4.14; 面積比(%): 97.97(最大), 97.64(254 nm)。
HPLC - Rt(分): 4.14; 面積比(%): 96.54(最大), 95.92(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.83-7.79(m, 2H), 7.35-7.29(m, 3H), 7.16(d, J = 8.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.95(s, 3H), 3.90(s, 3H), 3.26(t, J = 8.00 Hz, 2H), 2.42(s, 3H)。
LC-MS: 質量の実測値(M+, 336)。Rt(分): 3.84; 面積比(%): 98.37(最大), 98.63(254 nm)。
HPLC - Rt(分): 3.84; 面積比(%): 97.96(最大), 97.30(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.46(s, 1H), 8.24(d, J = 8.00 Hz, 1H), 7.78(dt, J = 7.73, 1.20 Hz, 1H), 7.58(t, J = 8.00 Hz, 1H), 7.34(d, J = 2.00 Hz, 1H), 7.17(dd, J = 8.40, 2.00 Hz, 1H), 6.90(d, J = 8.00 Hz, 1H), 4.28(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.93(s, 3H), 3.30(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 325)。Rt(分): 4.74; 面積比(%): 98.76(最大), 98.56(254 nm)。
HPLC - Rt(分): 4.72; 面積比(%): 97.48(最大), 97.51(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.00(s, 1H), 7.95(d, J = 8.00 Hz, 1H), 7.49(t, J = 8.00 Hz, 1H), 7.36-7.34(m, 2H), 7.16(dd, J = 8.00, 4.00 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 4.27(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.90(s, 3H), 3.29(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 354)。Rt(分): 2.65; 面積比(%): 98.79(最大), 99.07(254 nm)。
HPLC - Rt(分): 2.65; 面積比(%): 96.98(最大), 96.66(254 nm)。
1H NMR 400 MHz, DMSO-d6: δ 7.28-7.22(m, 4H), 7.15(d, J = 4.00 Hz, 1H), 7.03(d, J = 12.00 Hz, 1H), 6.87(dd, J = 8.00, 4.00 Hz, 1H), 4.07(t, J = 8.00 Hz, 2H), 3.79(s, 3H), 3.75(s, 3H), 3.27(t, J = 12.00 Hz, 2H), 2.92(s, 6H)。
LC-MS: 質量の実測値(M+, 417)。Rt(分): 4.87; 面積比(%): 94.89(最大), 93.72(254 nm)。
HPLC - Rt(分): 4.88; 面積比(%): 94.10(最大), 91.01(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.80-7.70(m, 1H), 7.64(d, J = 8.00 Hz, 1H), 7.45-7.32(m, 7H), 7.17(dd, J = 8.00, 4.00 Hz, 1H), 7.12(dd, J = 4.60, 2.80 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 5.12(s, 2H), 4.26(t, J = 12.00 Hz, 2H), 3.95(s, 3H), 3.99(s, 3H), 3.26(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 369)。Rt(分): 4.45; 面積比(%): 97.00(最大), 96.31(254 nm)。
HPLC - Rt(分): 4.48; 面積比(%): 97.23(最大), 95.98(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.56(d, J = 8.00 Hz, 2H), 7.35-7.27(m, 2H), 7.02(dt, J = 8.13, 0.80 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.62-4.59(m, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.89(s, 3H), 3.26(t, J = 8.00 Hz, 2H), 1.36(s, 3H), 1.35(s, 3H)。
LC-MS: 質量の実測値(M+, 403)。Rt(分): 4.80; 面積比(%): 97.93(最大), 96.41(254 nm)。
HPLC - Rt(分): 4.85; 面積比(%): 97.21(最大), 95.15(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.77-7.73(m, 2H), 7.42(t, J = 8.00 Hz, 1H), 7.34-7.30(m, 3H), 7.17-7.03(m, 5H), 6.87(d, J = 8.00 Hz, 1H), 4.24(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.83(s, 3H), 3.25(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 387)。Rt(分): 4.79; 面積比(%): 99.10(最大), 99.47(254 nm)。
HPLC - Rt(分): 4.85; 面積比(%): 97.41(最大), 98.79(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.32(s, 1H), 7.98(d, J = 8.00 Hz, 1H), 7.74-7.71(m, 1H), 7.65(d, J = 8.00 Hz, 2H), 7.53(t, J = 4.00 Hz, 1H), 7.46-7.42(m, 2H), 7.38-7.34(m, 2H), 7.14(dd, J = 8.00, 4.00 Hz, 1H), 6.87(d, J = 8.00 Hz, 1H), 4.30(t, J = 8.00 Hz, 2H), 3.92(s, 3H), 3.73(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 408)。Rt(分): 4.05; 面積比(%): 98.13(最大), 98.83(254 nm)。
HPLC - Rt(分): 4.05; 面積比(%): 98.86(最大), 99.07(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.51(s, 1H), 8.11(d, J = 8.00 Hz, 1H), 7.96(d, J = 8.00 Hz, 1H), 7.52(t, J = 4.00 Hz, 1H), 7.40-7.36(m, 1H), 7.27-7.26(m, 1H), 7.16(d, J = 8.00 Hz, 1H), 6.87(d, J = 8.00 Hz, 1H), 4.28(t, J = 12.00 Hz, 2H), 3.92(s, 3H), 3.80(s, 3H), 3.28(t, J = 12.00 Hz, 2H), 2.83(s, 3H)。
LC-MS: 質量の実測値(M+, 367)。Rt(分): 4.91; 面積比(%): 94.01(最大), 92.83(254 nm)。
HPLC - Rt(分): 4.95; 面積比(%): 97.22(最大), 95.98(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.08(s, 1H), 7.80(d, J = 8.00 Hz, 1H), 7.51(dd, J = 5.00, 2.00 Hz, 1H), 7.38(dd, J = 10.00, 8.00 Hz, 2H), 7.15(dd, J = 11.00, 2.00 Hz, 1H), 6.88(d, J = 12.00 Hz, 1H), 4.27(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.87(s, 3H), 3.27(t, J = 8.00 Hz, 2H), 1.38(s, 9H)。
LC-MS: 質量の実測値(M+, 339)。Rt(分): 4.45; 面積比(%): 92.47(最大), 91.15(220 nm)。
HPLC - Rt(分): 4.46; 面積比(%): 92.59(最大), 91.02(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.86(s, 1H), 7.81(d, J = 8.00 Hz, 1H), 7.38-7.31(m, 3H), 7.16(dd, J = 8.00, 4.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.26(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.89(s, 3H), 3.26(t, J = 12.00 Hz, 2H), 2.72(q, J = 8.00 Hz, 2H), 1.29(t, J = 8.00 Hz, 3H)。
LC-MS: 質量の実測値(M+, 389)。Rt(分): 3.36; 面積比(%): 98.64(最大), 98.30(254 nm)。
HPLC - Rt(分): 3.35; 面積比(%): 99.08(最大), 98.77(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.86(s, 1H), 8.30(d, J = 8.00 Hz, 1H), 8.07(dt, J = 8.13, 1.20 Hz, 1H), 7.68(t, J = 8.00 Hz, 1H), 7.45(d, J = 1.60 Hz, 1H), 7.14(dd, J = 8.40, 2.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.29(t, J = 8.00 Hz, 2H), 3.95(s, 3H), 3.93(s, 3H), 3.31(t, J = 8.00 Hz, 2H), 3.08(s, 3H)。
LC-MS: 質量の実測値(M+, 327)。Rt(分): 3.23; 面積比(%): 97.80(最大), 97.47(254 nm)。
HPLC - Rt(分): 3.24; 面積比(%): 97.68(最大), 96.88(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.59(s, 2H), 7.33-7.27(m, 3H), 7.19(d, J = 8.00 Hz, 1H), 7.00-6.97(m, 1H), 6.89-6.86(m, 1H), 4.25(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.90(s, 3H), 3.26(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 377)。Rt(分): 4.28; 面積比(%): 94.48(最大), 93.62(254 nm)。
HPLC - Rt(分): 4.30; 面積比(%): 97.41(最大), 97.37(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.90-7.86(m, 2H), 7.45(t, J = 8.00 Hz, 1H), 7.36(d, J = 2.00 Hz, 1H), 7.25(d, J = 4.00 Hz, 1H), 7.17(dd, J = 8.00, 4.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 6.76-6.39(m, 1H), 4.26(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.90(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 368)。Rt(分): 3.13; 面積比(%): 96.09(最大), 96.43(254 nm)。
HPLC - Rt(分): 3.09; 面積比(%): 98.62(最大), 98.33(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.12(s, 1H), 7.76(d, J = 8.00 Hz, 1H), 7.71(d, J = 8.00 Hz, 1H), 7.42-7.37(m, 2H), 7.33(s, 1H), 7.17(d, J = 8.00 Hz, 1H), 6.88(d, J = 12.00 Hz, 1H), 4.25(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.92(s, 3H), 3.26(t, J = 12.00 Hz, 2H), 2.19(s, 3H)。
LC-MS: 質量の実測値(M+, 329)。Rt(分): 4.06; 面積比(%): 98.85(最大), 98.98(254 nm)。
HPLC - Rt(分): 4.05; 面積比(%): 98.89(最大), 98.62(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.07-8.04(m, 2H), 7.31(d, J = 1.60 Hz, 1H), 7.19(dd, J = 8.00, 4.00 Hz, 1H), 7.14-7.10(m, 2H), 6.89(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.91(s, 3H), 3.27(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 347)。Rt(分): 4.29; 面積比(%): 99.49(最大), 99.34(254 nm)。
HPLC - Rt(分): 4.32; 面積比(%): 99.39(最大), 98.67(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.02-7.97(m, 1H), 7.86-7.83(m, 1H), 7.33(d, J = 4.00 Hz, 1H), 7.24-7.21(m, 1H), 7.19(dd, J = 8.00, 4.00 Hz, 1H), 6.90(d, J = 8.00 Hz, 1H), 4.25(t, J = 12.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.28(t, J = 4.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 397)。Rt(分): 4.86; 面積比(%): 97.60(最大), 97.07(254 nm)。
HPLC - Rt(分): 4.97; 面積比(%): 97.92(最大), 97.38(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.90(t, J = 12.00 Hz, 2H), 7.69(t, J = 4.00 Hz, 1H), 7.30(d, J = 4.00 Hz, 1H), 7.20(dd, J = 8.00, 4.00 Hz, 1H), 6.90(d, J = 8.00 Hz, 1H), 4.27(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.31(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 343)。Rt(分): 4.36; 面積比(%): 96.11(最大), 97.09(254 nm)。
HPLC - Rt(分): 4.37; 面積比(%): 98.71(最大), 98.42(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.76(dd, J = 16.00, 8.00 Hz, 2H), 7.36(d, J = 1.60 Hz, 1H), 7.27-7.17(m, 2H), 6.89(d, J = 8.00 Hz, 1H), 4.25(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.92(s, 3H), 3.26(t, J = 12.00 Hz, 2H), 2.35(s, 3H)。
LC-MS: 質量の実測値(M+, 343)。Rt(分): 4.36; 面積比(%): 98.34(最大), 98.75(254 nm)。
HPLC - Rt(分): 4.37; 面積比(%): 99.08(最大), 98.92(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.93(dd, J = 9.20, 4.00 Hz, 1H), 7.80(d, J = 8.00 Hz, 1H), 7.47(t, J = 8.00 Hz, 1H), 7.33(d, J = 1.60 Hz, 1H), 7.19(dd, J = 8.00, 4.00 Hz, 1H), 6.90(d, J = 12.00 Hz, 1H), 4.25(t, J = 12.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.28(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 359)。Rt(分): 4.04; 面積比(%): 98.61(最大), 99.28(254 nm)。
HPLC - Rt(分): 4.03; 面積比(%): 98.30(最大), 97.91(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.98(dd, J = 12.80, 1.60 Hz, 1H), 7.89(d, J = 8.00 Hz, 1H), 7.37(d, J = 2.00 Hz, 1H), 7.19(dd, J = 8.20, 2.00 Hz, 1H), 7.01(t, J = 8.00 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 4.25(t, J = 12.00 Hz, 2H), 3.96(s, 3H), 3.94(s, 3H), 3.93(s, 3H), 3.25(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 409)。Rt(分): 4.62; 面積比(%): 95.45(最大), 96.43(254 nm)。
HPLC - Rt(分): 4.63; 面積比(%): 95.39(最大), 95.86(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.90(dd, J = 9.60, 1.60 Hz, 1H), 7.73(d, J = 8.00 Hz, 1H), 7.63(t, J = 8.00 Hz, 1H), 7.32(d, J = 2.00 Hz, 1H), 7.19(dd, J = 8.20, 2.00 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 4.25(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 347)。Rt(分): 3.99; 面積比(%): 98.85(最大), 99.26(254 nm)。
HPLC - Rt(分): 4.07; 面積比(%): 98.85(最大), 98.67(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.36-7.33(m, 1H), 7.28-7.27(m, 1H), 7.22(d, J = 2.00 Hz, 1H), 7.18-7.12(m, 2H), 6.85(d, J = 8.00 Hz, 1H), 4.25(t, J = 4.00 Hz, 2H), 3.91(s, 3H), 3.85(s, 3H), 3.32(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 343)。Rt(分): 4.05; 面積比(%): 98.93(最大), 99.15(254 nm)。
HPLC - Rt(分): 4.13; 面積比(%): 98.99(最大), 99.12(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.22-7.20(m, 2H), 7.16(d, J = 4.00 Hz, 1H), 7.13-7.07(m, 2H), 6.84(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.90(s, 3H), 3.83(s, 3H), 3.30(t, J = 12.00 Hz, 2H), 2.27(s, 3H)。
LC-MS: 質量の実測値(M+, 397)。Rt(分): 4.39; 面積比(%): 93.14(最大), 92.71(254 nm)。
HPLC - Rt(分): 4.44; 面積比(%): 93.80(最大), 91.92(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.61-7.60(m, 1H), 7.30-7.28(m, 2H), 7.16(d, J = 4.00 Hz, 1H), 7.08(dd, J = 8.00, 4.00 Hz, 1H), 6.83(d, J = 8.00 Hz, 1H), 4.21(t, J = 8.00 Hz, 2H), 3.90(s, 3H), 3.82(s, 3H), 3.31(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 363)。Rt(分): 4.09; 面積比(%): 96.66(最大), 95.86(254 nm)。
HPLC - Rt(分): 4.12; 面積比(%): 97.87(最大), 97.52(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.34-7.28(m, 2H), 7.24-7.19(m, 1H), 7.16(d, J = 4.00 Hz, 1H), 7.12(dd, J = 8.00, 4.00 Hz, 1H), 6.84(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.90(s, 3H), 3.83(s, 3H), 3.32(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 365)。Rt(分): 4.27; 面積比(%): 99.31(最大), 99.04(254 nm)。
HPLC - Rt(分): 4.30; 面積比(%): 99.02(最大), 98.68(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.38-7.30(m, 1H), 7.22(d, J = 4.00 Hz, 1H), 7.14(dd, J = 8.00, 4.00 Hz, 1H), 7.08-7.01(m, 1H), 6.86(d, J = 8.00 Hz, 1H), 4.23(t, J = 12.00 Hz, 2H), 3.92(s, 3H), 3.87(s, 3H), 3.32(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 361)。Rt(分): 4.29; 面積比(%): 97.01(最大), 96.49(220 nm)。
HPLC - Rt(分): 4.35; 面積比(%): 98.83(最大), 98.99(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.26-7.24(m, 2H), 7.24(d, J = 2.00 Hz, 1H), 7.14(dd, J = 8.40, 2.00 Hz, 1H), 7.00(t, J = 8.00 Hz, 1H), 4.24(t, J = 8.00 Hz, 2H), 3.91(s, 3H), 3.87(s, 3H), 3.31(t, J = 8.00 Hz, 2H), 2.37(s, 3H)。
LC-MS: 質量の実測値(M+, 377)。Rt(分): 4.02; 面積比(%): 97.62(最大), 97.66(254 nm)。
HPLC - Rt(分): 4.05; 面積比(%): 97.43(最大), 97.79(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.37-7.33(m, 1H), 7.26(d, J = 1.60 Hz, 1H), 7.14(dd, J = 8.00, 4.00 Hz, 1H), 6.86(d, J = 8.00 Hz, 1H), 6.83-6.79(m, 1H), 4.23(t, J = 8.00 Hz, 2H), 3.96(s, 3H), 3.91(s, 3H), 3.87(s, 3H), 3.30(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 383)。Rt(分): 4.52; 面積比(%): 97.94(最大), 97.96(254 nm)。
HPLC - Rt(分): 4.63; 面積比(%): 97.82(最大), 97.91(254 nm)。
1H NMR 400 MHz, DMSO-d6: δ 7.64-7.59(m, 1H), 7.21(d, J = 8.00 Hz, 1H), 7.14(d, J = 1.60 Hz, 1H), 7.01(d, J = 12.00 Hz, 1H), 4.09(t, J = 8.00 Hz, 2H), 3.78(s, 3H), 3.72(s, 3H), 3.38(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 389)。Rt(分): 4.33; 面積比(%): 98.31(最大), 98.28(220 nm)。
HPLC - Rt(分): 4.34; 面積比(%): 97.52(最大), 98.07(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.82(s, 1H), 7.51(d, J = 8.00 Hz, 1H), 7.40(d, J = 4.00 Hz, 1H), 7.17(dd, J = 8.40, 2.00 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 6.12(s, 2H), 4.24(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.25(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 433)。Rt(分): 3.95; 面積比(%): 98.38(最大), 98.32(254 nm)。
HPLC - Rt(分): 3.94; 面積比(%): 97.76(最大), 98.98(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.22(d, J = 4.00 Hz, 1H), 7.15(dd, J = 8.00, 4.00 Hz, 1H), 7.04(s, 1H), 6.93(s, 1H), 6.85(d, J = 8.00 Hz, 1H), 6.03(s, 2H), 4.22(t, J = 12.00 Hz, 2H), 3.91(s, 3H), 3.87(s, 3H), 3.29(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 400)。Rt(分): 3.75; 面積比(%): 94.53(最大), 92.65(254 nm)。
HPLC - Rt(分): 3.78; 面積比(%): 93.42(最大), 91.57(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.56(s, 1H), 7.12(d, J = 2.00 Hz, 1H), 7.05-7.01(m, 2H), 6.82(d, J = 8.00 Hz, 1H), 6.18(s, 2H), 4.20(t, J = 12.00 Hz, 2H), 3.94(s, 3H), 3.89(s, 3H), 3.27(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 391)。Rt(分): 4.69; 面積比(%): 93.95(最大), 93.64(220 nm)。
HPLC - Rt(分): 4.72; 面積比(%): 97.44(最大), 97.76(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.86(d, J = 8.00 Hz, 2H), 7.31(d, J = 4.00 Hz, 1H), 7.20(d, J = 8.00 Hz, 1H), 7.13(d, J = 8.00 Hz, 1H), 6.90(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.28(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 371)。Rt(分): 3.62; 面積比(%): 95.22(最大), 95.61(254 nm)。
HPLC - Rt(分): 3.62; 面積比(%): 95.26(最大), 95.30(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.17-7.07(m, 3H), 6.99(d, J = 8.00 Hz, 2H), 6.82(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.90(s, 9H), 3.76(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 371)。Rt(分): 3.59; 面積比(%): 96.83(最大), 96.46(254 nm)。
HPLC - Rt(分): 3.61; 面積比(%): 96.33(最大), 96.54(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.20(d, J = 1.60 Hz, 1H), 7.11(dd, J = 8.20, 2.00 Hz, 1H), 7.01(d, J = 2.40 Hz, 1H), 6.96-6.88(m, 2H), 6.84(d, J = 8.00 Hz, 1H), 4.25(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.90(s, 3H), 3.79(s, 3H), 3.78(s, 3H), 3.27(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 357)。Rt(分): 3.22; 面積比(%): 90.88(最大), 90.37(254 nm)。
HPLC - Rt(分): 3.19; 面積比(%): 91.29(最大), 90.03(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.74(d, J = 8.00 Hz, 1H), 7.68(d, J = 2.00 Hz, 1H), 7.36(d, J = 4.00 Hz, 1H), 7.19(dd, J = 8.00, 4.00 Hz, 1H), 6.97(d, J = 12.00 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 5.89(s, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.92(s, 3H), 3.91(s, 3H), 3.25(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 357)。Rt(分): 3.23; 面積比(%): 97.05(最大), 97.01(254 nm)。
HPLC - Rt(分): 3.19; 面積比(%): 97.08(最大), 97.03(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.75(s, 1H), 7.65(d, J = -4.00 Hz, 1H), 7.38(s, 1H), 7.19(dd, J = -4.00, -8.00 Hz, 1H), 6.90(t, J = -8.00 Hz, 2H), 4.25(t, J = -8.00 Hz, 2H), 3.96(s, 3H), 3.93(s, 6H), 3.24(t, J = -12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 353)。Rt(分): 3.85; 面積比(%): 97.90(最大), 98.57(254 nm)。
HPLC - Rt(分): 3.84; 面積比(%): 97.54(最大), 98.84(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.93-7.90(m, 2H), 7.36(d, J = 2.00 Hz, 1H), 7.18(dd, J = 8.00, 4.00 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 6.82(d, J = 8.00 Hz, 1H), 4.65(t, J = 8.00 Hz, 2H), 4.25(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.91(s, 3H), 3.25(q, J = 8.00 Hz, 4H)。
LC-MS: 質量の実測値(M+, 351)。Rt(分): 4.54; 面積比(%): 97.17(最大), 98.23(254 nm)。
HPLC - Rt(分): 4.52; 面積比(%): 98.03(最大), 98.59(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.88(s, 1H), 7.80(d, J = 8.00 Hz, 1H), 7.36(s, 1H), 7.29(s, 1H), 7.17(dd, J = 8.00, 4.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.91(s, 3H), 3.25(t, J = 8.00 Hz, 2H), 2.96(t, J = 8.00 Hz, 4H), 2.16-2.10(m, 2H)。
LC-MS: 質量の実測値(M+, 394)。Rt(分): 3.68; 面積比(%): 96.28(最大), 95.65(220 nm)。
HPLC - Rt(分): 3.68; 面積比(%): 98.12(最大), 98.84(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.58(s, 1H), 8.33(d, J = 8.00 Hz, 1H), 7.92(d, J = 8.00 Hz, 1H), 7.34(s, 1H), 7.16(d, J = 8.00 Hz, 1H), 6.89(d, J = 12.00 Hz, 1H), 4.29(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.91(s, 3H), 3.32(t, J = 8.00 Hz, 2H), 3.22(s, 3H)。
LC-MS: 質量の実測値(M+, 366)。Rt(分): 2.95; 面積比(%): 98.45(最大), 98.53(254 nm)。
HPLC - Rt(分): 3.00; 面積比(%): 98.86(最大), 99.05(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.80-7.60(m, 1H), 7.52-7.31(m, 2H), 7.29-7.27(m, 2H), 7.25-7.00(m, 1H), 6.89(d, J = 8.00 Hz, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.90(s, 3H), 3.60(s, 2H), 3.28(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 394)。Rt(分): 3.44; 面積比(%): 90.94(最大), 92.33(254 nm)。
HPLC - Rt(分): 3.37; 面積比(%): 90.93(最大), 90.20(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.24(d, J = 8.00 Hz, 1H), 7.98(d, J = 8.00 Hz, 1H), 7.86(s, 1H), 7.34(s, 1H), 7.17(d, J = 8.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 4.25(t, J = 8.00 Hz, 2H), 4.13(t, J = 8.00 Hz, 2H), 3.95(s, 3H), 3.93(s, 3H), 3.25(q, J = 8.00 Hz, 4H), 2.27(s, 3H)。
LC-MS: 質量の実測値(M+, 366)。Rt(分): 2.94; 面積比(%): 90.16(最大), 90.02(254 nm)。
HPLC - Rt(分): 2.93; 面積比(%): 92.14(最大), 90.70(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.99(d, J = 8.00 Hz, 1H), 7.97(s, 1H), 7.54(d, J = 4.00 Hz, 1H), 7.32(d, J = 4.00 Hz, 1H), 7.19(d, J = 8.00 Hz, 1H), 6.90(t, J = 8.00 Hz, 2H), 4.26(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.91(s, 3H), 3.59(s, 2H), 3.26(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 368)。Rt(分): 3.25; 面積比(%): 98.89(最大), 98.63(254 nm)。
HPLC - Rt(分): 3.27; 面積比(%): 98.75(最大), 98.64(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.99(s, 1H), 7.90(d, J = 8.00 Hz, 1H), 7.75(s, 1H), 7.29-7.19(m, 3H), 6.90(d, J = 8.00 Hz, 1H), 4.27(t, J = 12.00 Hz, 2H), 3.94(s, 3H), 3.90(s, 3H), 3.29(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 366)。Rt(分): 2.82; 面積比(%): 93.91(最大), 94.20(220 nm)。
HPLC - Rt(分): 2.82; 面積比(%): 96.33(最大), 96.44(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.71(s, 1H), 8.25-8.22(m, 1H), 7.56(d, J = 8.00 Hz, 1H), 7.42(d, J = 4.00 Hz, 1H), 7.15(d, J = 8.00 Hz, 1H), 6.87(d, J = 8.00 Hz, 1H), 6.18(s, 1H), 4.53(s, 2H), 4.30(t, J = 8.00 Hz, 2H), 3.94(s, 3H), 3.93(s, 3H), 3.29(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 351)。Rt(分): 4.07; 面積比(%): 97.88(最大), 98.80(254 nm)。
HPLC - Rt(分): 4.06; 面積比(%): 97.93(最大), 98.39(254 nm)。
1H NMR 400 MHz, CDCl3: δ 8.32(s, 1H), 8.00(d, J = 8.00 Hz, 1H), 7.69(d, J = 4.00 Hz, 1H), 7.54(d, J = 8.00 Hz, 1H), 7.33(s, 1H), 7.19(dd, J = 8.00, 4.00 Hz, 1H), 6.88(d, J = 8.00 Hz, 1H), 6.85(dd, J = 2.00, 0.80 Hz, 1H), 4.29(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.88(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 362)。Rt(分): 2.56; 面積比(%): 98.56(最大), 99.01(254 nm)。
HPLC - Rt(分): 2.61; 面積比(%): 99.09(最大), 99.08(254 nm)。
1H NMR 400 MHz, CDCl3: δ 9.02(d, J = 3.20 Hz, 1H), 8.56(s, 1H), 8.40-8.36(m, 2H), 8.30-8.28(m, 1H), 7.58-7.52(m, 1H), 7.31(d, J = 4.00 Hz, 1H), 7.20(dd, J = 8.20, 1.60 Hz, 1H), 6.89(d, J = 8.00 Hz, 1H), 4.33(t, J = 8.00 Hz, 2H), 3.95(s, 3H), 3.86(s, 3H), 3.33(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 369)。Rt(分): 3.79; 面積比(%): 98.91(最大), 99.13(254 nm)。
HPLC - Rt(分): 3.86; 面積比(%): 99.02(最大), 99.47(254 nm)。
1H NMR 400 MHz, CDCl3: δ 7.69(s, 1H), 7.62(d, J = 8.00 Hz, 1H), 7.37(s, 1H), 7.19(dd, J = 10.80, 1.60 Hz, 1H), 6.90(dd, J = 8.00, 4.00 Hz, 2H), 4.33-4.28(m, 4H), 4.24(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.92(s, 3H), 3.23(t, J = 12.00 Hz, 2H)。
スキーム8
工程1:ピラゾリジン-3-オンの調製
黄色の油状液体;46.13%の収率
400 MHz, CDCl3: δ 7.06(s, 1H), 5.50(s, 1H), 3.52(t, J = 8.00 Hz, 2H), 2.50(t, J = 8.00 Hz, 2H)。
黄色の油状物質;32%の収率
LC-MS:質量の実測値(M+、209)
方法:A-0.1%のHCOOH、B-MeOH-1ml/分。Atlantis dC18(50 X 4.6mm、5μm)。Rt(分):1.64;面積比(%):98.34。
400 MHz, CDCl3: δ 9.20(s, 1H), 7.47-7.38(m, 2H), 7.34-7.31(m, 1H), 7.27-7.21(m, 1H), 4.17(t, J = 8.00 Hz, 2H), 2.81(t, J = 4.00 Hz, 2H)。
くすんだ緑色の固体;88.9%の収率
LC-MS:質量の実測値(M+、227)
方法:A-水中に0.1%のTFA、B-ACN中に0.1%のTFA:流量-0.6ml/分。カラム:Xbridge C8(50 X 4.6mm、3.5μm)。Rt(分):3.57;面積比(%):97.92(最大)、97.52(254nm)。
400 MHz, CDCl3: δ 7.65(d, J = 1.60 Hz, 1H), 7.59-7.55(m, 1H), 7.42-7.37(m, 1H), 7.21-7.16(m, 1H), 4.26(t, J = 4.00 Hz, 2H), 3.19(t, J = 4.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 298.3)。Rt(分): 3.91; 面積比(%): 92.20(最大), 92.90(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 3.96; 面積比(%): 93.79(最大), 92.74(254 nm)。
400 MHz, CDCl3: δ 7.71-7.69(m, 2H), 7.39-7.27(m, 6H), 7.25-7.09(m, 1H), 4.38(s, 2H), 4.15(t, J = 8.00 Hz, 2H), 2.89(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 316)。Rt(分): 3.99; 面積比(%): 97.94(最大), 97.97(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 4.03; 面積比(%): 96.51(最大), 97.27(254 nm)。
400 MHz, CDCl3: δ 7.71-7.69(m, 2H), 7.35-7.26(m, 3H), 7.15-7.11(m, 1H), 7.05(t, J = 4.00 Hz, 2H), 4.35(s, 1H), 4.34(s, 2H), 4.16(t, J = 4.00 Hz, 2H), 2.89(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 334)。Rt(分): 4.14; 面積比(%): 96.06(最大), 97.06(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 4.14; 面積比(%): 98.13(最大), 98.46(254 nm)。
400 MHz, DMSO-d6: δ 7.61(d, J = 8.00 Hz, 1H), 7.56-7.53(m, 1H), 7.43-7.32(m, 3H), 7.28-7.17(m, 2H), 7.05-7.01(m, 1H), 4.22(d, J = 8.00 Hz, 2H), 3.90(t, J = 8.00 Hz, 2H), 2.84(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 334)。Rt(分): 4.11; 面積比(%): 90.56(最大), 91.60(254 nm)。
HPLC -流速- 1.0 ml/分. Rt(分): 4.18; 面積比(%): 93.32(最大), 92.10(254 nm)。
400 MHz, CDCl3: δ 7.67-7.61(m, 2H), 7.33(dd, J = 16.00, 8.00 Hz, 1H), 7.17-7.10(m, 3H), 7.04(s, 1H), 4.47(s, 1H), 4.31(d, J = 8.00 Hz, 2H), 4.15(t, J = 8.00 Hz, 2H), 2.89(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 330.3)。Rt(分): 4.36; 面積比(%): 91.22(最大), 95.34(254 nm)。
HPLC -流速- 1.0ml/分. Rt(分): 4.38; 面積比(%): 93.82(最大), 95.05(254 nm)。
400 MHz, CDCl3: δ 7.79-7.74(m, 2H), 7.35-7.30(m, 1H), 7.21-7.17(m, 2H), 7.12-7.01(m, 3H), 4.37(s, 2H), 4.19(t, J = 8.00 Hz, 2H), 2.96(t, J = 12.00 Hz, 2H), 2.91(s, 3H)。
LC-MS: 質量の実測値(M+, 342.3)。Rt(分): 4.26; 面積比(%): 95.68(最大), 96.68(254 nm)。
HPLC -流速- 1.0ml/分. Rt(分): 4.27; 面積比(%): 93.14(最大), 95.01(254 nm)。
400 MHz, CDCl3: δ 7.81(t, J = 8.00 Hz, 2H), 7.36-7.26(m, 2H), 7.12-7.07(m, 1H), 6.85-6.76(m, 3H), 4.40(s, 2H), 4.21(t, J = 8.00 Hz, 2H), 3.78(s, 3H), 2.98(t, J = 8.00 Hz, 2H), 2.94(s, 3H)。
LC-MS: 質量の実測値(M+, 330.3)。Rt(分): 4.34; 面積比(%): 91.12(最大), 94.21(254 nm)。
HPLC -流速- 1.0ml/分. Rt(分): 4.37; 面積比(%): 91.70(最大), 94.99(254 nm)。
400 MHz, CDCl3: δ 7.79-7.74(m, 2H), 7.35-7.27(m, 2H), 7.13-7.08(m, 1H), 7.01-6.92(m, 3H), 4.42(s, 2H), 4.21(t, J = 8.00 Hz, 2H), 3.02(t, J = 8.00 Hz, 2H), 2.96(s, 3H)。
スキーム9
方法:A-水中に0.1%のTFA、B-ACN中に0.1%のTFA:流量-2ml/分;カラム:XBridge c8(50 X 4.6mm、3.5μm);別段の記述のない限り。
LC-MS: 質量の実測値(M+, 269.0)。Rt(分): 4.47; 面積比(%): 99.47(最大), 99.55(220 nm)。
HPLC - Rt(分): 4.55; 面積比(%): 98.88(最大), 99.70(254 nm)。
400 MHz, CDCl3: δ 7.76-7.70(m, 4H), 7.45-7.40(m, 4H), 7.23-7.18(m, 1H), 4.28(t, J = 8.00 Hz, 2H), 3.30(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 283.0)。Rt(分): 4.80; 面積比(%): 97.87(最大), 97.31(254 nm)。
HPLC - Rt(分): 4.87; 面積比(%): 99.21(最大), 99.0(254 nm)。
400 MHz, CDCl3: δ 7.82-7.80(m, 1H), 7.77-7.75(m, 1H), 7.61-7.59(m, 2H), 7.45-7.40(m, 1H), 7.24-7.18(m, 3H), 4.26(t, J = 9.76 Hz, 2H), 3.28(t, J = 10.12 Hz, 2H), 2.40(s, 3H)。
LC-MS: 質量の実測値(M+, 345.3)。Rt(分): 5.35; 面積比(%): 98.25(最大), 94.69(254 nm)。
HPLC - Rt(分): 5.43; 面積比(%): 98.34(最大), 95.50(254 nm)。
400 MHz, CDCl3: δ 7.82-7.76(m, 4H), 7.68-7.62(m, 4H), 7.50-7.40(m, 4H), 7.38-7.21(m, 1H), 4.30(t, J = 9.60 Hz, 2H), 3.37-3.32(m, 2H)。
LC-MS: 質量の実測値(M+, 361)。流速- 0.6 ml/分. Rt(分): 5.40; 面積比(%): 95.59(最大), 94.88(220 nm)。
HPLC - Rt(分): 3.45; 面積比(%): 97.77(最大), 97.44(220 nm)。
400 MHz, CDCl3: δ 7.80(d, J = 8.00 Hz, 1H), 7.75-7.73(m, 1H), 7.69-7.66(m, 2H), 7.44-7.37(m, 3H), 7.22-7.16(m, 2H), 7.07-7.00(m, 4H), 4.27(t, J = 8.00 Hz, 2H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 313)。流速- 0.6ml/分. Rt(分): 3.65; 面積比(%): 98.41(最大), 97.27(220 nm)。
HPLC - Rt(分): 3.60; 面積比(%): 97.42(最大), 94.73(254 nm)。
400 MHz, DMSO-d6: δ 13.00(brs, 1H), (8.00(d, J =8.00 Hz, 2H), 7.79(d, J = 12.00 Hz, 2H), 7.70(d, J = 8.00 Hz, 1H), 7.64-7.60(m, 1H), 7.57-7.52(m, 1H), 7.42-7.37(m, 1H), 4.14(t, J = 12.00 Hz, 2H), 3.36-3.34(m, 2H)。
LC-MS: 質量の実測値(M+, 337.0)。流速- 0.6 ml/分. Rt(分): 5.22; 面積比(%): 98.50(最大), 97.31(254 nm)。
HPLC - Rt(分): 5.28; 面積比(%): 98.50(最大), 99.20(254 nm)。
400 MHz, CDCl3: δ 7.80-7.73(m, 3H), 7.71-7.67(m, 3H), 7.47-7.42(m, 1H), 7.25-7.20(m, 1H), 4.32(t, J = 9.76 Hz, 2H), 3.32(t, J = 10.36 Hz, 2H)。
LC-MS: 質量の実測値(M+, 295.0)。Rt(分): 4.90; 面積比(%): 97.52(最大), 95.52(220 nm)。
HPLC - Rt(分): 5.02; 面積比(%): 96.52(最大), 96.25(220 nm)。
400 MHz, CDCl3: δ 7.80-7.77(m, 1H), 7.74-7.68(m, 1H), 7.66-7.47(m, 2H), 7.46-7.41(m, 3H), 7.24-7.19(m, 1H), 6.78-6.71(m, 1H), 5.84(d, J = 16.96 Hz, 1H), 5.35(d, J = 11.28 Hz, 1H), 4.28(t, J = 9.72 Hz, 2H), 3.30(t, J = 10.36 Hz, 2H)。
LC-MS: 質量の実測値(M+, 299.0)。Rt(分): 3.36; 面積比(%): 98.53(最大), 96.80(220 nm)。
HPLC - Rt(分): 3.45; 面積比(%): 99.82(最大), 99.46(254 nm)。
400 MHz, CDCl3: δ 7.82-7.76(m, 1H), 7.74-7.33(m, 1H), 7.70-7.68(m, 2H), 7.46-7.40(m, 3H), 7.23-7.18(m, 1H), 4.75(s, 2H), 4.24(t, J = 9.64 Hz, 2H), 3.30-3.25(m, 2H)。
LC-MS: 質量の実測値(M+, 297.2)。Rt(分): 5.13; 面積比(%): 99.3(最大), 99.21(254 nm)。
HPLC - Rt(分): 5.21; 面積比(%): 99.42(最大), 98.15(254 nm)。
400 MHz, CDCl3: δ 7.82-7.80(m, 1H), 7.77-7.74(m, 1H), 7.64-7.62(m, 2H), 7.45-7.39(m, 1H), 7.24-7.22(m, 2H), 7.21-7.17(m, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.31-3.26(m, 2H), 2.72-2.66(m, 2H), 1.26(t, J = 4.00 Hz, 3H)。
LC-MS: 質量の実測値(M+, 325.3)。流速- 0.6ml/分. Rt(分): 5.64; 面積比(%): 91.91(最大), 90.29(220 nm)。
HPLC - Rt(分): 5.67; 面積比(%): 99.16(最大), 99.52(254 nm)。
400 MHz, CDCl3: δ 7.82(d, J = 8.00 Hz, 1H), 7.77(d, J = 12.00 Hz, 1H), 7.66(d, J = 12.00 Hz, 2H), 7.46-7.40(m, 3H), 7.23-7.18(m, 1H), 4.27(t, J = 8.00 Hz, 2H), 3.29(t, J = 12.00 Hz, 2H), 1.35(s, 9H)。
LC-MS: 質量の実測値(M+, 311.3)。Rt(分): 5.39; 面積比(%): 98.99(最大), 99.09(254 nm)。
HPLC - Rt(分): 5.49; 面積比(%): 99.35(最大), 98.07(254 nm)。
400 MHz, CDCl3: δ 7.82-7.80(m, 1H), 7.77-7.74(m, 1H), 7.65-7.63(m, 2H), 7.44-7.39(m, 1H), 7.28-7.27(m, 2H), 7.22-7.17(m, 1H), 4.26(t, J = 9.60 Hz, 2H), 3.30(t, J = 3.60 Hz, 2H), 2.98-2.91(m, 1H), 1.28(s, 3H), 1.27(d, J = 8 Hz, 3H)。
LC-MS: 質量の実測値(M+, 285.2)。流速- 0.6 ml/分。Rt(分): 4.26; 面積比(%): 92.32(最大), 98.21(254 nm)。
HPLC - Rt(分): 4.29; 面積比(%): 95.02(最大), 97.61(254 nm)。
400 MHz, CDCl3: δ 7.57(d, J = 8.00 Hz, 1H), 7.50-7.47(m, 1H), 7.41-7.37(m, 2H), 7.36-7.29(m, 3H), 7.25-7.22(m, 1H), 7.17-7.13(m, 1H), 4.25(t, J = 8.00 Hz, 2H), 3.21(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 353.0)。Rt(分): 5.28; 面積比(%): 98.08(最大), 98.31(254 nm)。
HPLC - Rt(分): 5.34; 面積比(%): 98.97(最大), 98.90(254 nm)。
400 MHz, CDCl3: δ 7.75-7.71(m, 4H), 7.46-7.44(m, 1H), 7.43-7.41(m, 1H), 7.24-7.19(m, 2H), 4.32-4.27(m, 2H), 3.32-3.27(m, 2H)。
LC-MS: 質量の実測値(M+, 311.3)。流速- 0.6 ml/分. Rt(分): 4.10; 面積比(%): 98.68(最大), 97.93(254 nm)。
HPLC - Rt(分): 4.13; 面積比(%): 99.20(最大), 98.38(254 nm)。
400 MHz, CDCl3: δ 8.01(d, J = 8.00 Hz, 2H), 7.81-7.72(m, 4H), 7.47-7.42(m, 1H), 7.23-7.21(m, 1H), 4.32(t, J = 8.00 Hz, 2H), 3.33(t, J = 12.00 Hz, 2H), 2.64(s, 3H)。
LC-MS: 質量の実測値(M+, 326.3)。流速- 0.6 ml/分. Rt(分): 2.75; 面積比(%): 97.95(最大), 97.13(254 nm)。
HPLC - Rt(分): 2.71; 面積比(%): 98.51(最大), 97.78(254 nm)。
400 MHz, CDCl3: δ 7.81(d, J = 8.00 Hz, 1H), 7.76-7.74(m, 1H), 7.67(d, J = 8.00 Hz, 2H), 7.45-7.40(m, 1H), 7.37(d, J = 8.00 Hz, 2H), 7.23-7.18(m, 1H), 4.27(t, J = 12.00 Hz, 2H), 3.47(s, 2H), 3.30(t, J = 8.00 Hz, 2H), 2.26(s, 6H)。
LC-MS: 質量の実測値(M+, 347.0)。Rt(分): 3.60; 面積比(%): 97.31(最大), 96.0(220 nm)。
HPLC - Rt(分): 3.73; 面積比(%): 98.07(最大), 96.61(254 nm)。
400 MHz, CDCl3: δ 8.01-7.99(m, 2H), 7.89-7.87(m, 2H), 7.78-7.76(m, 1H), 7.72-7.69(m, 1H), 7.48-7.42(m, 1H), 7.28-7.23(m, 1H), 4.34(t, J =9.80 Hz, 2H), 3.36-3.31(m, 2H), 3.08(s, 3H)。
LC-MS: 質量の実測値(M+, 340.0)。Rt(分): 3.44; 面積比(%): 97.35(最大), 98.22(254 nm)。
HPLC - Rt(分): 3.56; 面積比(%): 97.53(最大), 97.70(254 nm)。
400 MHz, CDCl3: δ 7.75-7.73(m, 1H), 7.73-7.72(m, 3H), 7.50-7.47(m, 2H), 7.46-7.41(m, 1H), 7.24-7.19(m, 1H), 4.32-4.27(m, 2H), 3.34-3.29(m, 2H), 3.06(brs, 6H)。
LC-MS: 質量の実測値(M+, 341.0)。Rt(分): 5.21; 面積比(%): 95.26(最大), 95.0(254 nm)。
HPLC - Rt(分): 5.31; 面積比(%): 95.36(最大), 95.12(254 nm)。
400 MHz, CDCl3: δ 7.80(d, J = 8.00 Hz, 1H), 7.76-7.73(m, 1H), 7.64-7.61(m, 2H), 7.44-7.39(m, 1H), 7.22-7.17(m, 1H), 7.05-7.01(m, 2H), 4.25(t, J = 12.00 Hz, 2H), 3.27(t, J = 12.00 Hz, 2H), 1.39(s, 9H)。
LC-MS: 質量の実測値(M+, 376.0)。Rt(分): 4.21; 面積比(%): 99.06(最大), 98.96(220 nm)。
HPLC - Rt(分): 4.32; 面積比(%): 99.11(最大), 98.07(254 nm)。
400 MHz, CDCl3: δ 7.87-7.84(m, 4H), 7.83-7.77(m, 1H), 7.73-7.72(m, 1H), 7.48-7.42(m, 1H), 7.28-7.23(m, 1H), 4.33(t, J = 9.76 Hz, 2H), 3.33(t, J = 10.56 Hz, 2H), 2.74(s, 6H)。
LC-MS: 質量の実測値(M+, 313.3)。流速- 0.6 ml/分. Rt(分): 3.68; 面積比(%): 96.31(最大), 97.70(254 nm)。
HPLC - Rt(分): 3.66; 面積比(%): 96.38(最大), 97.14(254 nm)。
400 MHz, DMSO-d6: δ 13.25(brs, 1H), 8.18(brs, 1H), 8.01(d, J = 8.00 Hz, 1H), 7.92(d, J = 8.00 Hz, 1H), 7.69(d, J = 8.00 Hz, 1H), 7.64-7.52(m, 3H), 7.42-7.37(m, 1H), 4.14(t, J = 8.00 Hz, 2H), 3.41-3.32(m, 2H)。
LC-MS: 質量の実測値(M+, 283.0)。Rt(分): 4.77; 面積比(%): 96.24(最大), 97.25(254 nm)。
HPLC - Rt(分): 4.88; 面積比(%): 96.34(最大), 96.52(254 nm)。
400 MHz, CDCl3: δ 7.81(d, J = 8.00 Hz, 1H), 7.76-7.74(m, 1H), 7.52-7.50(m, 2H), 7.46-7.42(m, 1H), 7.33-7.29(m, 1H), 7.24-7.18(m, 2H), 4.26(t, J = 12.00 Hz, 2H), 3.29(t, J = 8.00 Hz, 2H), 2.40(s, 3H)。
LC-MS: 質量の実測値(M+, 337.0)。Rt(分): 5.12; 面積比(%): 98.56(最大), 98.32(254 nm)。
HPLC - Rt(分): 5.22; 面積比(%): 99.58(最大), 99.09(254 nm)。
400 MHz, CDCl3: δ 7.93(d, J = 8.00 Hz, 1H), 7.88(brs, 1H), 7.78(d, J = 8.00 Hz, 1H), 7.72-7.68(m, 2H), 7.58-7.54(m, 1H), 7.47-7.41(m, 1H), 7.25-7.20(m, 1H), 4.32(t, J = 8.00 Hz, 2H), 3.33(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 284)。Rt(分): 2.61; 面積比(%): 96.86(最大), 93.73(254 nm)。
HPLC - Rt(分): 2.60; 面積比(%): 96.52(最大), 93.72(254 nm)。
400 MHz, CDCl3: δ 7.79(d, J = 8.00 Hz, 1H), 7.75-7.72(m, 1H), 7.45-7.40(m, 1H), 7.23-7.18(m, 2H), 7.07-7.01(m, 2H), 6.78-6.75(m, 1H), 4.25(t, J = 12.00 Hz, 2H), 3.78(brs, 2H), 3.26(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 326.3)。Rt(分): 3.51; 面積比(%): 98.63(最大), 99.22(254 nm)。
HPLC - Rt(分): 3.50; 面積比(%): 98.69(最大), 99.55(254 nm)。
400 MHz, CDCl3: δ 7.79(d, J = 8.00 Hz, 1H), 7.74-7.71(m, 1H), 7.66(d, J = 8.00 Hz, 1H), 7.47-7.36(m, 3H), 7.24-7.21(m, 2H), 4.28(t, J = 8.00 Hz, 2H), 3.30(t, J = 12.00 Hz, 2H), 2.21(s, 3H)。
LC-MS: 質量の実測値(M+, 326.3)。Rt(分): 4.61; 面積比(%): 99.22(最大), 98.49(254 nm)。
HPLC - Rt(分): 4.63; 面積比(%): 99.50(最大), 98.40(254 nm)。
400 MHz, CDCl3: δ 7.79(d, J = 4.00 Hz, 1H), 7.73-7.70(m, 1H), 7.48-7.38(m, 4H), 7.24-7.19(m, 1H), 7.17-7.12(m, 1H), 4.29(t, J = 12.00 Hz, 2H), 3.31-3.26(m, 2H)。
LC-MS: 質量の実測値(M+, 313.0)。Rt(分): 4.83; 面積比(%): 97.72(最大), 98.24(254 nm)。
HPLC - Rt(分): 4.91; 面積比(%): 98.07(最大), 98.95(254 nm)。
400 MHz, CDCl3: δ 7.94-7.74(m, 2H), 7.45-7.39(m, 2H), 7.35-7.31(m, 1H), 7.28-7.24(m, 1H), 7.22-7.19(m, 1H), 6.98-6.95(m, 1H), 4.26(t, J = 12.00 Hz, 2H), 4.09-4.04(m, 2H), 3.28(t, J = 8.00 Hz, 2H), 1.44(t, J =8.00 Hz, 3H)。
LC-MS: 質量の実測値(M+, 285.3)。Rt(分): 3.70; 面積比(%): 93.85(最大), 95.49(254 nm)。
HPLC - Rt(分): 3.72; 面積比(%): 97.02(最大), 96.72(254 nm)。
400 MHz, DMSO-d6: δ 7.69(d, J = 8.00 Hz, 1H), 7.63-7.61(m, 1H), 7.56-7.51(m, 1H), 7.41-7.36(m, 1H), 7.26(t, J = 8.00 Hz, 1H), 7.11-7.10(m, 2H), 6.86-6.84(m, 1H), 4.09(t, J = 12.00 Hz, 2H), 3.32-3.26(m, 2H)。
LC-MS: 質量の実測値(M+, 311.3)。Rt(分): 5.39; 面積比(%): 98.67(最大), 97.0(254 nm)。
HPLC - Rt(分): 5.49; 面積比(%): 98.55(最大), 96.42(254 nm)。
400 MHz, CDCl3: δ 7.89-7.86(m, 1H), 7.82-7.79(m, 1H), 7.54-7.52(m, 2H), 7.43-7.42(m, 1H), 7.35-7.30(m, 2H), 7.26-7.20(m, 1H), 4.27(t, J = 8.00 Hz, 2H), 3.30(t, J = 12.00 Hz, 2H), 2.97-2.93(m, 1H), 1.28(s, 3H), 1.26(s, 3H)。
LC-MS: 質量の実測値(M+, 299.3)。Rt(分): 3.51; 面積比(%): 97.69(最大), 95.92(254 nm)。
HPLC - Rt(分): 3.52; 面積比(%): 97.98(最大), 95.78(254 nm)。
400 MHz, CDCl3: δ 7.80(d, J = 8.00 Hz, 1H), 7.75-7.72(m, 1H), 7.69-7.65(m, 2H), 7.46-7.41(m, 3H), 7.24-7.18(m, 1H), 4.76(d, J = 4.00 Hz, 2H), 4.28(t, J = 8.00 Hz, 2H), 3.31(t, J = 12.00 Hz, 2H), 1.80(t, J = 8.00 Hz, 1H)。
LC-MS: 質量の実測値(M+, 345.3)。Rt(分): 5.40; 面積比(%): 98.51(最大), 99.15(254 nm)。
HPLC - Rt(分): 5.42; 面積比(%): 99.52(最大), 98.95(254 nm)。
400 MHz, CDCl3: δ 7.88(brs, 1H), 7.82(d, J = 8.00 Hz, 1H), 7.78-7.71(m, 2H), 7.68-7.65(m, 1H), 7.62-7.60(m, 2H), 7.52-7.38(m, 5H), 7.24-7.19(m, 1H), 4.31(t, J = 8.00 Hz, 2H), 3.36(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 294.0)。Rt(分): 4.22; 面積比(%): 97.71(最大), 98.24(254 nm)。
HPLC - Rt(分): 4.25; 面積比(%): 98.09(最大), 98.66(254 nm)。
400 MHz, CDCl3: δ 7.95-7.93(m, 2H), 7.77-7.66(m, 3H), 7.58-7.53(m, 1H), 7.49-7.43(m, 1H), 7.24-7.21(m, 1H), 4.33(t, J = 8.00 Hz, 2H), 3.31(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 312.3)。Rt(分): 3.0; 面積比(%): 98.03(最大), 96.58(254 nm)。
HPLC - Rt(分): 3.01; 面積比(%): 98.58(最大), 97.49(254 nm)。
400 MHz, CDCl3: δ 7.83-7.78(m, 2H), 7.43-7.38(m, 1H), 7.30-7.27(m, 1H), 7.21-7.16(m, 1H), 7.08(brs, 1H), 7.04-7.02(m, 1H), 6.83-6.80(m, 1H), 4.26(t, J = -8.00 Hz, 2H), 3.32-3.27(m, 2H), 2.98(s, 6H)。
LC-MS: 質量の実測値(M+, 315.3)。Rt(分): 4.89; 面積比(%): 95.38(最大), 94.13(254 nm)。
HPLC - Rt(分): 4.90; 面積比(%): 96.80(最大), 95.64(254 nm)。
400 MHz, CDCl3: δ 7.80(d, J = 8.00 Hz, 1H), 7.77-7.74(m, 1H), 7.58(brs, 1H), 7.48-7.42(m, 2H), 7.37-7.30(m, 2H), 7.24-7.21(m, 1H), 4.28(t, J = 12.00 Hz, 2H), 3.29(t, J = 8.00 Hz, 2H), 2.52(s, 3H)。
LC-MS: 質量の実測値(M+, 353.0)。Rt(分): 5.26; 面積比(%): 99.73(最大), 99.55(254 nm)。
HPLC - Rt(分): 5.34; 面積比(%): 99.59(最大), 98.97(254 nm)。
400 MHz, CDCl3: δ 7.78(d, J = 8.00 Hz, 1H), 7.71(d, J = 8.00 Hz, 1H), 7.63(d, J = 8.00 Hz, 1H), 7.53(brs, 1H), 7.48-7.41(m, 2H), 7.30-7.28(m, 1H), 7.24-7.19(m, 1H), 4.30(t, J =8.00 Hz, 2H), 3.29(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 362.0)。Rt(分): 3.62; 面積比(%): 99.17(最大), 98.40(254 nm)。
HPLC - Rt(分): 3.77; 面積比(%): 99.44(最大), 99.11(254 nm)。
400 MHz, CDCl3: δ 7.78(d, J = 8.00 Hz, 1H), 7.72(d, J =8.00 Hz, 1H), 7.54-7.53(m, 1H), 7.51-7.48(m, 1H), 7.45-7.41(m, 2H), 7.34-7.32(m, 1H), 7.24-7.19(m, 1H), 6.56(brs, 1H), 4.29(t, J = 8.00 Hz, 2H), 3.29(t, J = 12.00 Hz, 2H), 3.04(s, 3H)。
LC-MS: 質量の実測値(M+, 326.0)。Rt(分): 3.31; 面積比(%): 98.77(最大), 99.10(254 nm)。
HPLC - Rt(分): 3.40; 面積比(%): 98.47(最大), 99.25(254 nm)。
400 MHz, CDCl3: δ 8.05(brs, 1H), 7.90-7.88(m, 1H), 7.79-7.77(m, 2H), 7.72(d, J = 12.00 Hz, 1H), 7.51-7.41(m, 2H), 7.24-7.19(m, 1H), 6.19(brs, 1H), 4.29(t, J = 12.00 Hz, 2H), 3.33(t, J = 12.00 Hz, 2H), 3.05(d, J = 4.00 Hz, 3H)。
LC-MS: 質量の実測値(M+, 380.0)。Rt(分): 4.32; 面積比(%): 93.75(最大), 94.50(254 nm)。
HPLC - Rt(分): 4.44; 面積比(%): 93.94(最大), 94.41(254 nm)。
400 MHz, CDCl3: δ 8.05(brs, 1H), 7.88-7.86(m, 1H), 7.80-7.75(m, 3H), 7.50-7.40(m, 2H), 7.24-7.19(m, 1H), 4.45-4.39(m, 1H), 4.30(t, J = 8.00 Hz, 2H), 3.36-3.31(m, 2H), 2.15-2.08(m, 2H), 1.77-1.68(m, 4H), 1.56-1.49(m, 2H)。
LC-MS: 質量の実測値(M+, 335.0)。Rt(分): 4.33; 面積比(%): 98.42(最大), 98.52(254 nm)。
HPLC - Rt(分): 4.35; 面積比(%): 98.50(最大), 98.49(254 nm)。
400 MHz, CDCl3: δ 8.01(brs, 1H), 7.97(d, J = 4.00 Hz, 1H), 7.81-7.66(m, 5H), 7.53-7.47(m, 1H), 7.46-7.42(m, 1H), 7.25-7.20(m, 1H), 6.52-6.51(m, 1H), 4.31(t, J = 12.00 Hz, 2H), 3.36(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 317.3)。Rt(分): 4.49; 面積比(%): 99.44(最大), 99.09(254 nm)。
HPLC - Rt(分): 4.50; 面積比(%): 99.48(最大), 99.51(254 nm)。
400 MHz, CDCl3: δ 7.72-7.70(m, 2H), 7.53-7.40(m, 3H), 7.23-7.18(m, 1H), 7.00-6.96(m, 1H), 4.26(t, J = 12.00 Hz, 2H), 3.94(s, 3H), 3.27-3.22(m, 2H)。
LC-MS: 質量の実測値(M+, 313.0)。Rt(分): 4.18; 面積比(%): 99.32(最大), 99.31(254 nm)。
HPLC - Rt(分): 4.98; 面積比(%): 97.95(最大), 99.85(254 nm)。
400 MHz, CDCl3: δ 7.81(d, J = 8.00 Hz, 1H), 7.76(d, J = 8.00 Hz, 1H), 7.52-7.50(m, 2H), 7.45-7.40(m, 1H), 7.22-7.17(m, 1H), 6.85(d, J = 8.00 Hz, 1H), 4.24(t, J = 12.00 Hz, 2H), 3.88(s, 3H), 3.26(t, J = 12.00 Hz, 2H), 2.24(s, 3H)。
LC-MS: 質量の実測値(M+, 344.0)。Rt(分): 4.45; 面積比(%): 93.51(最大), 91.34(254 nm)。
HPLC - Rt(分): 4.40; 面積比(%): 94.94(最大), 94.32(220 nm)。
400 MHz, CDCl3: δ 7.94(s, 1H), 7.76(d, J = 8.00 Hz, 1H), 7.69(d, J = 8.00 Hz, 1H), 7.53-7.41(m, 1H), 7.72-7.14(m, 3H), 4.30(t, J = 12.00 Hz, 2H), 4.02(s, 3H), 3.29(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 383.0)。Rt(分): 5.14; 面積比(%): 97.77(最大), 98.83(254 nm)。
HPLC - Rt(分): 5.13; 面積比(%): 98.99(最大), 98.49(254 nm)。
400 MHz, CDCl3: δ 7.83(d, J = 8.00 Hz, 2H), 7.44-7.38(m, 2H), 7.22-7.17(m, 1H), 7.15-7.13(m, 1H), 6.87(d, J = 8.00 Hz, 1H), 4.80-4.76(m, 1H), 4.26(t, J = 12.00 Hz, 2H), 3.90(s, 3H), 3.27(t, J = 8.00 Hz, 2H), 2.02-1.83(m, 6H), 1.66-1.65(m, 2H)。
LC-MS: 質量の実測値(M+, 333.0)。Rt(分): 4.74; 面積比(%): 97.19(最大), 95.73(254 nm)。
HPLC - Rt(分): 4.74; 面積比(%): 96.09(最大), 95.64(254 nm)。
400 MHz, CDCl3: δ 7.79(d, J = 4.00 Hz, 1H), 7.73-7.71(m, 2H), 7.60-7.57(m, 1H), 7.46-7.41(m, 1H), 7.24-7.19(m, 1H), 6.98-6.96(m, 1H), 4.27(t, J =8.00 Hz, 2H), 3.92(s, 3H), 3.25(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 314.0)。Rt(分): 2.72; 面積比(%): 96.03(最大), 93.93(220 nm)。
HPLC - Rt(分): 2.70; 面積比(%): 96.75(最大), 94.64(254 nm)。
400 MHz, CDCl3: δ 7.80(d, J = 8.00 Hz, 1H), 7.75(d, J = 8.00 Hz, 1H), 7.45-7.39(m, 1H), 7.22-7.17(m, 1H), 7.15-7.12(m, 1H), 7.03-7.01(m, 1H), 6.80(d, J = 12.00 Hz, 1H), 4.23(t, J = 12.00 Hz, 2H), 3.90(s, 5H), 3.24(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 343.3)。Rt(分): 3.39; 面積比(%): 92.46(最大), 92.31(254 nm)。
HPLC - Rt(分): 3.40; 面積比(%): 94.26(最大), 93.30(220 nm)。
400 MHz, DMSO-d6: δ 12.87(brs, 1H), 7.91(d, J = 4.00 Hz, 1H), 7.83-7.80(m, 1H), 7.69(d, J = 8.00 Hz, 1H), 7.64-7.61(m, 1H), 7.56-7.50(m, 1H), 7.40-7.35(m, 1H), 7.23(d, J = 12.00 Hz, 1H), 4.10(t, J = 12.00 Hz, 2H), 3.86(s, 3H), 3.32(m, 2H)。
LC-MS: 質量の実測値(M+, 367.0)。Rt(分): 5.06; 面積比(%): 98.62(最大), 98.09(254 nm)。
HPLC - Rt(分): 5.07; 面積比(%): 98.87(最大), 98.88(254 nm)。
400 MHz, CDCl3: δ 7.91-7.90(m, 1H), 7.88(brs, 1H), 7.79(d, J = 8.00 Hz, 1H), 7.73(d, J = 12.00 Hz, 1H), 7.46-7.40(m, 1H), 7.24-7.19(m, 1H), 7.06(d, J = 8.00 Hz, 1H), 4.29(t, J = 8.00 Hz, 2H), 3.97(s, 3H), 3.29(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 448.0)。Rt(分): 3.87; 面積比(%): 99.57(最大), 99.73(220 nm)。
HPLC - Rt(分): 3.93; 面積比(%): 96.23(最大), 98.86(254 nm)。
400 MHz, CDCl3: δ 8.08-8.07(m, 1H), 8.02-7.99(m, 1H), 7.78(d, J = 8.00 Hz, 1H), 7.75-7.70(m, 1H), 7.46-7.41(m, 1H), 7.23-7.18(m, 1H), 6.99-6.97(m, 1H), 4.29(t, J = 8.00 Hz, 2H), 4.00-3.99(m, 4H), 3.76-3.73(m, 4H), 3.32-3.26(m, 5H)。
LC-MS: 質量の実測値(M+, 434.0)。Rt(分): 4.54; 面積比(%): 98.98(最大), 98.55(254 nm)。
HPLC - Rt(分): 4.60; 面積比(%): 98.91(最大), 98.61(254 nm)。
400 MHz, CDCl3: δ 8.12(d, J = 4.00 Hz, 1H), 7.98-7.96(m, 1H), 7.79(d, J = 8.00 Hz, 1H), 7.72(d, J = 8.00 Hz, 1H), 7.46-7.40(m, 1H), 7.23-7.18(m, 1H), 7.05(d, J = 12.00 Hz, 1H), 4.28(t, J = 12.00 Hz, 2H), 3.99(s, 3H), 3.39-3.28(m, 6H), 1.15-1.11(m, 6H)。
LC-MS: 質量の実測値(M+, 468.0)。Rt(分): 4.46; 面積比(%): 98.14(最大), 98.48(254 nm)。
HPLC - Rt(分): 4.57; 面積比(%): 98.34(最大), 98.23(220 nm)。
400 MHz, CDCl3: δ 8.07-0.00(m, 1H), 8.02-8.01(m, 1H), 8.00-7.99(m, 1H), 7.81-7.79(m, 1H), 7.47-7.42(m, 1H), 7.28-7.21(m, 4H), 7.21-7.12(m, 2H), 7.00-6.98(m, 1H), 5.15-5.12(m, 1H), 4.33-4.28(m, 2H), 4.14-4.13(m, 2H), 3.89(s, 3H), 3.33-3.29(m, 2H)。
LC-MS: 質量の実測値(M+, 343.0)。Rt(分): 4.34; 面積比(%): 91.93(最大), 93.17(254 nm)。
HPLC - Rt(分): 4.42; 面積比(%): 92.49(最大), 94.39(254 nm)。
400 MHz, CDCl3: δ 7.82-7.78(m, 2H), 7.54-7.42(m, 1H), 7.41-7.39(m, 1H), 7.20-7.16(m, 2H), 6.90-6.88(m, 1H), 4.26(t, J = 9.60 Hz, 2H), 4.16-4.11(m, 2H), 3.92(s, 3H), 3.27(t, J = 10.00 Hz, 2H), 1.49(t, J = -6.40 Hz, 3H)。
LC-MS: 質量の実測値(M+, 405.0)。Rt(分): 5.03; 面積比(%): 95.97(最大), 95.98(220 nm)。
HPLC - Rt(分): 5.09; 面積比(%): 95.49(最大), 93.96(254 nm)。
400 MHz, CDCl3: δ 7.76-7.74(m, 2H), 7.45-7.40(m, 3H), 7.36-7.31(m, 4H), 7.31-7.27(m, 1H), 7.23-7.21(m, 1H), 7.18-6.89(m, 1H), 5.31-5.19(m, 2H), 4.23(t, J = 9.60 Hz, 2H), 3.94(s, 3H), 3.21(t, J = 10.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 357.3)。Rt(分): 4.66; 面積比(%): 98.26(最大), 98.37(254 nm)。
HPLC - Rt(分): 4.72; 面積比(%): 90.49(最大), 91.41(254 nm)。
400 MHz, CDCl3: δ 7.82-7.78(m, 2H), 7.44-7.40(m, 1H), 7.38-7.36(m, 1H), 7.20-7.18(m, 2H), 6.90-6.88(m, 1H), 4.59-4.53(m, 1H), 4.28-4.23(m, 2H), 3.90(s, 3H), 3.28-3.23(m, 2H), 1.40-1.38(m, 6H)。
LC-MS: 質量の実測値(M+, 315)。Rt(分): 3.68; 面積比(%): 94.03(最大), 97.23(254 nm)。
HPLC - Rt(分): 3.63; 面積比(%): 95.31(最大), 97.24(254 nm)。
400 MHz, DMSO-d6: δ 9.32(brs, 1H), 7.69(d, J = 8.00 Hz, 1H), 7.63-7.61(m, 1H), 7.56-7.50(m, 1H), 7.40-7.35(m, 1H), 7.16-7.15(m, 1H), 7.10-7.07(m, 1H), 6.98(d, J = 12.00 Hz, 1H), 4.07(t, J = 8.00 Hz, 2H), 3.79(s, 3H), 3.26(t, J = 8.00 Hz, 2H).
LC-MS: 質量の実測値(M+, 283.0)。Rt(分): 4.80; 面積比(%): 99.36(最大), 99.56(254 nm)。
HPLC - Rt(分): 4.83; 面積比(%): 99.10(最大), 99.04(254 nm)。
400 MHz, CDCl3: δ 7.78-7.70(m, 2H), 7.45-7.37(m, 2H), 7.32-7.29(m, 2H), 7.28-7.27(m, 1H), 7.20-7.16(m, 1H), 4.22(t, J = 8.00 Hz, 2H), 3.37(t, J = 8.00 Hz, 2H), 2.52(s, 3H)。
LC-MS: 質量の実測値(M+, 345.3)。Rt(分): 5.26; 面積比(%): 97.11(最大), 97.01(254 nm)。
HPLC - Rt(分): 5.27; 面積比(%): 97.08(最大), 97.44(254 nm)。
400 MHz, CDCl3: δ 7.53-7.50(m, 1H), 7.48-7.40(m, 8H), 7.39-7.31(m, 3H), 7.14-7.13(m, 1H), 4.03(t, J = 8.00 Hz, 2H), 2.67(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 299.0)。Rt(分): 4.52; 面積比(%): 98.52(最大), 99.25(254 nm)。
HPLC - Rt(分): 4.58; 面積比(%): 99.29(最大), 99.59(254 nm)。
400 MHz, CDCl3: δ 7.83(d, J = 8.00 Hz, 2H), 7.74-7.72(m, 1H), 7.43-7.38(m, 2H), 7.21-7.16(m, 1H), 7.01-6.97(m, 2H), 4.21(t, J = 12.00 Hz, 2H), 3.91(s, 3H), 3.43(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 337.3)。Rt(分): 4.85; 面積比(%): 99.10(最大), 99.46(254 nm)。
HPLC - Rt(分): 4.87; 面積比(%): 97.36(最大), 98.45(254 nm)。
400 MHz, CDCl3: δ 7.78(d, J = 8.00 Hz, 1H), 7.73(d, J = 8.00 Hz, 1H), 7.68-7.64(m, 1H), 7.62-7.60(m, 1H), 7.57-7.53(m, 2H), 7.40-7.34(m, 1H), 7.18-7.13(m, 1H), 4.30(t, J = 8.00 Hz, 2H), 3.31(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M-, 283)。Method: A - 10mM NH4HCO3, B: ACN;流速Rate: 1.0 ml/分. Rt(分): 5.68; 面積比(%): 93.65(最大), 93.47(220 nm)。
HPLC - Rt(分): 4.36; 面積比(%): 95.36(最大), 96.10(254 nm)。
400 MHz, DMSO-d6: δ 10.04(brs, 1H), 7.60-7.48(m, 4H), 7.41-7.31(m, 2H), 6.95-6.90(m, 2H), 4.07(t, J = 12.00 Hz, 2H), 3.46(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 284.2)。Rt(分): 3.96; 面積比(%): 98.39(最大), 100.0(254 nm)。
HPLC - Rt(分): 3.90; 面積比(%): 97.96(最大), 98.62(254 nm)。
400 MHz, DMSO-d6: δ 7.52-7.50(m, 3H), 7.48-7.34(m, 1H), 7.28-7.25(m, 1H), 7.13-7.09(m, 1H), 6.70-6.68(m, 1H), 6.60-6.56(m, 1H), 4.48(m, 2H), 4.00(t, J = 8.00 Hz, 2H), 3.42-3.31(m, 2H)。
LC-MS: 質量の実測値(M+, 315)。Rt(分): 4.69; 面積比(%): 98.74(最大), 99.16(254 nm)。
HPLC - Rt(分): 4.61; 面積比(%): 98.13(最大), 99.03(254 nm)。
400 MHz, CDCl3: δ 7.98-7.95(m, 1H), 7.90-7.88(m, 1H), 7.46-7.37(m, 3H), 7.31-7.29(m, 1H), 7.22-7.19(m, 2H), 4.25(t, J = 8.00 Hz, 2H), 3.39(t, J = 8.00 Hz, 2H), 2.48(s, 3H)。
LC-MS: 質量の実測値(M+, 312.3)。Rt(分): 2.24; 面積比(%): 98.61(最大), 95.58(254 nm)。
HPLC - Rt(分): 2.32; 面積比(%): 99.74(最大), 96.54(254 nm)。
400 MHz, CDCl3: δ 7.83-7.78(m, 2H), 7.55-7.52(m, 1H), 7.43-7.35(m, 2H), 7.20-7.15(m, 1H), 7.12-7.10(m, 1H), 7.05-7.03(m, 1H), 4.23(t, J = 8.00 Hz, 2H), 3.42(t, J = 12.00 Hz, 2H), 2.73(s, 6H)。
LC-MS: 質量の実測値(M+, 294.0)。Rt(分): 3.96; 面積比(%): 94.87(最大), 96.73(254 nm)。
HPLC - Rt(分): 4.00; 面積比(%): 94.56(最大), 96.71(254 nm)。
400 MHz, CDCl3: δ 7.91(d, J = 8.00 Hz, 1H), 7.80-7.78(m, 2H), 7.72(d, J = 8.00 Hz, 1H), 7.67-7.64(m, 1H), 7.54-7.51(m, 1H), 7.47-7.41(m, 1H), 7.24-7.19(m, 1H), 4.34(t, J = 12.00 Hz, 2H), 3.46(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 362)。Rt(分): 3.87; 面積比(%): 97.67(最大), 98.43(254 nm)。
HPLC - Rt(分): 3.94; 面積比(%): 99.54(最大), 99.61(254 nm)。
400 MHz, CDCl3: δ 7.73(d, J = 8.00 Hz, 1H), 7.62-7.60(m, 1H), 7.55-7.42(m, 4H), 7.25-7.24(m, 1H), 7.19-7.14(m, 1H), 4.24(t, J = 12.00 Hz, 2H), 3.45(t, J = 12.00 Hz, 2H), 2.97(s, 3H)。
LC-MS: 質量の実測値(M+, 340.0)。Rt(分): 3.33; 面積比(%): 99.53(最大), 99.21(254 nm)。
HPLC - Rt(分): 3.39; 面積比(%): 99.31(最大), 99.28(254 nm)。
400 MHz, CDCl3: δ 7.66-7.63(m, 1H), 7.56-7.52(m, 2H), 7.46-7.40(m, 3H), 7.27-7.24(m, 1H), 7.21-7.18(m, 1H), 4.22(t, J = 12.00 Hz, 2H), 3.31(t, J =12.00 Hz, 2H), 2.69(s, 3H), 2.57(s, 3H)。
LC-MS: 質量の実測値(M+, 333.0)。Rt(分): 4.96; 面積比(%): 96.37(最大), 96.96(254 nm)。
HPLC - Rt(分): 4.92; 面積比(%): 97.08(最大), 96.70(254 nm)。
400 MHz, CDCl3: δ 7.80-7.74(m, 2H), 7.45-7.40(m, 2H), 7.33-0.00(m, 1H), 7.24-7.21(m, 1H), 7.17-7.14(m, 1H), 4.29(t, J = 12.00 Hz, 2H), 3.93(s, 3H), 3.29(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 343.0)。Rt(分): 3.50; 面積比(%): 91.12(最大), 90.07(254 nm)。
HPLC - Rt(分): 3.53; 面積比(%): 92.15(最大), 90.03(254 nm)。
400 MHz, DMSO-d6: δ 12.81(brs, 1H), 7.75-7.64(m, 3H), 7.57-7.52(m, 1H), 7.42-7.37(m, 1H), 7.33-7.31(m, 2H), 4.15(t, J = 8.00 Hz, 2H), 3.84(s, 3H), 3.40-3.32(m, 2H)。
LC-MS: 質量の実測値(M+, 317.0)。Rt(分): 4.56; 面積比(%): 91.74(最大), 97.03(254 nm)。
HPLC - Rt(分): 4.61; 面積比(%): 94.59(最大), 98.11(254 nm)。
400 MHz, CDCl3: δ 7.80-7.74(m, 2H), 7.45-7.38(m, 2H), 7.23-7.12(m, 3H), 4.29(t, J = 8.00 Hz, 2H), 3.94-3.92(m, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 313.0)。Rt(分): 4.93; 面積比(%): 96.69(最大), 97.70(254 nm)。
HPLC - Rt(分): 4.99; 面積比(%): 96.88(最大), 97.19(254 nm)。
400 MHz, CDCl3: δ 7.81(t, J = 8.00 Hz, 2H), 7.45-7.39(m, 1H), 7.24-7.19(m, 3H), 7.18-7.17(m, 2H), 4.27(t, J = 8.00 Hz, 2H), 3.86(s, 3H), 3.29(t, J = 12.00 Hz, 2H), 2.26(s, 3H)。
LC-MS: 質量の実測値(M+, 405.0)。Rt(分): 5.18; 面積比(%): 98.51(最大), 97.41(220 nm)。
HPLC - Rt(分): 5.19; 面積比(%): 97.35(最大), 99.08(254 nm)。
400 MHz, CDCl3: δ 7.79(t, J = 8.00 Hz, 2H), 7.45-7.31(m, 7H), 7.22-7.18(m, 1H), 7.13-7.10(m, 1H), 6.89(d, J = 8.00 Hz, 1H), 5.22(s, 2H), 4.25(t, J = 12.00 Hz, 2H), 3.92(s, 3H), 3.26(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 324.0)。Rt(分): 4.41; 面積比(%): 99.68(最大), 99.45(254 nm)。
HPLC - Rt(分): 4.49; 面積比(%): 99.48(最大), 99.19(254 nm)。
400 MHz, CDCl3: δ 7.62-7.60(m, 2H), 7.46-7.44(m, 1H), 7.42-7.40(m, 1H), 7.32-7.26(m, 1H), 7.24-7.20(m, 2H), 4.32(t, J = 12.00 Hz, 2H), 3.96(s, 3H), 3.30(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 329.0)。Rt(分): 4.47; 面積比(%): 97.16(最大), 98.36(254 nm)。
HPLC - Rt(分): 4.54; 面積比(%): 96.70(最大), 98.61(254 nm)。
400 MHz, CDCl3: δ 7.87-7.83(m, 2H), 7.68(d, J = 12.00 Hz, 1H), 7.43-7.37(m, 1H), 7.20-7.15(m, 1H), 6.54(dd, J = 8.00, 4.00 Hz, 1H), 6.50(d, J = 4.00 Hz, 1H), 4.18(t, J = 12.00 Hz, 2H), 3.88(s, 3H), 3.86(s, 3H), 3.38(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 313.3)。Rt(分): 4.71; 面積比(%): 99.43(最大), 99.14(254 nm)。
HPLC - Rt(分): 4.74; 面積比(%): 98.94(最大), 98.51(220 nm)。
400 MHz, CDCl3: δ 7.78-7.71(m, 2H), 7.42-7.36(m, 2H), 7.19-7.14(m, 1H), 6.80-6.78(m, 1H), 4.19(t, J = 8.00 Hz, 2H), 3.84(s, 3H), 3.33(t, J = 12.00 Hz, 2H), 2.51(s, 3H)。
LC-MS: 質量の実測値(M+, 367.0)。Rt(分): 4.90; 面積比(%): 95.75(最大), 97.14(254 nm)。
HPLC - Rt(分): 4.97; 面積比(%): 92.76(最大), 96.42(254 nm)。
400 MHz, CDCl3: δ 7.74(d, J = 8.00 Hz, 1H), 7.69-7.66(m, 1H), 7.50(d, J = 8.00 Hz, 1H), 7.40-7.34(m, 1H), 7.28-7.27(m, 1H), 7.18-7.14(m, 1H), 7.10-7.07(m, 1H), 4.27(t, J = 8.00 Hz, 2H), 3.89(s, 3H), 3.27(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 333)。Rt(分): 4.80; 面積比(%): 96.09(最大), 93.73(254 nm)。
HPLC - Rt(分): 4.79; 面積比(%): 96.35(最大), 94.47(254 nm)。
400 MHz, CDCl3: δ 7.82-7.75(m, 2H), 7.62(d, J = 12.00 Hz, 1H), 7.43-7.37(m, 1H), 7.21-7.15(m, 1H), 6.98(d, J = 4.00 Hz, 1H), 6.87-6.84(m, 1H), 4.25(t, J = 8.00 Hz, 2H), 3.85(s, 3H), 3.45(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 317.3)。Rt(分): 4.70; 面積比(%): 96.67(最大), 95.03(220 nm)。
HPLC - Rt(分): 4.62; 面積比(%): 98.12(最大), 97.77(254 nm)。
400 MHz, CDCl3: δ 7.81-7.74(m, 3H), 7.44-7.39(m, 1H), 7.22-7.17(m, 1H), 6.75(dd, J = 8.00 Hz, 4.00, Hz, 1H), 6.67-6.63(m, 1H), 4.23(t, J = 12.00 Hz, 2H), 3.85(s, 3H), 3.40-3.34(m, 2H)。
LC-MS: 質量の実測値(M+, 383.3)。Rt(分): 5.16; 面積比(%): 98.97(最大), 98.63(254 nm)。
HPLC - Rt(分): 5.16; 面積比(%): 99.47(最大), 99.84(254 nm)。
400 MHz, CDCl3: δ 7.79-7.69(m, 2H), 7.72-7.69(m, 1H), 7.43-7.38(m, 1H), 7.21-7.16(m, 1H), 6.89-6.84(m, 2H), 4.24(t, J = 8.00 Hz, 2H), 3.87(s, 3H), 3.35(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 329.0)。Rt(分): 3.48; 面積比(%): 99.68(最大), 99.46(254 nm)。
HPLC - Rt(分): 3.60; 面積比(%): 99.78(最大), 99.67(254 nm)。
400 MHz, CDCl3: δ 7.52-7.47(m, 1H), 7.46-7.40(m, 3H), 7.22-7.20(m, 1H), 7.19-7.17(m, 1H), 6.96-6.88(m, 1H), 4.51(s, 2H), 4.23(t, J = 8.00 Hz, 2H), 3.86(s, 3H), 3.41(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 317.0)。Rt(分): 4.41; 面積比(%): 99.73(最大), 99.92(254 nm)。
HPLC - Rt(分): 4.54; 面積比(%): 99.51(最大), 99.65(254 nm)。
400 MHz, CDCl3: δ 7.79-7.72(m, 1H), 7.44-7.42(m, 1H), 7.40-7.36(m, 2H), 7.22-7.19(m, 1H), 7.17-7.10(m, 1H), 7.10-7.00(m, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.92(s, 3H), 3.44-3.38(m, 2H)。
LC-MS: 質量の実測値(M+, 329.0)。Rt(分): 4.45; 面積比(%): 97.93(最大), 98.83(254 nm)。
HPLC - Rt(分): 4.46; 面積比(%): 97.56(最大), 98.13(254 nm)。
400 MHz, CDCl3: δ 7.80(d, J = 8.00 Hz, 1H), 7.76-7.73(m, 1H), 7.43-7.38(m, 1H), 7.34-7.32(m, 1H), 7.21-7.15(m, 1H), 7.08(t, J = 8.00 Hz, 1H), 6.99(dd, J = 8.00, 4.00 Hz, 1H), 4.23(t, J = 12.00 Hz, 2H), 3.90(s, 3H), 3.85(s, 3H), 3.43(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 315.0)。Rt(分): 3.95; 面積比(%): 97.35(最大), 97.55(254 nm)。
HPLC - Rt(分): 4.04; 面積比(%): 98.52(最大), 98.60(220 nm)。
400 MHz, CDCl3: δ 7.58-7.56(m, 1H), 7.49-7.42(m, 2H), 7.21-7.16(m, 1H), 7.01-6.95(m, 1H), 6.94-6.89(m, 2H), 4.24(t, J = 8.00 Hz, 2H), 3.91(s, 3H), 3.44(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 359.0)。Rt(分): 4.38; 面積比(%): 95.44(最大), 97.08(254 nm)。
HPLC - Rt(分): 4.40; 面積比(%): 95.40(最大), 96.51(254 nm)。
400 MHz, CDCl3: δ 7.81-7.75(m, 2H), 7.46-7.37(m, 2H), 7.20-7.15(m, 2H), 4.21(t, J = 8.00 Hz, 2H), 3.91(s, 6H), 3.88(s, 3H), 3.38(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 308.3)。Rt(分): 4.09; 面積比(%): 98.67(最大), 99.43(254 nm)。
HPLC - Rt(分): 4.10; 面積比(%): 98.73(最大), 99.13(254 nm)。
400 MHz, CDCl3: δ 8.32(brs, 1H), 7.91(brs, 1H), 7.87-7.80(m, 2H), 7.72(d, J = 8.00 Hz, 1H), 7.53-7.42(m, 2H), 7.27(s, 1H), 7.23-7.19(m, 1H), 6.63(brs, 1H), 4.29(t, J = 8.00 Hz, 2H), 3.39(t, J = 8.00 Hz, 2H).
LC-MS: 質量の実測値(M+, 311.0)。Rt(分): 4.33; 面積比(%): 98.26(最大), 97.53(254 nm)。
HPLC - Rt(分): 4.44; 面積比(%): 98.34(最大), 97.57(254 nm)。
400 MHz, CDCl3: δ 7.60-7.73(m, 1H), 7.45-7.45(m, 1H), 7.44-7.43(m, 1H), 7.42-7.39(m, 2H), 7.22-7.16(m, 1H), 6.81(d, J =8.40 Hz, 1H), 4.64(t, J = 8.00 Hz, 2H), 4.24(t, J = 8.00 Hz, 2H), 3.28-3.23(m, 4H).
LC-MS: 質量の実測値(M+, 308.0)。Rt(分): 4.35; 面積比(%): 94.89(最大), 98.41(254 nm)。
HPLC - Rt(分): 4.45; 面積比(%): 96.20(最大), 99.28(254 nm)。
400 MHz, CDCl3: δ 8.35(brs, 1H), 7.83-7.82(m, 3H), 7.79-7.76(m, 1H), 7.68-7.65(m, 1H), 7.54-7.51(m, 1H), 7.47-7.41(m, 1H), 7.27-7.21(m, 1H), 6.61-6.69(m, 1H), 4.31-4.26(m, 2H), 3.39-3.34(m, 2H).
LC-MS: 質量の実測値(M+, 322.0)。Rt(分): 4.53; 面積比(%): 98.26(最大), 98.89(254 nm)。
HPLC - Rt(分): 4.70; 面積比(%): 97.78(最大), 98.34(254 nm)。
400 MHz, CDCl3: δ 7.88-7.78(m, 4H), 7.47-7.45(m, 1H), 7.43-7.41(m, 1H), 7.35-7.33(m, 1H), 7.23-7.19(m, 1H), 7.11-7.10(m, 1H), 4.32-4.25(m, 2H), 3.83-3.79(m, 3H), 3.44-3.36(m, 2H)。
LC-MS: 質量の実測値(M+, 448.0)。Rt(分): 5.15; 面積比(%): 96.93(最大), 98.12(254 nm)。
HPLC - Rt(分): 5.16; 面積比(%): 97.39(最大), 98.18(254 nm)。
400 MHz, CDCl3: δ 8.26(s, 1H), 7.89-7.82(m, 4H), 7.68-7.65(m, 2H), 7.57-7.55(m, 2H), 7.48-7.44(m, 3H), 7.24-7.21(m, 1H), 6.71(d, J = 4.00 Hz, 1H), 4.32(t, J = 8.00 Hz, 2H), 3.39(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 309.0)。Rt(分): 4.76; 面積比(%): 99.04(最大), 97.95(254 nm)。
HPLC - Rt(分): 4.76; 面積比(%): 98.86(最大), 99.18(254 nm)。
400 MHz, CDCl3: δ 7.82-7.80(m, 1H), 7.76-7.73(m, 2H), 7.68-7.55(m, 1H), 7.53-7.47(m, 1H), 7.46-7.45(m, 1H), 7.44-7.42(m, 1H), 7.24-7.19(m, 1H), 6.83-6.80(m, 1H), 4.32-4.27(m, 2H), 3.37(t, J = 10.40 Hz, 2H)。
LC-MS: 質量の実測値(M+, 325.0)。Rt(分): 4.92; 面積比(%): 91.98(最大), 94.40(254 nm)。
HPLC - Rt(分): 4.92; 面積比(%): 91.38(最大), 93.89(254 nm)。
400 MHz, CDCl3: δ 7.82-7.81(m, 1H), 7.75-7.73(m, 2H), 7.65-7.56(m, 1H), 7.53-7.47(m, 1H), 7.46-7.43(m, 1H), 7.44-7.40(m, 1H), 7.24-7.19(d, J = 8Hz, 1H), 6.83(d, J = 8 Hz, 1H), 4.32-4.27(m, 2H), 3.35(t, J = 10.40 Hz, 2H)。
LC-MS: 質量の実測値(M+, 323.0)。Rt(分): 4.04; 面積比(%): 94.55(最大), 91.93(254 nm)。
HPLC - Rt(分): 4.12; 面積比(%): 96.92(最大), 96.75(254 nm)。
400 MHz, CDCl3: δ 8.00(s, 1H), 7.84-7.76(m, 1H), 7.74-7.73(m, 2H), 7.63-7.60(m, 2H), 7.48-7.42(m, 1H), 7.27-7.20(m, 1H), 4.33(t, J = 8.00 Hz, 2H), 4.13(s, 3H), 3.43-3.38(m, 2H)。
LC-MS: 質量の実測値(M+, 323.0)。Rt(分): 3.26; 面積比(%): 94.53(最大), 96.10(220 nm)。
HPLC - Rt(分): 2.67; 面積比(%): 98.44(最大), 97.92(254 nm)。
400 MHz, CDCl3: δ 10.23-10.21(s, 1H), 8.08-8.05(m, 1H), 7.95-7.93(m, 1H), 7.89-7.88(m, 1H), 7.77-7.76(m, 1H), 7.71-7.69(m, 1H), 7.52-7.45(m, 1H), 7.27-7.22(m, 1H), 4.36(t, J = 12.00 Hz, 2H), 4.27(s, 3H), 3.40(t, J = 12.00 Hz, 2H).
LC-MS: 質量の実測値(M+, 324.0)。Rt(分): 3.94; 面積比(%): 98.34(最大), 97.96(220 nm)。
HPLC - Rt(分): 3.93; 面積比(%): 99.03(最大), 97.94(254 nm)。
400 MHz, CDCl3: δ 7.83-7.80(m, 2H), 7.76-7.74(m, 1H), 7.68(d, J = 4.00 Hz, 2H), 7.47-7.42(m, 1H), 7.25-7.20(m, 1H), 4.31(t, J = 12.00 Hz, 2H), 3.36(t, J = 8.00 Hz, 2H), 2.68(s, 3H)。
LC-MS: 質量の実測値(M+, 309.2)。Rt(分): 5.19; 面積比(%): 96.85(最大), 98.04(254 nm)。
HPLC - Rt(分): 5.21; 面積比(%): 96.41(最大), 98.34(254 nm)。
400 MHz, CDCl3: δ 7.81(d, J = 8.00 Hz, 1H), 7.77-7.74(m, 1H), 7.49-7.40(m, 2H), 7.26-7.25(m, 2H), 7.23-7.18(m, 1H), 4.26(t, J = 8.00 Hz, 2H), 3.29(t, J = 8.00 Hz, 2H), 2.96-2.93(m, 4H), 2.15-2.08(m, 2H)。
LC-MS: 質量の実測値(M+, 324.0)。Rt(分): 3.11; 面積比(%): 97.97(最大), 98.73(254 nm)。
HPLC - Rt(分): 3.11; 面積比(%): 99.20(最大), 99.38(254 nm)。
400 MHz, CDCl3: δ 8.09-8.06(m, 2H), 7.79(d, J = 8.00 Hz, 1H), 7.73-7.71(m, 1H), 7.54(d, J = 8.00 Hz, 1H), 7.48-7.42(m, 1H), 7.24-7.20(m, 1H), 4.53(s, 2H), 4.34-4.29(m, 2H), 3.38-3.33(m, 2H)。
LC-MS: 質量の実測値(M+, 319.0)。Rt(分): 5.05; 面積比(%): 98.80(最大), 99.47(254 nm)。
HPLC - Rt(分): 5.10; 面積比(%): 99.48(最大), 99.72(254 nm)。
400 MHz, CDCl3: δ 7.98-7.96(m, 2H), 7.91-7.84(m, 4H), 7.81-7.79(m, 1H), 7.58-7.53(m, 2H), 7.49-7.43(m, 1H), 7.26-7.21(m, 1H), 4.34(t, J = 8.00 Hz, 2H), 3.46-3.41(m, 2H)。
LC-MS: 質量の実測値(M+, 327.0)。Rt(分): 4.34; 面積比(%): 95.92(最大), 98.10(254 nm)。
HPLC - Rt(分): 4.42; 面積比(%): 95.32(最大), 97.92(254 nm)。
400 MHz, CDCl3: δ 7.80-7.78(m, 1H), 7.73-7.71(m, 1H), 7.42-7.38(m, 1H), 7.26-7.16(m, 3H), 6.95-6.88(m, 1H), 4.31-4.26(m, 4H), 4.23-4.21(m, 2H), 3.23(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 320.0)。Rt(分): 2.75; 面積比(%): 94.85(最大), 96.42(254 nm)。
HPLC - Rt(分): 2.77; 面積比(%): 96.57(最大), 98.30(254 nm)。
400 MHz, CDCl3: δ 9.02-9.00(m, 1H), 8.68-8.66(m, 2H), 8.40-8.37(m, 1H), 8.14(s, 1H), 7.82-7.79(m, 2H), 7.73-7.71(m, 1H), 7.75-7.45(m, 1H), 7.28-7.23(m, 1H), 4.39(t, J = 8.00 Hz, 2H), 3.44(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 325.3)。Rt(分): 4.68; 面積比(%): 96.60(最大), 94.10(220 nm)。
HPLC - Rt(分): 2.41; 面積比(%): 99.93(最大), 99.28(254 nm)。
400 MHz, CDCl3: δ 7.81(d, J = 4.00 Hz, 1H), 7.76-7.74(m, 1H), 7.47-7.38(m, 3H), 7.22-7.17(m, 1H), 6.82(d, J = 8.00 Hz, 1H), 4.26-4.21(m, 4H), 3.27-3.22(m, 2H), 2.82(t, J = 8.00 Hz, 2H), 2.07-2.01(m, 2H)。
LC-MS: 質量の実測値(M+, 270.0)。Rt(分): 2.23; 面積比(%): 98.21(最大), 96.25(220 nm)。
HPLC - Rt(分): 2.27; 面積比(%): 98.52(最大), 95.92(254 nm)。
400 MHz, CDCl3: δ 8.71-8.69(m, 2H), 7.77(d, J = 8.00 Hz, 1H), 7.72-7.69(m, 1H), 7.55-7.54(m, 2H), 7.47-7.42(m, 1H), 7.24-7.21(m, 1H), 4.33(t, J =8.00 Hz, 2H), 3.30(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 318.0)。Rt(分): 4.36; 面積比(%): 97.91(最大), 95.52(220 nm)。
HPLC - Rt(分): 4.36; 面積比(%): 97.83(最大), 96.12(254 nm)。
400 MHz, CDCl3: δ 8.10(d, J = 4.00 Hz, 1H), 7.79-7.76(m, 1H), 7.72-7.68(m, 1H), 7.46-7.40(m, 1H), 7.24-7.19(m, 1H), 7.06(d, J = 4.00 Hz, 1H), 4.29(t, J = 8.00 Hz, 2H), 3.93(s, 3H), 3.40-3.34(m, 2H)。
LC-MS: 質量の実測値(M+, 334.0)。Rt(分): 4.56; 面積比(%): 97.24(最大), 97.32(220 nm)。
HPLC - Rt(分): 4.62; 面積比(%): 98.91(最大), 98.79(254 nm)。
400 MHz, CDCl3: δ 8.06(d, J = 8.00 Hz, 1H), 7.78-7.76(m, 1H), 7.73-7.69(m, 1H), 7.44-7.39(m, 1H), 7.23-7.17(m, 2H), 4.30(t, J = 8.00 Hz, 2H), 4.06(s, 3H), 3.51(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 300)。Rt(分): 2.49; 面積比(%): 99.66(最大), 99.21(254 nm)。
HPLC - Rt(分): 2.55; 面積比(%): 98.14(最大), 98.58(254 nm)。
400 MHz, CDCl3: δ 8.42(s, 1H), 8.30(d, J = 4.00 Hz, 1H), 7.80-7.76(m, 2H), 7.59(d, J = 4.00 Hz, 2H), 7.45-7.41(m, 1H), 7.24-7.19(m, 1H), 4.25(t, J = 12.00 Hz, 2H), 4.02(s, 3H), 3.43(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 300.3)。Rt(分): 3.87; 面積比(%): 94.48(最大), 90.84(220 nm)。
HPLC - Rt(分): 3.74; 面積比(%): 96.03(最大), 93.16(254 nm)。
400 MHz, CDCl3: δ 8.26-8.24(m, 1H), 7.76-7.74(m, 1H), 7.69-7.66(m, 1H), 7.47-7.41(m, 1H), 7.31-7.27(m, 1H), 7.23-7.21(m, 1H), 6.99(s, 1H), 4.32(t, J = 12.00 Hz, 2H), 4.14-4.10(m, 3H), 3.27(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 300.0)。Rt(分): 3.95; 面積比(%): 98.57(最大), 96.66(220 nm)。
HPLC - Rt(分): 3.94; 面積比(%): 98.84(最大), 98.34(254 nm)。
400 MHz, CDCl3: δ 8.40-8.39(m, 1H), 8.01-7.99(m, 1H), 7.79-7.71(m, 2H), 7.45-7.39(m, 1H), 7.23-7.18(m, 1H), 6.80(d, J = 8.00 Hz, 1H), 4.28(t, J = 8.00 Hz, 2H), 3.99(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 300.3)。Rt(分): 4.14; 面積比(%): 96.89(最大), 98.37(220 nm)。
HPLC - Rt(分): 4.05; 面積比(%): 99.08(最大), 99.25(254 nm)。
400 MHz, CDCl3: δ 8.24-8.22(m, 1H), 8.04-8.02(m, 1H), 7.81-7.78(m, 2H), 7.44-7.39(m, 1H), 7.22-7.17(m, 1H), 6.97-6.94(m, 1H), 4.23(t, J = 12.00 Hz, 2H), 4.04(s, 3H), 3.43(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 300.0)。Rt(分): 2.81; 面積比(%): 97.26(最大), 99.15(254 nm)。
HPLC - Rt(分): 2.81; 面積比(%): 99.26(最大), 99.24(254 nm)。
400 MHz, CDCl3: δ 8.61-8.54(m, 1H), 8.45-8.37(m, 1H), 7.95-7.91(m, 1H), 7.71-7.65(m, 1H), 7.64-7.61(m, 1H), 7.48-7.42(m, 1H), 7.27-7.22(m, 1H), 4.37(t, J = 8.00 Hz, 2H), 4.00(s, 3H), 3.33(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 318.0)。Rt(分): 4.24; 面積比(%): 95.74(最大), 90.08(220 nm)。
HPLC - Rt(分): 4.44; 面積比(%): 97.55(最大), 95.14(254 nm)。
400 MHz, CDCl3: δ 8.13(d, J = 4.00 Hz, 1H), 7.76-7.73(m, 2H), 7.69-7.66(m, 1H), 7.45-7.40(m, 1H), 7.23-7.19(m, 1H), 4.29(t, J = 8.00 Hz, 2H), 4.08(s, 3H), 3.27(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 334.0)。Rt(分): 4.87; 面積比(%): 92.17(最大), 93.85(254 nm)。
HPLC - Rt(分): 4.88; 面積比(%): 92.21(最大), 93.13(254 nm)。
400 MHz, CDCl3: δ 8.16-8.15(m, 1H), 7.97(d, J = 4.00 Hz, 1H), 7.76(t, J = 8.00 Hz, 2H), 7.46-7.41(m, 1H), 7.24-7.19(m, 1H), 4.24(t, J = 8.00 Hz, 2H), 4.02(s, 3H), 3.41(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 334.0)。Rt(分): 4.81; 面積比(%): 92.84(最大), 93.84(254 nm)。
HPLC - Rt(分): 4.93; 面積比(%): 94.76(最大), 94.37(254 nm)。
400 MHz, CDCl3: δ 8.16-8.15(m, 1H), 7.97(d, J = 4.00 Hz, 1H), 7.75(t, J = 8.00 Hz, 2H), 7.45-7.40(m, 1H), 7.23-7.18(m, 1H), 4.23(t, J = 12.00 Hz, 2H), 4.01(s, 3H), 3.40(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 314.0)。Rt(分): 3.78; 面積比(%): 97.78(最大), 98.61(254 nm)。
HPLC - Rt(分): 3.75; 面積比(%): 97.99(最大), 98.66(254 nm)。
400 MHz, CDCl3: δ 7.77(d, J = 8.00 Hz, 1H), 7.73-7.70(m, 1H), 7.61(d, J = 8.00 Hz, 1H), 7.43-7.37(m, 1H), 7.21-7.16(m, 1H), 6.64(d, J = 8.00 Hz, 1H), 4.22(t, J = 8.00 Hz, 2H), 3.97(s, 3H), 3.30(t, J = 8.00 Hz, 2H), 2.67(s, 3H)。
LC-MS: 質量の実測値(M+, 313.0)。Rt(分): 2.50; 面積比(%): 99.51(最大), 99.73(254 nm)。
HPLC - Rt(分): 2.55; 面積比(%): 99.37(最大), 99.47(254 nm)。
400 MHz, CDCl3: δ 8.40-8.39(m, 1H), 7.87-7.74(m, 3H), 7.43-7.38(m, 1H), 7.21-7.16(m, 1H), 6.55(d, J = 12.00 Hz, 1H), 4.23(t, J = 12.00 Hz, 2H), 3.24(t, J = 12.00 Hz, 2H), 3.16(s, 6H)。
LC-MS: 質量の実測値(M+, 309.0)。Rt(分): 3.11; 面積比(%): 96.77(最大), 96.14(254 nm)。
HPLC - Rt(分): 3.10; 面積比(%): 98.69(最大), 99.09(254 nm)。
400 MHz, CDCl3: δ 8.71-0.00(m, 1H), 8.27(s, 1H), 7.85-7.83(m, 1H), 7.79-7.76(m, 1H), 7.48-7.42(m, 1H), 7.39-7.38(m, 1H), 7.24-7.20(m, 1H), 6.60-6.59(m, 1H), 4.32(t, J = 8.00 Hz, 2H), 3.40(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 285.0)。Rt(分): 2.35; 面積比(%): 99.45(最大), 98.80(254 nm)。
HPLC - Rt(分): 2.33; 面積比(%): 98.97(最大), 98.92(254 nm)。
400 MHz, DMSO-d6: δ 8.19-8.18(m, 1H), 7.72-7.66(m, 2H), 7.63-7.61(m, 1H), 7.54-7.49(m, 1H), 7.39-7.33(m, 1H), 6.55(s, 2H), 6.48(d, J = 8.00 Hz, 1H), 4.05(t, J = 8.00 Hz, 2H), 3.25(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 271)。Rt(分): 2.80; 面積比(%): 95.20(最大), 96.55(254 nm)。
HPLC - Rt(分): 2.81; 面積比(%): 96.24(最大), 94.46(254 nm)。
400 MHz, CDCl3: δ 9.26(s, 1H), 9.04(s, 2H), 7.76(d, J = 8.00 Hz, 1H), 7.70-7.66(m, 1H), 7.47-7.42(m, 1H), 7.28-7.22(m, 1H), 4.35(t, J = 8.00 Hz, 2H), 3.33(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 301.2)。Rt(分): 2.80; 面積比(%): 98.80(最大), 98.32(254 nm)。
HPLC - Rt(分): 3.34; 面積比(%): 99.20(最大), 98.82(254 nm)。
400 MHz, CDCl3: δ 8.83(s, 2H), 7.76(d, J = 8.00 Hz, 1H), 7.70-7.67(m, 1H), 7.45-7.40(m, 1H), 7.24-7.19(m, 1H), 4.30(t, J = 12.00 Hz, 2H), 4.08(s, 3H), 3.28(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 285.0)。Rt(分): 4.19; 面積比(%): 99.30(最大), 98.66(254 nm)。
HPLC - Rt(分): 4.33; 面積比(%): 98.83(最大), 97.31(254 nm)。
400 MHz, CDCl3: δ 8.92(s, 2H), 7.76(d, J = 8.00 Hz, 1H), 7.71-7.67(m, 1H), 7.46-7.40(m, 1H), 7.25-7.20(m, 1H), 4.32(t, J = 12.00 Hz, 2H), 3.31(t, J = 8.00 Hz, 2H), 2.80(s, 3H)。
LC-MS: 質量の実測値(M+, 286.2)。Rt(分): 2.48; 面積比(%): 99.76(最大), 97.20(254 nm)。
HPLC - Rt(分): 2.43; 面積比(%): 98.82(最大), 96.54(254 nm)。
400 MHz, CDCl3: δ 8.61(s, 2H), 7.76(d, J = 8.00 Hz, 1H), 7.69(d, J = 8.00 Hz, 1H), 7.44-7.39(m, 1H), 7.23-7.18(m, 1H), 5.34-5.30(m, 2H), 4.26(t, J = 12.00 Hz, 2H), 3.23(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 314.3)。Rt(分): 3.49; 面積比(%): 99.52(最大), 98.83(254 nm)。
HPLC - Rt(分): 4.62; 面積比(%): 99.60(最大), 97.57(254 nm)。
400 MHz, CDCl3: δ 8.63(s, 2H), 7.79(d, J = 8.00 Hz, 1H), 7.73(d, J = 12.00 Hz, 1H), 7.42-7.37(m, 1H), 7.22-7.17(m, 1H), 4.24(t, J = 12.00 Hz, 2H), 3.26(s, 6H), 3.22(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 275.0)。Rt(分): 4.27; 面積比(%): 98.69(最大), 99.55(254 nm)。
HPLC - Rt(分): 4.27; 面積比(%): 97.97(最大), 98.53(254 nm)。
400 MHz, DMSO-d6: δ 7.98-7.97(m, 1H), 7.71(d, J = 8.00 Hz, 1H), 7.65-7.61(m, 2H), 7.55-7.49(m, 1H), 7.40-7.35(m, 2H), 4.08(t, J = 8.00 Hz, 2H), 3.32-3.27(m, 2H)。
LC-MS: 質量の実測値(M+, 309.0)。Rt(分): 4.70; 面積比(%): 98.71(最大), 98.00(220 nm)。
HPLC - Rt(分): 4.72; 面積比(%): 98.56(最大), 98.68(220 nm)。
400 MHz, CDCl3: δ 7.83(d, J = 4.00 Hz, 1H), 7.77-7.74(m, 1H), 7.63(d, J = 8.00 Hz, 1H), 7.56(d, J = 8.00 Hz, 1H), 7.48-7.37(m, 2H), 7.31-7.29(m, 1H), 7.25-7.21(m, 1H), 7.17-7.10(m, 1H), 4.31(t, J = 12.00 Hz, 2H), 3.36(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 351.0)。Rt(分): 5.24; 面積比(%): 98.94(最大), 98.59(254 nm)。
HPLC - Rt(分): 5.26; 面積比(%): 99.31(最大), 97.80(254 nm)。
400 MHz, CDCl3: δ 7.83(d, J = 4.00 Hz, 1H), 7.76(d, J = 8.00 Hz, 1H), 7.65-7.63(m, 2H), 7.47-7.39(m, 3H), 7.36-7.32(m, 1H), 7.30-7.29(m, 1H), 7.27-7.26(m, 1H), 7.24-7.19(m, 1H), 4.29(t, J = 12.00 Hz, 2H), 3.31(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 259.0)。Rt(分): 3.30; 面積比(%): 94.11(最大), 96.78(254 nm)。
HPLC - Rt(分): 3.36; 面積比(%): 96.98(最大), 97.91(254 nm)。
400 MHz, CDCl3: δ 8.12(d, J = 4.00 Hz, 1H), 7.73-7.71(m, 2H), 7.69-7.64(m, 1H), 7.44-7.39(m, 1H), 7.23-7.18(m, 1H), 6.49-6.47(m, 1H), 4.36(t, J = 12.00 Hz, 2H), 3.59(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 288.0)。Rt(分): 3.82; 面積比(%): 98.67(最大), 99.34(254 nm)。
HPLC - Rt(分): 3.85; 面積比(%): 99.67(最大), 99.65(254 nm)。
400 MHz, CDCl3: δ 7.72-7.70(m, 1H), 7.68-7.64(m, 1H), 7.43-7.37(m, 1H), 7.21-7.16(m, 1H), 4.22(t, J = 12.00 Hz, 2H), 3.26(t, J = 12.00 Hz, 2H), 2.58(s, 3H), 2.37(s, 3H)。
LC-MS: 質量の実測値(M+, 349.0)。Rt(分): 4.20; 面積比(%): 98.60(最大), 98.61(254 nm)。
HPLC - Rt(分): 4.31; 面積比(%): 99.31(最大), 98.84(254 nm)。
400 MHz, CDCl3: δ 8.85-8.81(m, 1H), 8.80-8.72(m, 1H), 8.71-8.65(m, 2H), 7.42-7.33(m, 4H), 7.27-7.23(m, 2H), 7.20-7.14(m, 1H), 5.33(s, 2H), 4.18(t, J = 8.00 Hz, 2H), 3.14(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 339.0)。Rt(分): 4.64; 面積比(%): 97.45(最大), 96.85(254 nm)。
HPLC - Rt(分): 4.66; 面積比(%): 97.47(最大), 96.13(254 nm)。
400 MHz, CDCl3: δ 7.82(d, J = 8.00 Hz, 1H), 7.76-7.73(m, 1H), 7.47-7.42(m, 2H), 7.25-7.20(m, 1H), 7.07-7.04(m, 2H), 7.00(dd, J = 8.00, 4.00 Hz, 1H), 4.30(t, J = 8.00 Hz, 2H), 3.86(s, 3H), 3.34(t, J = 12.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 259.0)。Rt(分): 3.31; 面積比(%): 97.42(最大), 96.70(254 nm)。
HPLC - Rt(分): 3.36; 面積比(%): 97.17(最大), 95.99(254 nm)。
400 MHz, CDCl3: δ 8.12-8.11(m, 1H), 7.73-7.71(m, 2H), 7.65(d, J = 8.00 Hz, 1H), 7.45-7.39(m, 1H), 7.23-7.18(m, 1H), 4.36(t, J = 12.00 Hz, 2H), 3.59(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 259)。Rt(分): 3.35; 面積比(%): 96.38(最大), 92.65(220 nm)。
HPLC - Rt(分): 3.34; 面積比(%): 99.36(最大), 99.07(254 nm)。
400 MHz, CDCl3: δ 8.12-8.11(m, 1H), 7.73-7.71(m, 2H), 7.65(d, J = 8.00 Hz, 1H), 7.45-7.39(m, 1H), 7.23-7.18(m, 1H), 6.49-6.47(m, 1H), 4.36(t, J = 12.00 Hz, 2H), 3.59(t, J = 8.00 Hz, 2H)。
LC-MS: 質量の実測値(M+, 350.0)。Rt(分): 2.33; 面積比(%): 98.97(最大), 99.03(254 nm)。
HPLC - Rt(分): 2.46; 面積比(%): 98.16(最大), 98.27(254 nm)。
400 MHz, CDCl3: δ 8.54(brs, 2H),7.79-7.76(m, 2H), 7.69-7.67(m, 1H), 7.63-7.61(m, 1H), 7.36-7.27(m, 1H), 7.13-7.08(m, 1H), 7.03-7.02(m, 2H), 5.31(s, 2H), 4.13(t, J = 8.00 Hz, 2H), 3.14-3.04(m, 2H)。
1ウェルあたり2500個のCho-FSHR-LUC-1-1-43細胞を、5μlのフェノールレッド不含DMEM/F12+1% FBS中で平板に蒔いた。細胞を、Multidropによって384ウェルの白一色の低容量プレート(Greiner784075)内で平板に蒔いた。384ウェルプレートにマークした2μlの試験化合物(化合物は1:50に希釈した)に、Multidropによって100μlのDMEM/F12+0.1%のBSA中の2x EC20 FSH/IBMXを添加することによって、細胞をアッセイした。最終的なFSH濃度は0.265pMになり、そして、最終的なIBMX濃度は200μMになった。化合物プレートマップは、以下の通りであった:第1列:2μlのDMSO;第2列:2μlのDMSO;第3〜12列及び第13〜24列:2μlの試験化合物、100%のDMSO中に1:4に希釈した、又は2μlのFSH、DMEM/F12+0.1%のBSA中に1:4に希釈した。FSHの開始濃度は、50nM(終濃度は0.5nM)であった。さらに、第23列には、0.5nMの終濃度にて2μlのEC100のFSH基準(100X)(DMEM/F12+0.1%のBSA中に希釈)が含まれ、そして、第24列には、2μlの1mM AS707664/2基準化合物2が含まれた。5μlの化合物+EC20 FSH混合物を、細胞プレートに移した(5μlの細胞培中に1:2希釈)。そのプレートを、室温にて1時間インキュベートした。1ウェルあたり10μlの混合HTRF(CisBio#62AM4PEC)試薬を加え、そして、37℃にて1時間インキュベートした。そのプレートを、cAMP HTRF-低容量384ウェルプロトコールを使用してEnvisionにより読み出した。読み出し値は、計算した蛍光比(665nm/620nm)であった。結果を表1に示す。
アッセイを、Yanofsky et al.(2006)Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists. JBC 281(19): 13226-13233(参照により本発明の開示に援用する)の教示に従って実施した。結果を表1に示す。
(A)注射用バイアル:100gの本発明の活性成分と5gのリン酸水素二ナトリウムの3lの再蒸留水溶液を、2N塩酸を使用して調整してpH6.5とし、滅菌濾過し、注射バイアルに移し、無菌条件下で冷凍乾燥させ、無菌条件下で密封した。各注射用バイアルは、5mgの活性成分を含有していた。
(B)坐剤:20gの本発明の活性成分の混合物を100gのダイズレシチン及び1400gのカカオバターと共に溶解し、型に注入し、冷却させた。各坐剤は、20mgの活性成分を含有していた。
(D)軟膏:500mgの本発明の活性成分を無菌条件下で99.5gのワセリンと混合した。
(E)錠剤:1kgの本発明の活性成分、4kgのラクトース、1.2kgのジャガイモデンプン、0.2kgのタルクと0.1kgのステアリン酸マグネシウムの混合物を、各錠剤が10mgの活性成分を含有するように従来の方法で圧縮して錠剤とした。
(F)コーティング錠:錠剤を例Eと類似の方法で圧縮し、その後、従来の方法でスクロース、ジャガイモデンプン、タルク、トラガカント及び染料のコーティングでコーティングした。
(H)アンプル:1kgの本発明の活性成分の60lの再蒸留水溶液を滅菌濾過し、アンプルに移し、無菌条件下で冷凍乾燥させ、無菌条件下で密封した。各アンプルは10mgの活性成分を含有していた。
(I)吸入スプレー:14gの本発明の活性成分を10lの等張NaCl溶液に溶解し、該溶液を市販のスプレー容器にポンプ機構で移した。該溶液は、口又は鼻にスプレーすることができた。1回のスプレーショット(約0.1ml)は、約0.14mgの用量に相当した。
Claims (15)
- 式(I)
R、Lは、Ar1又はHet1であり、
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、NHCOY、CN、SO2Y、-E-(CY2)p-Ar2、-E-(CY2)p-Het1又は-E-(CY2)p-Het3であり、
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COY、COOY、CONY2、-CONY-Cyc、-O-Cyc、NO2、CN、SY、SOY、SO2Y、SO2NY2、NHSO2Y、アルケニル又は-E-(CY2)p-Ar2であり、
R3、R4、R5、R6は、互いに独立してH、A又はAr2であり、
R7は、Y、OY又はNY2であり、
X1、X2、X3、X4は、互いに独立してO、NY又は単結合であり、但し、X1及びX2が単結合の場合、mは0であり、
Eは、-C≡C-、SO2、-SO2-NY-、O、NY又は単結合であり、
Yは、H又はAであり、
Aは、1-10個の炭素原子を有する非分岐又は分岐のアルキルであると共に、1-7個の水素原子はHalと置換可能であり、
Cycは、3-7個の炭素原子を有するシクロアルキルであると共に、1-4個の水素原子は互いに独立してHal又はAと置換可能であり、
Ar1は、飽和、不飽和又は芳香族の、3-10個の炭素原子を有する単環又は二環式の炭素環であると共に、R1、R2及び-C≡C-C(A)2OHの群から選択される少なくとも1つの置換基によって置換可能であり、且つ/又はCyc、Het1又はHet3に融合可能であり、
Ar2は、6-10個の炭素原子を有する芳香族の、単環又は二環式の炭素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het1は、3-8個の炭素原子及び1-4個のN、O及び/又はS原子を有する不飽和又は芳香族単環又は二環式の複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、-(CY2)p-Ar2、-CO-Ar2、SO2-Ar2、-(CY2)p-Het2、Het3及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Het2は、5-7個の炭素原子及び1-3個のN原子を有する芳香族単環式複素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het3は、3-7個の炭素原子及び1-4個のN、O及び/又はS原子を有する飽和単環式複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、COY、-CONY2、=O及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Halは、F、Cl、Br又はIであり、
m、n、pは、互いに独立して0、1、2、3又は4である)
の化合物、及び/又は生理的に許容されるその塩。 - R、LがAr1である、請求項1に記載の化合物。
- X1、X2、X3、X4が単結合であり、
mが0である、請求項1又は2に記載の化合物。 - Ar1が、5-8個の炭素原子を有する芳香族の単環式炭素環であると共に、R1及びR2の群から選択される少なくとも1つの置換基によって一、二又は三置換された、請求項1〜3のいずれか1項に記載の化合物。
- Het1が、3-6個の炭素原子及び1-3個のN、O及び/又はS原子を有する不飽和又は芳香族単環式複素環であると共に、Hal、A及びOAの群から選択される少なくとも1つの置換基によって置換された、請求項1〜4のいずれか1項に記載の化合物。
- 式(I-A)
R1が、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、CONY2、NHCOA、CN、SO2A、-E-(CY2)p-Ar2、Het1又は-E-Het3であり、
R2が、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、CONY2、-CONH-Cyc、NO2、CN、SA、SOA、SO2A、SO2NY2、NHSO2A、アルケニル、-E-(CY2)p-Ar2又はHet1であり、
R3、R4、R5、R6が、互いに独立してH又はAであり、
R7が、H、OA又はNA2であり、
Eが、-C≡C-、SO2、-SO2-NH-、O又は単結合であり、
Yが、H又はAであり、
Aが、1-5個の炭素原子を有する非分岐又は分岐のアルキルであると共に、1-3個の水素原子はHalと置換可能であり、
Cycが、3-5個の炭素原子を有するシクロアルキルであり、
Ar1が、5-8個の炭素原子を有する芳香族の単環式炭素環であり、
Ar2が、フェニルであり、
Het1が、3-6個の炭素原子及び1-3個のN、O及び/又はS原子を有する不飽和又は芳香族単環式複素環であると共に、Hal、A及びOAの群から選択される少なくとも1つの置換基によって置換可能であり、
Het3が、3-6個の炭素原子及び1-2個のN及び/又はO原子を有する飽和単環式複素環であると共に、Hal、COA及び=Oの群から選択される少なくとも1つの置換基によって置換可能であり、
Halが、F、Cl、Br又はIであり、
m、p、qが、互いに独立して0、1、2又は3である)
を有する、請求項1〜3のいずれか1項に記載の化合物、及び/又は生理的に許容されるその塩。 - 式(I-B)
R1が、Hal、A、CN、-E-フェニル又はHet3であり、
R2が、Hal、A、OA、NH2、CN、SA、SO2A、SO2NH2、O-フェニル又はHet1であり、
R3、R4がHでありR5、R6がAである、又はR3、R4がAでありR5、R6がHであり、
Eが、O又は単結合であり、
Aが、1-5個の炭素原子を有する非分岐又は分岐のアルキルであり、
Het1が、ピロリル、フリル、チオフェニル、イミダゾリル、ピラジル、イソオキサジル、チアジル又はピリジルであると共に、Hal、A及びOAの群から選択される少なくとも1つの置換基で一又は二置換されることができ、
Het3が、ピロリジニル、テトラヒドロフリル、オキサゾリジニル、ジオキサラニル、ピペラジニル、モルフォリニル又はジオキサニルであると共に、Hal、COA及び=Oの群から選択される少なくとも1つの置換基によって一又は二置換されることができ、
Halが、F、Cl又はBrであり、
mが、0又は1である)
を有する、請求項1〜3又は6のいずれか1項に記載の化合物、及び/又は生理的に許容されるその塩。 - 少なくとも1つの請求項1〜8のいずれか1項に記載の化合物、及び/又は生理的に許容されるその塩を含む、医薬。
- 少なくとも1つの請求項1〜8のいずれか1項に記載の化合物及び/又は生理的に許容されるその塩の有効量を有効成分として、経口投与のための医薬的に許容できるアジュバントと共に、任意には少なくとも1つの他の医薬有効成分と組み合わせて含む、医薬組成物。
- FSH受容体を調節する方法であって、
FSH受容体を発現している系を、少なくとも1つの式(I)
R、Lは、互いに独立してAr1、Het1、A又はOYであり、
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、NHCOY、CN、SO2Y、-E-(CY2)p-Ar2、-E-(CY2)p-Het1又は-E-(CY2)p-Het3であり、
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COY、COOY、CONY2、-CONY-Cyc、-O-Cyc、NO2、CN、SY、SOY、SO2Y、SO2NY2、NHSO2Y、アルケニル又は-E-(CY2)p-Ar2であり、
R3、R4、R5、R6は、互いに独立してH、A又はAr2であり、
R7は、Y、OY又はNY2であり、
X1、X2、X3、X4は、互いに独立してO、NY又は単結合であり、
Eは、-C≡C-、SO2、-SO2-NY-、O、NY又は単結合であり、
Yは、H又はAであり、
Aは、1-10個の炭素原子を有する非分岐又は分岐のアルキルであると共に、1-7個の水素原子はHalと置換可能であり、
Cycは、3-7個の炭素原子を有するシクロアルキルであると共に、1-4個の水素原子は互いに独立してHal又はAと置換可能であり、
Ar1は、3-10個の炭素原子を有する飽和、不飽和又は芳香族の、単環又は二環式の炭素環であると共に、R1、R2及び-C≡C-C(A)2OHの群から選択される少なくとも1つの置換基によって置換可能であり、且つ/又はCyc、Het1又はHet3に融合可能であり、
Ar2は、6-10個の炭素原子を有する芳香族の、単環又は二環式の炭素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het1は、3-8個の炭素原子及び1-4個のN、O及び/又はS原子を有する不飽和又は芳香族単環又は二環式の複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、-(CY2)p-Ar2、-CO-Ar2、SO2-Ar2、-(CY2)p-Het2、Het3及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Het2は、5-7個の炭素原子及び1-3個のN原子を有する芳香族単環式複素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het3は、3-7個の炭素原子及び1-4個のN、O及び/又はS原子を有する飽和単環式複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、COY、-CONY2、=O及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Halは、F、Cl、Br又はIであり、
m、n、pは、互いに独立して0、1、2、3又は4である)
の化合物、及び/又は生理的に許容されるその塩と接触させることを含む方法。 - 受精障害(fertility disorder)の予防若しくは治療及び/又はモニタリングにおける使用のための、
式(I)
R、Lは、互いに独立してAr1、Het1、A又はOYであり、
R1は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、CONY2、NHCOY、CN、SO2Y、-E-(CY2)p-Ar2、-E-(CY2)p-Het1又は-E-(CY2)p-Het3であり、
R2は、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COY、COOY、CONY2、-CONY-Cyc、-O-Cyc、NO2、CN、SY、SOY、SO2Y、SO2NY2、NHSO2Y、アルケニル又は-E-(CY2)p-Ar2であり、
R3、R4、R5、R6は、互いに独立してH、A又はAr2であり、
R7は、Y、OY又はNY2であり、
X1、X2、X3、X4は、互いに独立してO、NY又は単結合であり、
Eは、-C≡C-、SO2、-SO2-NY-、O、NY又は単結合であり、
Yは、H又はAであり、
Aは、1-10個の炭素原子を有する非分岐又は分岐のアルキルであると共に、1-7個の水素原子はHalと置換可能であり、
Cycは、3-7個の炭素原子を有するシクロアルキルであると共に、1-4個の水素原子は互いに独立してHal又はAと置換可能であり、
Ar1は、飽和、不飽和又は芳香族の、3-10個の炭素原子を有する単環又は二環式の炭素環であると共に、R1、R2及び-C≡C-C(A)2OHの群から選択される少なくとも1つの置換基によって置換可能であり、且つ/又はCyc、Het1又はHet3に融合可能であり、
Ar2は、6-10個の炭素原子を有する芳香族の、単環又は二環式の炭素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het1は、3-8個の炭素原子及び1-4個のN、O及び/又はS原子を有する不飽和又は芳香族単環又は二環式の複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、-(CY2)p-Ar2、-CO-Ar2、SO2-Ar2、-(CY2)p-Het2、Het3及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Het2は、5-7個の炭素原子及び1-3個のN原子を有する芳香族単環式複素環であると共に、Hal、A及び-(CY2)p-OYの群から選択される少なくとも1つの置換基によって置換可能であり、
Het3は、3-7個の炭素原子及び1-4個のN、O及び/又はS原子を有する飽和単環式複素環であると共に、Hal、A、-(CY2)p-OY、-(CY2)p-NY2、COOY、COY、-CONY2、=O及びCNの群から選択される少なくとも1つの置換基によって置換可能であり、
Halは、F、Cl、Br又はIであり、
m、n、pは、互いに独立して0、1、2、3又は4である)
の化合物、及び/又は生理的に許容されるその塩。 - 受精障害を治療するための方法であって、少なくとも1つの請求項13に記載の化合物及び/又は生理的に許容されるその塩の有効量を、受精障害の治療を必要とする哺乳類に投与することを含む方法。
- インビトロ(in-vitro)における受精のための方法であって、
(a)請求項14に記載の方法に従って哺乳類を治療する工程、
(b)上記哺乳類から卵を回収する工程、
(c)上記卵を受精させる工程、及び
(d)上記受精卵を宿主哺乳類に移植する工程、
を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161503694P | 2011-07-01 | 2011-07-01 | |
US61/503,694 | 2011-07-01 | ||
PCT/US2012/044169 WO2013006308A2 (en) | 2011-07-01 | 2012-06-26 | Dihydropyrazoles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017127781A Division JP6438079B2 (ja) | 2011-07-01 | 2017-06-29 | ジヒドロピラゾール |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014520803A true JP2014520803A (ja) | 2014-08-25 |
JP6170043B2 JP6170043B2 (ja) | 2017-07-26 |
Family
ID=46513842
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014518909A Active JP6170043B2 (ja) | 2011-07-01 | 2012-06-26 | ジヒドロピラゾール |
JP2017127781A Active JP6438079B2 (ja) | 2011-07-01 | 2017-06-29 | ジヒドロピラゾール |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017127781A Active JP6438079B2 (ja) | 2011-07-01 | 2017-06-29 | ジヒドロピラゾール |
Country Status (10)
Country | Link |
---|---|
US (4) | US8791114B2 (ja) |
EP (1) | EP2726463B1 (ja) |
JP (2) | JP6170043B2 (ja) |
CN (1) | CN103827091B (ja) |
AU (2) | AU2012279416B2 (ja) |
CA (1) | CA2837524C (ja) |
ES (1) | ES2796774T3 (ja) |
HK (1) | HK1197235A1 (ja) |
IL (1) | IL230219B (ja) |
WO (1) | WO2013006308A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2734517B1 (en) * | 2011-07-18 | 2017-08-30 | Merck Patent GmbH | Benzamides |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015196335A1 (en) | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
EP3109237A1 (en) | 2015-06-22 | 2016-12-28 | AnaMar AB | Novel 5-ht2 antagonists |
CN105777730A (zh) * | 2016-04-07 | 2016-07-20 | 陈思思 | 一种治疗男性不育的药物组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56139464A (en) * | 1980-03-10 | 1981-10-30 | Stauffer Chemical Co | 1-(3,5-dichlorobenzoyl)-3-phenylpyrazolines, mildewcidal composition and application thereof |
WO2001032173A1 (fr) * | 1999-10-29 | 2001-05-10 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de neurocytotoxicite de l'acide kainique |
JP2001261675A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬 |
JP2005526091A (ja) * | 2002-03-08 | 2005-09-02 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害薬 |
WO2007038425A2 (en) * | 2005-09-27 | 2007-04-05 | Regents Of The University Of Minnesota | Anti-viral compouinds |
JP2010523579A (ja) * | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Cftr阻害剤化合物およびそれらの使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4511042B2 (ja) | 1998-08-07 | 2010-07-28 | メルク セローノ ソシエテ アノニム | 不妊症の治療のためのfsh模倣物 |
JP2004505051A (ja) | 2000-07-27 | 2004-02-19 | スミスクライン ビーチャム コーポレーション | 卵胞刺激ホルモン活性のアゴニスト |
CA2466288A1 (en) * | 2002-07-18 | 2004-01-29 | Sri International | Methods of treating conditions associated with an edg-1 receptor |
DE102005038537A1 (de) * | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
JP2010513519A (ja) * | 2006-12-22 | 2010-04-30 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼインヒビター活性を有するある種のピラゾリン誘導体 |
WO2008137408A1 (en) * | 2007-04-30 | 2008-11-13 | Genentech, Inc. | Pyrazole inhibitors of wnt signaling |
DE102008025750A1 (de) * | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | Dihydropyrazolderivate |
TWI461426B (zh) | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | (二氫)咪唑並異〔5,1-a〕喹啉類 |
-
2012
- 2012-06-26 US US13/533,759 patent/US8791114B2/en active Active
- 2012-06-26 CA CA2837524A patent/CA2837524C/en active Active
- 2012-06-26 WO PCT/US2012/044169 patent/WO2013006308A2/en active Application Filing
- 2012-06-26 EP EP12735378.7A patent/EP2726463B1/en active Active
- 2012-06-26 JP JP2014518909A patent/JP6170043B2/ja active Active
- 2012-06-26 ES ES12735378T patent/ES2796774T3/es active Active
- 2012-06-26 AU AU2012279416A patent/AU2012279416B2/en active Active
- 2012-06-26 CN CN201280032620.2A patent/CN103827091B/zh active Active
-
2013
- 2013-12-29 IL IL230219A patent/IL230219B/en active IP Right Grant
-
2014
- 2014-06-10 US US14/300,945 patent/US9517227B2/en active Active
- 2014-10-24 HK HK14110638.1A patent/HK1197235A1/zh unknown
-
2016
- 2016-11-03 US US15/342,550 patent/US9775830B2/en active Active
-
2017
- 2017-06-21 AU AU2017204191A patent/AU2017204191B2/en active Active
- 2017-06-29 JP JP2017127781A patent/JP6438079B2/ja active Active
- 2017-08-23 US US15/684,117 patent/US20170368030A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56139464A (en) * | 1980-03-10 | 1981-10-30 | Stauffer Chemical Co | 1-(3,5-dichlorobenzoyl)-3-phenylpyrazolines, mildewcidal composition and application thereof |
WO2001032173A1 (fr) * | 1999-10-29 | 2001-05-10 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de neurocytotoxicite de l'acide kainique |
JP2001261675A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬 |
JP2005526091A (ja) * | 2002-03-08 | 2005-09-02 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害薬 |
WO2007038425A2 (en) * | 2005-09-27 | 2007-04-05 | Regents Of The University Of Minnesota | Anti-viral compouinds |
JP2010523579A (ja) * | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Cftr阻害剤化合物およびそれらの使用 |
Non-Patent Citations (7)
Title |
---|
ALFONS L. BAUMSTARK ET AL: "Synthesis of 4,4-dimethyl -3,4-dihydro-3,3,5-trisubstituted -2H-pyrazoles and N-benzoyl derivatives", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 27, JPN6015053045, 1990, pages 291 - 294, XP002688948, ISSN: 0003229478, DOI: 10.1002/jhet.5570270233 * |
CHAN, D. M. T. ET AL.: "Synthesis and Bilogical Activity of Semicarbazone Insecticides", ACS SYMPOSIUM SERIES, SYNTHESIS AND CHEMISTRY OF AGROCHEMICALS VI, JPN6015053042, 2001, pages 14 - 144, ISSN: 0003229475 * |
GEMBUS, VINCENT; BONNET, JEAN-JACQUES; JANIN, FRANCOIS; BOHN, PIERRE; LEVACHER, VINCENT; BRIERE, JEA: "Synthesis of pyrazolines by a site isolated resin-bound reagents methodology", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 8(14), JPN6015053041, 2010, pages 3287 - 3293, ISSN: 0003229474 * |
GIORGIO CIGNARELLA ET AL: "Reinvestigation of the reaction of 3-hydroxy-2-methyl-1-aryl-propanones and related compounds with h", SYNTHESIS, JPN6015053046, 1989, pages 320 - 321, XP002688949, ISSN: 0003229479, DOI: 10.1055/s-1989-27242 * |
M. ENCARNACION CAMACHO ET AL: "4,5-Dihydro-1H-pyrazole derivatives with inhibitory nNOS activity in Rat brain: Synthesis and Struct", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47(23), JPN6015053043, 2004, pages 5641 - 5650, ISSN: 0003229476 * |
MAHE, OLIVIER; DEZ, ISABELLE; LEVACHER, VINCENT; BRIERE, JEAN-FRANCOIS: "Enantioselective Phase-Transfer Catalysis: Synthesis of Pyrazolines", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 49(39), JPN6015053040, 2010, pages 7072 - 7075, ISSN: 0003229473 * |
MARIA J. V. DE OLIVEIRA ET AL: "Transformations of penicillin", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, JPN6015053044, 1977, pages 1477 - 1500, ISSN: 0003229477 * |
Also Published As
Publication number | Publication date |
---|---|
AU2017204191A1 (en) | 2017-07-13 |
HK1197235A1 (zh) | 2015-01-09 |
WO2013006308A2 (en) | 2013-01-10 |
WO2013006308A3 (en) | 2013-05-10 |
ES2796774T3 (es) | 2020-11-30 |
US8791114B2 (en) | 2014-07-29 |
US20170071910A1 (en) | 2017-03-16 |
US9517227B2 (en) | 2016-12-13 |
US9775830B2 (en) | 2017-10-03 |
US20130172351A1 (en) | 2013-07-04 |
CN103827091B (zh) | 2016-05-18 |
CN103827091A (zh) | 2014-05-28 |
JP6438079B2 (ja) | 2018-12-12 |
AU2012279416A1 (en) | 2014-01-16 |
IL230219A0 (en) | 2014-03-06 |
JP6170043B2 (ja) | 2017-07-26 |
AU2017204191B2 (en) | 2019-10-31 |
JP2017206537A (ja) | 2017-11-24 |
CA2837524C (en) | 2019-08-20 |
EP2726463B1 (en) | 2020-03-11 |
US20140296238A1 (en) | 2014-10-02 |
IL230219B (en) | 2018-08-30 |
CA2837524A1 (en) | 2013-01-10 |
AU2012279416B2 (en) | 2017-04-06 |
US20170368030A1 (en) | 2017-12-28 |
EP2726463A2 (en) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6438079B2 (ja) | ジヒドロピラゾール | |
JP6254730B2 (ja) | ベンズアミド類 | |
US6787651B2 (en) | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-γ binding agents | |
EP2021330B1 (en) | Benzimidazole modulators of vr1 | |
JP6219844B2 (ja) | 卵胞刺激ホルモンの調節因子としてのベンズアミド誘導体 | |
JP2011502148A (ja) | 疼痛の治療用としてのp2x3受容体アンタゴニスト | |
TW202012379A (zh) | 化合物 | |
JP2006045118A (ja) | 新規ピラゾロキノロン誘導体 | |
CN117794898A (zh) | 3-吡咯基磺酰胺化合物作为gpr17拮抗剂 | |
CN115232144A (zh) | 含氮稠环类衍生物、药物组合物及其制备方法和应用 | |
WO2019191410A1 (en) | Inhibitors for the β-catenin / t-cell factor protein–protein interaction | |
TW201307294A (zh) | 雜環化合物及其用途 | |
KR20110094566A (ko) | 1-(6,7-다이플루오르-3-메톡시퀴녹살린-2-일)-3-[1-(헤테로아릴메틸)피페리딘-4-일] 우레아 유도체, 그 제조방법 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150407 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170519 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170530 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170629 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6170043 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |